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SUMMARY 
Dysregulation of gene expression is a hallmark of cancer. Broadly speaking, my 
research is focused on the changes in gene expression that characterize the transition from 
normal to cancerous states, i.e. tumorigenesis. To study such changes, I performed 
integrated analysis of next generation sequencing data for matched normal and primary 
tumor samples from hundreds of patients across numerous different cancer types. By 
analyzing this sequencing data, I have been able to explore the global landscape of 
transcriptional reprogramming in cancer and discover how changes in the regulation of 
gene expression may be implicated in tumorigenesis. My thesis is focused on four specific 
areas of transcriptional reprogramming in cancer: (1) changes in the expression and activity 
of transposable elements (TEs), (2) changes in alternative splicing induced by TEs, (3) 
allele-specific expression of tumor suppressor genes (TSGs), and (4) gene expression 
changes that are implicated in cancer drug response. 
TEs are known to be uniformly overexpressed in cancer, suggesting a possible role 
for their activity in tumorigenesis. I discovered a class of long interspersed nuclear 
elements (the LINE-1 family) with elevated levels of expression and activity in three 
different cancer types, and I showed examples where cancer-specific LINE-1 insertions 
disrupt enhancers, leading to the down-regulation of TSGs. 
TEs are also implicated in the creation of novel splicing isoforms, and aberrant 
alternative splicing has been associated with tumorigenesis for a number of different 
cancers. Integrated analysis of genome sequence and transcriptome data revealed 
thousands of TE-generated alternative splice events genome-wide, including close to 5,000 
 xiv 
events distributed among cancer associated genes. I explored the functional implications 
of specific cases of isoform switching, whereby TE-induced isoforms of cancer associated 
genes show elevated levels of relative expression in tumor samples. 
A closer look at TSG expression in matched normal and tumor samples indicated 
that functionally important changes in patterns of allele-specific expression in individuals 
heterozygous for loss-of-function TSG alleles is a significant factor in cancer 
onset/progression. These results identified a variety of molecular mechanisms that 
contribute to the observed changes in allele-specific expression patterns in cancer with 
allele-specific alternative splicing mediated by anti-sense RNA emerging as a predominant 
factor. Furthermore, analysis of the genomic variation for world-wide human populations 
demonstrates that loss-of-function TSG alleles are segregating at remarkedly high 
frequencies implying that a significant fraction of otherwise healthy individuals may be 
pre-disposed to developing cancer. 
For the final study of my thesis research, I applied the gene expression data from 
primary tumor samples to build predictive models of cancer drug response for two common 
chemotherapeutics: 5-Fluorouracil and Gemcitabine. My gene expression based models 
predict whether patients will respond to individual therapies with up to 86% accuracy. The 
genes that I found to be most informative for predicting drug response were enriched in 
well-known cancer signaling pathways highlighting their potential significance in 
prognosis of chemotherapy. 
Research Advance 1: Patterns of transposable element (TE) expression and TE 
insertion activity in matched normal and primary tumor samples were analyzed for three 
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cancer types: breast invasive carcinoma, head and neck squamous cell carcinoma, and lung 
adenocarcinoma.  We found high levels of somatic TE activity in normal and cancer 
samples across these diverse tissue types.  We also observe a consistent increase in L1 
transcript expression and L1 insertional activity in primary tumor samples for all three 
cancer types.  Finally, we were able to investigate specific cases of putative cancer-causing 
TE mutations in further detail using genome feature analysis.  These results inform the TE 
research community about unexpectedly high levels of somatic TE activity and a uniform 
increase in L1 expression and transposition across diverse cancer tissue types. 
Research Advance 2: This chapter broadly characterizes the role of human TEs in 
generating alternatively spliced isoforms in cancer. To do so, we screened for the presence 
of TE-derived sequences co-located with alternative splice sites that are differentially 
utilized in paired normal versus cancer tissues. We analyzed a comprehensive set of 
alternative splice variants from 614 matched normal-tumor tissue pairs characterized via 
RNA-seq as part of The Cancer Genome Atlas (TCGA). Our algorithm uncovered close to 
5,000 TE-generated alternative splice events distributed among Catalogue Of Somatic 
Mutations In Cancer (COSMIC) census genes that have been causally implicated in cancer. 
SINEs and LINEs were found to contribute the majority of TE-generated alternative splice 
sites in cancer genes. Differential expression analysis was used to detect TE-derived 
splicing events that are over-expressed in cancer tissues. A number of cancer-associated 
genes – MYH11, WHSC1, and CANT1 – were shown to have overexpressed TE-generated 
isoforms across a range of cancer types. 
Research Advance 3: Cancer has long thought to be a disease which develops from 
de novo cancer driver mutations in oncogenes and tumor suppressor genes (TSGs). The 
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purpose of this chapter is to examine how TSGs contribute to tumorigenesis. Accordingly, 
loss-of-function (LoF) mutations in TSGs were analyzed within 2504 individuals from 
1000 Genomes Project (1KGP) and 233 patients across four diverse cancer types from The 
Cancer Genome Atlas (TCGA). A large fraction of 1KGP individuals were identified as 
carriers of heterozygous LoF mutations in TSGs. However, compound heterozygosity of 
LoF mutations in at least one TSG was only found in 20% of our TCGA patients. Further, 
analysis of allele specific expression (ASE) in these tumors identified several TSGs where 
the mutant allele is overexpressed relative to the reference allele. This evidence of ASE 
suggests TSGs have the potential to drive tumorigenesis in the heterozygous condition, if 
the reference allele is sufficiently repressed. A variety of molecular mechanisms 
contributing to ASE were identified including allele-specific alternative splicing induced 
by anti-sense RNA. 
Research Advance 4:  Both clinical and gene expression data from TCGA primary 
tumor biopsies were used to build models that predict patient response to cancer drugs.  
Our research focused on two common chemotherapeutics, Fluorouracil and Gemcitabine, 
and developed models with prediction accuracy up to 86%. These models will provide 
much needed decision support for oncologists when selecting second-line therapies. 
Traditionally, when oncologists are faced with this decision, they have little to no 
information about which drug will perform best for an individual patient.  Therefore, our 
models, which create personalized predictions of response, provide essential information 
for these clinicians.  
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CHAPTER 1. INTRODUCTION 
1.1 Transposable Elements (TEs) 
Transposable elements (TEs) are DNA sequences, typically repetitive, that are 
capable of replicating and moving themselves in the host genome.  TEs or “jumping genes” 
were first discovered in 1950 by Barbara McClintock while she was studying the maize 
genome at Cold Spring Harbor Laboratory in New York [1]. Eukaryotic TEs are broken 
down into two distinct classes based on the mechanism by which they transpose [2]. Class 
I TEs, or retrotransposons, require reverse transcription in order to transpose, following a 
“copy-and-paste” mechanism. Class II TEs, or DNA transposons, “cut-and-paste” simply 
moving their location instead of replicating. 
 
1.1.1 L1 Insertions 
Recent estimates suggest that close to 50% of the human genome is derived from 
TEs [3]. While most of these TEs are ancient remnants and no longer active, three families 
of TEs continue to retrotranspose in the human genome: Alu, L1 and SVA [4]. Of the three, 
L1s have been conclusively shown to be uniformly over expressed in several cancer types 
[5-9]. Unlike single nucleotide changes, L1 insertions are potentially far more disruptive 
and deleterious to the host genome. Consequently, their retrotransposition in the cell is 
normally suppressed via numerous mechanisms targeting different stages of the 
retrotransposition. These cellular inhibitory mechanisms include RNA degradation, 
autophagy-signaling pathways, inhibition of RNP formation and/or localization to stress 
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granules Each of these mechanisms/pathways is controlled by a set of genes that act as 
multiple failsafes.  Failure in some (or all) of these machineries can lead to deleterious L1 
insertions. Other mechanistic failures that can lead to the increase of L1 insertions in the 
genome include epigenetic changes such hypomethylation (or failure of maintaining 
methylated L1).  
 L1 insertions may contribute to tumorigenesis if the insertion causes genomic 
instability (improper chromosomal pairing during mitosis and meiosis), large genomic 
deletions, or disruption of cancer driver genes by inserting nearby (Figure 1). 
 
Figure 1 Contribution of TE insertions to tumorigenesis. 
 
1.2 Alternative Splicing 
Recent studies estimate there are over 21,000 human protein-coding genes [10, 11]. 
DNA is transcribed into RNA where it may undergo a process called alternative splicing. 
Alternative splicing is an editing process that involves removing intronic regions, leaving 
only protein-coding regions (i.e. exons) to make up the final processed messenger RNA 
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(mRNA). Through this process a single gene can code for multiple proteins. It is estimated 
that there are ~100,000 human proteins resulting from just ~21,000 genes.  
 There are five main types of alternative splicing: 1) alternative 3’ splice site, 2) 
alternative 5’ splice site, 3) intron retention, 4) exon skipping, and 5) mutually exclusive 
exons.  All of these alternative-splicing events contribute to transcriptome and proteome 
diversity, significantly affecting the function of molecular processes that could contribute 
to disease states such as cancer.  In fact aberrant alternative splicing has been associated 
with many cancers [12, 13].  
 The mechanism of alternative splicing has been attributed mainly to cis-acting 
regulatory elements in the mRNA sequence. These elements determine which exons are 
spliced by binding splicing facilitator proteins that act in trans to suppress splicing. 
Splicing inhibitors, splicing silencers and splicing activators all have a role in determining 
the location and ability of the spliceosome to assemble.  It has also been shown that 
antisense RNAs play a vital role in alternative splicing. An antisense transcription-
mediated mechanism of splicing has been described in humans where matching sense and 
antisense transcripts form double-stranded RNA leading to splice site masking [14]. 
Furthermore, antisense oligonucleotides have been designed to interfere with splice sites 




1.3 Tumor Suppressor Genes (TSGs) 
Cancer is thought to arise from mutations in genes that control cellular proliferation, 
differentiation and homeostasis [18]. These cancer-associated genes can be classified in 
two categories: oncogenes and tumor-suppressor genes (TSGs). Jointly, over expression of 
oncogenes and loss of TSG function drive tumorigenesis. Loss-of-function (LoF) 
mutations in TSGs can be confidently characterized with existing genomic techniques. This 
enables us to study the impact of these mutations on tumorigenesis. LoF mutations 
affecting TSGs frequently act in a recessive manner - and therefore must occur in both 
alleles of a TSG for a cell to become cancerous. This idea, known as the “two-hit” 
hypothesis, was formulated by geneticist Alfred Knudson in 1971 [19]. While studying 
retinoblastoma, a rare form of childhood cancer where tumor formation occurs in the back 
of the eye, Knudson looked at 48 patients and logged age, family history, and whether the 
disease was unilateral or bilateral. Using mathematics, Knudson was able to determine that 
the data followed a two-hit model as well as differences between hereditary and non-
hereditary groups. Given that LoF, by mutation or deletion, of TSGs is common in cancer, 
learning more about them is critical for understanding carcinogenesis. 
 
1.4 Allele-Specific Expression (ASE) 
Humans are diploid organisms and as such inherit two copies of each gene – one 
maternal and one paternal. Allele-specific expression refers to the phenomena where one 
of these copies of a gene, or allele, is expressed significantly higher or lower than the other. 
Imprinted genes are examples of extreme ASE or monoallelic expression.  
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Allele-specific expression analysis is a powerful method for discovering cis-
regulatory variability by comparing expression levels of reference (wild type) and 
alternative (mutant) alleles at all heterozygous variant positions in the exome [20]. 
Analyzing ASE in matched normal and tumor samples will uncover changes in quantities 
or patterns of ASE between samples. 
 There are various reasons why the expression of alleles may vary. One explanation 
is there is an imbalance of the alleles in the DNA. This could be due to tumor heterogeneity; 
since tumors are polyclonal, some single nucelotide polymorphisms (SNPs) may be 
specific to a clone in high or low frequency. It may also be attributed to DNA copy number 
variations (CNVs), which have been shown to be widespread in cancer [21]. Another 
possibility includes regulatory mutations. Cis-acting mutations such as expression 
quantitation trait loci (eQTLs) in promoter or enhancer regions may alter the expression of 
just one allele. Other scenarios include environmental factors that silence the maternal or 
paternal allele. Imprinter genes are a fine example of this, as is X-chromosome inactivation, 
whereby the inactive allele is packaged as heterochromatin such that it is transcriptionally 
inactive. Global DNA hypomethylation and tumor suppressor hypermethylation are two 
epigenetic alterations associated with many cancers that could play a role in allele-specific 
expression. 
 
1.5 Precision Oncology 
Precision oncology revolves around the idea that every patient’s cancer is different and 
thus each patient should be treated differently.  There are a number of diverse strategies in 
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cancer medicine that can be classified as precision oncology. These methods range from 
“targeted” approaches – whereby specific genes that are over expressed in the tumor are 
identified and reversed – to more modern-day approaches such as utilizing next-generation 
sequencing data to guide therapies.  While traditional approaches have relied on knowledge 
of molecular pathways, (i.e. “cause and effect”) [22], it’s become increasingly apparent 
that our understanding of such processes is still limited [23]. 
One alternative approach to selecting therapies based on casual inference is guiding 
treatment decision through significant correlations in data. This is becoming more possible 
with the continued generation of big data in genomics as well as advances in one branch 
of artificial intelligence called machine learning. Toward that end, several machine-
learning algorithms have been adopted for predicting cancer drug response including 
logistic regression, support vector machine, and random forest [24-26]. 
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CHAPTER 2. PATTERNS OF TRANSPOSABLE ELEMENT 
EXPRESSION AND INSERTION IN CANCER 
2.1 Abstract 
Human transposable element (TE) activity in somatic tissues causes mutations that 
can contribute to tumorigenesis.  Indeed, TE insertion mutations have been implicated in 
the etiology of a number of different cancer types.  Nevertheless, the full extent of somatic 
TE activity, along with its relationship to tumorigenesis, have yet to be fully explored.  
Recent developments in bioinformatics software make it possible to analyze TE expression 
levels and TE insertional activity directly from transcriptome (RNA-seq) and whole 
genome (DNA-seq) next-generation sequence data.  We applied these new sequence 
analysis techniques to matched normal and primary tumor patient samples from the Cancer 
Genome Atlas (TCGA) in order to analyze the patterns of TE expression and insertion for 
three cancer types: breast invasive carcinoma, head and neck squamous cell carcinoma, 
and lung adenocarcinoma.  Our analysis focused on the three most abundant families of 
active human TEs: Alu, SVA and L1.  We found evidence for high levels of somatic TE 
activity for these three families in normal and cancer samples across diverse tissue types.  
Abundant transcripts for all three TE families were detected in both normal and cancer 
tissues along with an average of ~80 unique TE insertions per individual patient/tissue.  We 
observed an increase in L1 transcript expression and L1 insertional activity in primary 
tumor samples for all three cancer types.  Tumor-specific TE insertions are enriched for 
private mutations, consistent with a potentially causal role in tumorigenesis.  We used 
genome feature analysis to investigate two specific cases of putative cancer-causing TE 
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mutations in further detail.  An Alu insertion in an upstream enhancer of the CBL tumor 
suppressor gene is associated with down-regulation of the gene in a single breast cancer 
patient, and an L1 insertion in the first exon of the BAALC gene also disrupts its expression 
in head and neck squamous cell carcinoma.  Our results are consistent with widespread 
somatic activity of human TEs leading to numerous insertion mutations that can contribute 
to tumorigenesis in a variety of tissues.   
 
2.2 Introduction 
More than 50% of the human genome sequence is derived from transposable element 
(TE) insertions [3, 27].  The vast majority of TE-derived sequences in the human genome 
correspond to relatively ancient insertions that are no longer capable of transposition [4].  
However, there are several families of human TEs that remain active to this day.  The most 
abundant families of active TEs in the human genome are the Alu and SVA short 
interspersed nuclear elements (SINEs) along with the L1 Long Interspersed Nuclear 
Element (LINE) family [28-33].  Alu and SVA SINEs are non-autonomous TEs that are 
mobilized via the transpositional machinery encoded by the autonomous L1 family of 
LINEs.  Recent evidence indicates that a handful of HERV-K endogenous retroviral 
elements also remain active in the human genome [34].   
Active TE families are of great interest since they have the ability to generate de novo 
mutations, many of which have been linked to human disease [35, 36].  For instance, TE 
insertions have been shown to contribute to the etiology of a variety of different cancer 
types [37, 38].  Numerous recent studies have used a combination of next-generation 
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sequence analysis, followed by validation with PCR and/or Sanger sequencing, to elucidate 
connections between TE activity and cancer [35, 39-42].  L1 insertions in particular have 
been implicated as potential cancer causing mutations in those and other studies [6-9, 43].  
L1 activity is thought to promote tumor development by causing genomic instability, via 
impaired chromosomal pairing during mitosis, and/or by disrupting coding or regulatory 
sequences [44].   
Many of the studies that have related TEs to cancer have considered TE expression, at 
the transcript or protein level, and TE insertional activity separately.  A number of different 
cancer types are positive for L1 transcript expression [45], and L1 proteins have been 
shown to be ubiquitously expressed in both normal and tumor samples from the same 
individuals [42, 46-50].  There is also evidence suggesting that L1 protein expression can 
be limited to tumor tissues and thereby serve as a useful cancer biomarker; nearly half of 
all human cancers are exclusively immunoreactive for L1-ORF1 encoded proteins [51].  
The expression of L1 proteins in tumors has been shown to affect the expression of a 
number of cancer-related genes, including the down-regulation of tumor suppressors [52].  
With respect to TE insertional activity, studies on matched normal and tumor tissues have 
found that novel L1 insertions occur at high frequencies in lung cancer genomes (Iskow et 
al., 2010).  Such insertions frequently occur in oncogenes and tumor suppressors, 
underscoring their putative role in tumorigenesis (Lee et al., 2012).   
A principal challenge when interpreting cancer genomes is distinguishing between so-
called passenger and driver mutations.  While passenger mutations are present in cancer 
genomes, they are not considered to contribute to cancer progression; instead, they are 
simply somatic mutations that arise during carcinogenesis and are carried along during 
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clonal expansion.  Driver mutations, on the other hand, are causal mutations that are 
directly implicated in carcinogenesis and the promotion of cancer growth [53-55].  To date, 
only a few studies have directly implicated TE insertions as cancer driver mutations.  One 
such study analyzed 19 hepatocellular carcinoma genomes utilizing the RC-Seq 
methodology [56] and discovered two separate L1 insertions that initiate tumorigenesis via 
distinct oncogenic pathways [41].  This study found L1 insertions in two different tumor 
suppressor genes: Mutated in Colorectal Cancers (MCC) and Suppression of 
Tumorigenicity (ST18).  Most recently, a role for L1 insertional activity was conclusively 
demonstrated for colorectal cancer caused by an insertion in the APC tumor suppressor 
gene [43].  This paper describes a somatic L1 insertion into one copy of the APC gene that, 
when coupled with a point mutation in the other copy of the gene, initiates tumorigenesis 
through the two hit colorectal cancer pathway. 
Owing to parallel developments in genomics and bioinformatics, it is now possible to 
jointly analyze the patterns of TE transcript expression and TE insertional activity in human 
cancers.  The Cancer Genome Atlas (TCGA) provides access to both transcriptome 
sequence data (RNA-seq) and whole genome sequence data (DNA-seq) for a number of 
matched normal and primary tumor sample pairs from individual patients [57].  In addition, 
recently developed bioinformatics algorithms allow for the detection of TE transcripts 
directly from RNA-seq data [58] as well as for the characterization of novel TE insertions 
from DNA-seq data [59, 60].  We took advantage of these developments in order to 
evaluate the patterns of both TE expression and insertional activity in three cancer types: 
breast invasive carcinoma, head and neck squamous cell carcinoma, and lung 
adenocarcinoma (Figure 2 and Figure 21).  We observed a simultaneous increase of L1 
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transcript expression and L1 insertional activity for primary tumor samples for all three 
cancers, and we evaluate individual cases of TE insertions that are implicated as potential 
cancer-causing mutations. 
 
Figure 2 Scheme of the analytical design used in this study. 
Matched normal and primary tumor samples for three cancer types were analyzed using 
transcriptome (RNA-seq) and whole genome (DNA-seq) data.  RNA-seq data was analyzed 
to compare normal versus cancer expression levels, and DNA-seq data was analyzed to 
identify somatic TE insertion events.  The main bioinformatics programs (wrench) and 
databases (cylinder) used for each phase of the analysis are indicated. 
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2.3 Materials and Methods 
2.3.1 Genome and Transcriptome Sequence Data 
 Whole genome sequence data (DNA-seq), transcriptome sequence data (RNA-seq) 
and patient metadata for matched normal and primary tumor tissue samples from nine 
cancer patients were acquired from The Cancer Genome Atlas (TCGA) [57] via the Cancer 
Genomics Hub (CGHub) using the download client GeneTorrent [61].  The nine 
participants included three breast invasive carcinoma patients, three head and neck 
squamous cell carcinoma patients and three lung adenocarcinoma patients (Table 1).  
DNA-seq and RNA-seq data were accessed as BAM files of paired-end Illumina sequence 
data aligned against the human genome reference sequence (build hg19).  BAM files 
containing sequence alignments were validated for quality using FASTQC [62], and 
autosomes were extracted from the BAM files for downstream analysis using SAMtools 
[63]. 
Table 1 TCGA whole genome (DNA-seq) and transcriptome (RNA-seq) data sources 
for the patients analyzed in this study. 

































NT-W 42.4 100 
TCGA-BH-A0B3-11B-21R-A089-07 NT-R 5.5 50 
TCGA-BH-A0B3-01A-11D-A128-09 TP-W 40.2 100 








NT-W 54.1 100 
TCGA-BH-A0BW-11A-12R-A115-07 NT-R 7 50 
TCGA-BH-A0BW-01A-11D-A10Y-09 TP-W 46.1 100 








NT-W 63.3 100 
TCGA-BH-A0DT-11A-12R-A12D-07 NT-R 7.7 50 
TCGA-BH-A0DT-01A-21D-A12B-09 TP-W 79.9 100 


































NT-W 6.9 101 
TCGA-CV-7255-11A-01R-2016-07 NT-R 7.5 48 
TCGA-CV-7255-01A-11D-2276-10 TP-W 5.8 101 







NT-W 7.7 101 
TCGA-CV-7416-11A-01R-2081-07 NT-R 5.9 48 
TCGA-CV-7416-01A-11D-2334-08 TP-W 28.6 101 







NT-W 38.3 51 
TCGA-CV-6959-11A-01R-1915-07 NT-R 8.5 48 
TCGA-CV-6959-01A-11D-1911-02 TP-W 31.4 51 




















a F 60 
NT-W 38.9 51 
TCGA-44-6776-11A-01R-1858-07 NT-R 5.4 48 
TCGA-44-6776-01A-11D-1853-02 TP-W 6.9 51 








NT-W 34.6 101 
TCGA-50-5932-11A-01R-1755-07 NT-R 4.2 48 
TCGA-50-5932-01A-11D-1753-08 TP-W 44.5 101 








NT-W 36.2 101 
TCGA-55-6984-11A-01R-1949-07 NT-R 4.9 48 
TCGA-55-6984-01A-11D-1945-08 TP-W 41 101 
TCGA-55-6984-01A-11R-1949-07 TP-R 5.2 48 
a NT-D=Normal tissue DNA-seq, NT-R=Normal tissue RNA-seq, TP-D=Tumor primary 
DNA-seq, TP-R=Tumor primary RNA-seq 
 
2.3.2 Gene and Transposable Element (TE) Expression Levels 
Gene and TE expression levels were measured using RNA-seq data for the nine 
matched normal and primary tumor tissue samples.  Gene expression levels were quantified 
as read counts mapped to NCBI RefSeq gene annotations [64].  TE expression levels – for 
Alu, L1 and SVA elements – were quantified using reads mapped to RepeatMasker 
annotations, which were subsequently analyzed with the TEtranscripts package [58]. The 
TEtranscripts program uses an expectation maximization (EM) algorithm to choose 
optimal unique TE locations for multi-mapped reads, thereby allowing for accurate 
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expression level measurements for active TE families.  The TEtranscripts method was 
recently shown to yield more reliable measures of TE transcription levels compared to 
previously published methods, such as HTSeq-count, Cufflinks and RepEnrich [65-67]. 
The L1Base database was used to identify the genomic locations of 145 full length, intact 
elements from the most recently active L1 subfamily [68]. The set of full-length intact L1 
sequences from the L1Base was generated by performing a BLAST search using the human 
genomic DNA sequences against the L1 template sequence [68]. L1Base was used to 
facilitate measures of active L1 element expression by limiting our analysis to RNA-seq 
reads that map to full-length, intact L1 sequences which retain the potential to be 
transpositionally active.  This was done in an effort to ensure that the reads we analyzed 
were taken from potentially active L1 elements as opposed to older fixed elements, which 
could represent read-through transcripts initiated from nearby genomic promoters.  The 
expression levels of these potentially active L1 elements were analyzed separately using 
the TEtranscripts method. 
Differential expression levels between normal and cancer tissue pairs, for genes and 
TEs, were evaluated by comparing distributions of log10 transformed RNA-seq expression 
levels characterized as described above.  The statistical significance levels of the observed 
differential expression between normal and cancer pairs were evaluated by comparing 
these distributions using the non-parametric Kolmogorov-Smirnov test.  Statistical 
comparisons were done separately for each tissue (cancer) type: breast invasive carcinoma, 
head and neck squamous cell carcinoma and lung adenocarcinoma. 
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2.3.3 Transposable Element Insertion Detection 
The genomic locations of novel TE insertions from matched normal and primary tumor 
tissue samples were predicted based on discordant read-pair mapping of DNA-seq data 
[39] (Table 2 Numbers of MELT and Mobster predicted TE insertions in matched normal 
(N) and primary tumor (T) samples across 9 individuals..  A scheme of our TE insertion 
detection analysis pipeline is shown in Figure 22. DNA-seq BAM files were realigned 
according to GATK’s standard indel realignment method [69] to facilitate TE insertion 
detection.  The programs MELT [59] and Mobster [60] were used together for TE insertion 
detection.  These two programs were selected owing to their previously demonstrated 
superior performance for human TE insertion detection [70].  Only TE insertion sites that 
were found by both methods (i.e., the intersection of the predictions) were used for 
subsequent analysis.  TE insertion predictions made by the individual programs were 
considered to represent the same insertion if they were found within ±100bp of each other.  
An additional filtering step was applied based on the number of mapped sequence reads 
(coverage) that support each TE insertion prediction.  Only predictions with a minimum 
coverage of 5 reads and a maximum coverage of 4X the average sequencing depth of the 
sample were used for subsequent analysis.  These upper and lower cut-off thresholds were 
empirically chosen based on the observed distributions of the numbers of discordant 
mapped read pairs used to call individual TE insertions.  Read count distributions were 
computed individually for each program (MELT, Mobster) used and for each sample 
(Figure 23). The resulting distributions were typically bimodal with a lower peak (i.e., with 
lower read count support) that we considered to be enriched for potential false positive TE 
insertion calls.  The lower cut-off threshold of 5 reads was chosen to minimize such false 
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positives, and the upper cut-off threshold was chosen to remove calls made in genomic 
regions that show anomalously high numbers of mapped reads, which tend to be enriched 
for ambiguously mapped reads. 
The number of observed versus expected counts of unique L1 insertions were compared 
for matched normal and primary tumor tissue samples.  The observed counts were taken 
from the TE detection pipeline, and the expected counts were computed as the ratio of 
unique insertions seen in matched normal versus primary tissue for all TEs multiplied by 
the total number of observed L1 insertions.  The significance of the difference between the 
observed versus expected counts of unique L1 insertions was evaluated using the Fisher’s 
exact test.  Counts of TE insertions for matched normal and primary tumor tissue samples 
were characterized based on their frequencies from the 1000 Genomes Project (1KGP) [59] 
and grouped into three distinct frequency bins.  The distributions of TE insertion counts 
across the three frequency bins were compared for matched normal and cancer samples for 
the different tissue types analyzed here, and the significance of the differences between 
these distributions were evaluated using the Kolmogorov-Smirnov test. 
Table 2 Numbers of MELT and Mobster predicted TE insertions in matched 
normal (N) and primary tumor (T) samples across 9 individuals. 
Participant 
ID 
TE Insertions in Matched Normal 
Tissue 
TE Insertions in Tumor Primary 
Tissue 
Alu SVA L1 Total Alu SVA L1 Total 
Breast 1 913 28 127 1,069 853 33 110 997 
Breast 2 1,004 21 121 1,147 1,160 54 143 1,358 
Breast 3 1,012 63 139 1,215 952 60 136 1,149 
Head 1 984 72 140 1,197 741 66 107 915 
Head 2 945 25 131 1,102 832 26 138 997 
Head 3 860 36 108 1,005 819 41 112 973 
Lung 1 716 29 92 838 780 36 113 930 
Lung 2 806 25 103 935 701 20 94 816 
 17 
Lung 3 856 21 110 988 746 14 100 861 
         
2.3.4 TE Insertion Genome Feature Analysis 
The genomic locations of novel TE insertions were considered with respect to several 
genomic features using the BEDTools program [71]: RefSeq genes [64], COSMIC tumor 
suppressor genes [72], and enhancer elements defined by chromatin states [73].  The 
population allele frequencies of the predicted TE insertions were computed from the Phase 
3 release of the 1KGP [59] as previously described [74]. 
 
2.4 Results and Discussion 
2.4.1 TE Expression Levels in Matched Normal versus Primary Tumor Tissue Samples 
RNA-seq data were used to evaluate the differences in TE expression levels between 
matched normal and primary tumor tissue samples as described in the Materials and 
Methods.  The observed differences in gene expression levels between normal and tumor 
tissue were compared to differences in TE expression levels for breast invasive carcinoma, 
head and neck squamous cell carcinoma and lung adenocarcinoma.  There are no 
significant differences observed for the distributions of gene expression levels between 
matched normal and primary tumor tissue pairs for any of the three cancer types analyzed 
here (Figure 3).  Similarly, when all three families of potentially active TEs (Alu, L1 and 
SVA) are considered together, there is no significant difference seen for the overall levels 
of expression between matched normal and tumor tissue.  However, when full-length, 
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potentially active L1 sequences are considered alone, we observe statistically significant 
increases in L1 expression levels for all three cancer types. 
 
Figure 3 Gene expression dynamics for matched normal versus primary tumor 
tissue pairs. 
Normal tissue (NT) and tumor primary (TP) expression levels were measured for genes, 
transposable elements (TEs) and LINE1 elements (L1s) via analysis of RNA-seq data as 
described in the Materials and Methods.  Expression levels are shown as distributions of 
log10 transformed read counts, and normal versus tumor comparisons are shown for breast 
invasive carcinoma (green), head and neck squamous cell carcinoma (red) and lung 
adenocarcinoma (blue).  For each tissue type, the significance levels of the differences in 
L1 expression between normal and cancer pairs are indicated with P-values from the 
Kolmogorov-Smirnov test.   
The methods that we used to characterize TE expression levels include several 
analytical controls aimed to ensure that only genuine TE-initiated transcripts, from 
members of potentially active families, are measured. Nevertheless, the lack of a difference 
between normal and tumor expression levels observed when all three active TE families 
were considered together could reflect technical difficulties with identifying bona fide TE 
transcripts that are initiated from element promoters as opposed to TE sequences that are 
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passively expressed as part of longer genic transcripts.  This is particularly true for Alu 
elements, many of which are found in the introns of human genes and transcribed as read-
through transcripts initiated from RNA Pol II gene promoters [75].  Our confidence in the 
ability to measure L1-initiated transcripts is higher owing to the focus on previously 
identified full-length, intact elements that are located in intergenic regions.  In any case, 
the up-regulation of L1s in cancer that we observed has potential implications for increased 
TE insertional activity for all three families, since L1 encoded proteins are responsible for 
the cis retrotransposition of L1s as well as the trans activation of Alu and SVA elements 
[76, 77].  We analyzed the same pairs of matched normal and primary tumor tissues to 
evaluate whether the observed increase in L1 expression corresponds to increased 
transpositional activity of human TEs. 
 
2.4.2 Novel TE Insertions in Matched Normal and Primary Tumor Tissue Samples 
It is now possible to characterize the genomic locations and copy numbers of 
individual TE insertions from whole genome DNA-seq data owing to recent developments 
in computational genomics software [39, 70].  This technological advance is exemplified 
by the recent Phase 3 release of the 1KGP, which includes a complete genome-wide census 
of polymorphic TE insertion sites for 2,504 individuals across 26 human populations [59].  
We analyzed whole genome DNA-seq data using computational methods for TE insertion 
detection (see Materials and Methods) in order to compare TE insertional activity between 
matched normal versus primary tumor tissue samples. 
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When all three families of active human TEs are considered together, we observed 
a total of 3,672 TE insertions across the nine individuals analyzed for normal and cancer 
tissue pairs, 693 of which are unique insertions found in only one individual and one tissue 
type.  In other words, we observe an average of ~77 unique somatic TE insertions per 
person, i.e., ‘private’ TE insertions.  This estimate is similar to the value of ~90 unique 
(presumably germline) TE insertions that we previously observed for individuals from the 
1KGP [74].  A large majority of the observed TE insertions – 81% for all TEs and 62% for 
L1s alone – are shared between the normal and tumor tissue types of an individual, 
suggesting that they represent germline insertions (Figure 4A).  There are 1.3x more unique 
TE insertions seen for tumor compared to normal tissue, and this effect is more pronounced 
for L1s alone, which are 2x more abundant in tumor tissue samples.  Accordingly, there is 
a statistically significant excess of observed versus expected L1 insertions in tumor versus 
normal tissue (P = 0.019) (Figure 4B).  These results are consistent with a potential role 
for L1 transpositional activity in tumorigenesis for the cancer types analyzed here, as has 
been previously suggested for several different cancers (Morse et al., 1988; Iskow et al., 
2010; Lee et al., 2012; Scott et al., 2016). 
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Figure 4 TE insertional activity in matched normal versus primary tumor tissue 
pairs. 
Given the relatively high level of L1 insertional activity in the tumor tissue samples 
analyzed here, we tested whether tumor-specific L1 insertions are found at lower 
frequencies among the (presumably) healthy donors from the 1KGP compared to L1 
insertions found in matched normal tissue.  The idea was to evaluate whether the tumor-
specific L1 insertions represent mutations that are private, and thereby more likely to be 
deleterious or disease-causing.  To do this, individual TE insertions were classified as high 
frequency (>0.05), low frequency (<0.05) or private (absent) according to their previously 
characterized population (allele) frequencies from the 1KGP [59, 74].   
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When all three cancer types are considered together, there is a statistically significant 
excess of private and low frequency TE insertions observed for tumor compared to normal 
tissue (P = 1.9e-61) (Figure 4C).  This effect is even more pronounced when L1 insertions 
are considered alone (P = 2.7e-23).  The same pattern of an increased frequency of private 
L1 insertions in tumor tissue is observed (P < 2.0e-7) when all three cancer types are 
analyzed for sets of patients (Figure 4D-F) and when samples for individual patients are 
analyzed separately (Figure 24).  The strongest effect is seen for head and neck squamous 
cell carcinoma.  The pattern of a significant excess of private L1 insertions in tumor 
compared to normal tissue, observed for all three cancer types studied here, provides 
further evidence in support of a possible role for L1 activity in tumorigenesis. 
It should be noted TE insertions found in low copy numbers may not be detectable 
using next-generation sequence analysis, whereas such insertions may be uncovered using 
more sensitive PCR-based approaches.  False negatives of this kind will be more prevalent 
at low levels of sequence coverage.  We have tried to control for this by using relatively 
high sequence coverage (~35X) studies here, but the conservative lower read count cut-off 
of 5 reads per TE insertion call that we used may still lead to missing TE insertion calls.  
Sequence based predictions can also yield false-positive TE insertion calls.  In an effort to 
deal with this issue, we have only used high-confidence calls produced by two independent 
programs – MELT and Mobster – that we have recently shown to be most reliable for the 
detection of human TE insertions [70].   
One other potential problem with the sequence based analysis relates to the base pair 
resolution with which TE insertions can be called via computational analysis of next-
generation sequence data.  Currently, the most accurate programs for calling TE insertions 
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from next-generation sequence data do not yet allow for the insertions to be precisely 
located to genomic regions at single base pair resolution.  To account for this fact, TE 
insertions called within a window of ±100bp are considered to be co-located (Figure 22).  
It is possible that this approximation can lead to multiple TE insertion events being 
collapsed into a single event.  Subsequent experimental confirmation of individual TE 
insertion calls of interest (e.g. potentially tumorigenic TE insertions) should help to provide 
certainty with respect to both their validity and their precise genomic locations. 
 
2.4.3 Potentially Tumorigenic TE Insertions 
Having established a potential role for transpositional activity in tumorigenesis 
using the genome-wide approaches described above, we wanted to search for specific 
examples where individual TE insertions could be implicated as possible cancer driver 
mutations.  To do so, we performed an integrated analysis of TE insertion, gene expression 
and chromatin data (see Materials and Methods) in an effort to identify the cancer-specific 
TE insertions that are most likely to play a causal role in tumorigenesis.  We considered 
TE insertions that are co-located with either exons or regulatory elements of previously 
characterized tumor suppressor genes to have the highest likelihood of being functionally 
relevant.  We observed a total of 141 intragenic (35.9%) insertions and 246 intronic 
insertions (62.6%) out of the 393 total cancer-specific insertions in our dataset.  None of 
these intergenic or intronic cancer-specific TE insertions were found to disrupt any known 
functional (regulatory) sequence element.  Thus, consistent with previous studies, the vast 
majority of TE insertions that we observed are not likely to affect gene function or 
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expression in cancer.  We did find 4 exonic TE insertions, along with 2 insertions located 
in regulatory elements, for known tumor suppressor genes (1.5% of the total).  Here, we 
focus on two of these potential cases of cancer driver TE insertions, which could prove to 
be of interest to the TE and/or cancer research communities. 
There is a private, breast cancer tumor-specific Alu insertion that is located within 
an upstream enhancer element that helps to regulate the expression of the Cbl Proto-
Oncogene (CBL) gene (Figure 5A).  CBL is classified as a tumor suppressor gene by the 
COSMIC database [72].  It has been found to be mutated or translocated in a number of 
cancers including acute myeloid leukemia [78, 79]; mutations in CBL are also the cause of 
Noonan syndrome-like disorder [80].  The CBL encoded protein functions as a negative 
regulator of signal transduction pathways [81], activation of which have been associated 
with cancer [82].  The tumor-specific Alu enhancer insertion that we characterized is 
associated with down-regulation of CBL expression, consistent with a potential role in 




Figure 5 Private TE insertions implicated as potential cancer driver mutations. 
We also found a private L1 insertion that was unique to a head and neck squamous cell 
carcinoma tissue sample, located within the first exon of the Brain and Acute Leukemia, 
Cytoplasmic (BAALC) gene (Figure 5B).  As its name implies, the BAALC gene is 
expressed in the brain and related neural tissues, and it was first identified by association 
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with acute myeloid leukemia where it was shown to be overexpressed [83, 84].  TE 
insertions within exons are extremely rare and would presumably have a dramatic effect 
on gene function.  Indeed, this particular insertion is associated with nearly complete 
inactivation of the BAALC gene.  This is consistent with previous results showing that the 
presence of fixed L1 insertions genome-wide is strongly associated with the down-
regulation of human gene expression [85].  A recent study has demonstrated that BAALC 
can inhibit extracellular signal-regulated kinase (ERK) mediated monocytic differentiation 
of AML cells [86].  Thus, down-regulation of BAALC would presumably result in a loss of 
control over cellular differentiation, consistent with a possible role in tumorigenesis.  A 
recent study discovered a role for the change in methylation status of a cancer-specific L1 
insertion in tumorigenesis (Scott et al., 2016); this could be an additional mechanism by 
which the BAALC L1 insertion observed here exerts a regulatory effect. 
 
2.5 Conclusion 
The results of our analysis show a surprisingly high level of somatic TE activity in 
the human genome.  Abundant transcripts from members of all three active human TE 
families analyzed here – Alu, SVA and L1 – can be identified for both normal and cancer 
tissue samples.  In addition, after filtering for high confidence TE insertion calls, we 
identified an average of close to 80 unique insertions for each tissue among the individual 
patients in our study.  Thus, active human TE families retain the ability to transpose in 
somatic tissue thereby generating substantial levels of cellular heterogeneity among diverse 
tissues. 
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We also observe a correlated increase in both transcript expression levels and 
transpositional activity for L1 elements in cancer tissue samples when compared to 
matched normal tissue.  Increased cancer expression of L1 elements is particularly relevant 
for TE insertional activity, since the L1 transpositional machinery is responsible for 
transposing non-autonomous Alu and SVA elements in trans along with L1 elements in 
cis.  Our results are consistent with previous studies showing expression of L1 transcripts 
in lung cancer [45] and expression of L1 ORF1p in breast cancer [87], and tumor-specific 
L1 insertions have also previously been found in breast (Morse et al., 1988), head and neck 
(Helman et al., 2014), and lung tumors (Helman et al., 2014).  We confirmed the presence 
of numerous tumor-specific L1 insertions in these three cancer types and identify two 
potentially tumorigenic TE insertions, an Alu insertion in the enhancer region of the tumor 
suppressor gene CBL and an L1 insertion in the first exon of the BAALC gene.  These 
results underscore the potential for somatic TE activity to generate cellular heterogeneity 





CHAPTER 3. TRANSPOSABLE ELEMENT INDUCED 
ALTERNATIVE SPLICING IN CANCER 
3.1 Abstract 
Transposable element (TE) derived sequences comprise more than half of the human 
genome, and their presence has been documented to alter gene expression in a number of 
different ways, including the generation of alternatively spliced transcript isoforms.  
Alternative splicing has been associated with tumorigenesis for a number of different 
cancers.  The objective of this study was to broadly characterize the role of human TEs in 
generating alternatively spliced transcript isoforms in cancer.  To do so, we screened for 
the presence of TE-derived sequences co-located with alternative splice sites that are 
differentially utilized in normal versus cancer tissues.  We analyzed a comprehensive set 
of alternative splice variants characterized for 614 matched normal-tumor tissue pairs 
across 13 cancer types, resulting in the discovery of 4,820 TE-generated alternative splice 
events distributed among 723 cancer-associated genes.  SINEs (Alu) and LINEs (L1) were 
found to contribute the majority of TE-generated alternative splice sites in cancer genes.  
A number of cancer-associated genes – including MYH11, WHSC1, and CANT1 – were 
shown to have overexpressed TE-induced isoforms across a range of cancer types.  TE-
induced isoforms were also linked to cancer-specific fusion transcripts, suggesting a novel 
mechanism for the generation of transcriptome diversity via trans-splicing mediated by 
dispersed TE repeats.  
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3.2 Background 
Half or more of the human genome is derived from transposable element (TE) 
sequences, remnants of formerly mobile genetic elements that can replicate to extremely 
high copy numbers over time [88, 89].  TE sequences contribute to human gene regulation 
through a variety of distinct mechanisms [90-93].  Previous work from our own lab has 
documented the presence of TE-derived transcription factor binding sites [94-97], 
enhancers [98-102], chromatin insulators [103], microRNAs [104, 105], and anti-sense 
RNAs [106] along with TE-derived alternative transcription initiation [107-109] and 
termination sites [110].   
The provisioning of alternative splice sites is another way that TEs can contribute to 
the complexity of the human transcriptome [111-113].  A role for TEs in alternative 
splicing of human genes was discovered via classic studies on Alu elements in the early 
2000s.  Investigators from the laboratories of Gil Ast and Dan Graur uncovered evidence 
of Alu-derived splice sites, as well as the inclusion of Alu elements in alternatively spliced 
exons, for a number of human genes [114, 115].  These studies suggested a potential role 
for TE-induced alternative splicing in disease, cancer in particular [116].  Nevertheless, 
compelling proof for such a connection has remained elusive. 
The role of TEs in cancer has received substantial attention as of late [8, 37, 43, 117-
119], and alternative splicing has itself been widely associated with tumorigenesis [12, 
120-126].  As such, it seems reasonable to hypothesize that TE-induced alternative splicing 
could play an important role in cancer.  Despite the seemingly obvious connections among 
– TEs, alternative splicing, and cancer – there has yet to be any systematic analysis on the 
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contribution of TEs to alternative splicing events in tumor tissue.  The goals of this study 
were to (1) survey the global landscape of TE-induced alternative splicing across a variety 
of cancer types, and (2) identify individual cases where TE-derived splice sites are linked 
to splicing (isoform) alterations in cancer. 
We analyzed 614 matched normal-tumor samples pairs for 13 cancer types, 
characterized as part of The Cancer Genome Atlas (TCGA).  Integrated analysis of RNA-
seq data and genome annotations were used to generate a genome-wide atlas of TE-derived 
alternative splice sites, and differential expression analysis of alternative splice variants 
was used to identify ‘isoform switch’ events, with TE-induced splice isoforms that show 
increased utilization in cancer samples.  Our atlas of TE-induced alternative splice variants 
is made available to the research community via the UCSC Genome Browser.  We go on 
to propose a potentially novel mechanism, whereby the dispersed repetitive nature of TE 
sequences facilitates the generation of fusion transcripts via trans-splicing events.  Our TE 
trans-splicing mechanism is admittedly speculative at this time, and we suggest the kinds 




A schematic overview of the analysis pipeline used for this study can be seen in 
Figure 1.  A list of all data sources, programs, and statistical methods used in the study can 
be seen in Table 10. 
 
Figure 6 Bioinformatics analysis pipeline used for this study. 
RNA-seq datasets from 658 paired normal-tumor TCGA samples from 22 cancer types 
were analyzed in this study.  The schematic can be broadly divided into four stages: (row 
1) detection of alternative splicing event and per-exon expression quantification, (row 2) 
identification of TE-derived alternative splicing events for cancer-associated genes, (row 
3) statistical testing for differences in alternative splicing expression levels between 
normal and tumor tissues, and (row 4) evaluation of cases of interest to explore the 
potential functional impact of TE-derived alternative splicing on cancer. 
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3.3.1 Genomic Data 
All analyses are based on the human genome reference sequence build hg19 
(GRCh37).  Genomic coordinates for NCBI RefSeq [127] and Ensembl transcript models, 
i.e. exon/intron boundaries, were taken from the UCSC Genome Browser [128].  Genomic 
coordinates for TE sequences were taken from the RepeatMasker annotations [129].  
Overlap analysis of gene, TE, and alternative splice event coordinates were performed 
using the BEDTools program [71]. 
 
3.3.2 Alternative Splicing 
The Catalogue Of Somatic Mutations In Cancer (COSMIC) Cancer Gene Census 
(CGC) was used to identify cancer-associated genes – oncogenes, tumor suppressor genes, 
and fusion genes – for subsequent alternative splicing analysis [130].  Transcriptome 
(RNA-seq) data for matched normal-tumor sample pairs of individual patients, across a 
variety of distinct cancer types, were taken from from The Cancer Genome Atlas (TCGA) 
for alternative splice site analysis (Figure 25).  RNA-seq data were mapped to the human 
reference genome sequence and processed using the program SplAdder, as previously 
described [122], in order to characterize alternative splice events in cancer-associated 
genes.  Four kinds of alternative splice events were analyzed here: intron retention, exon 
skipping, alternate 3’ splicing, and alternate 5’ splicing (Figure 26).  For all observed 
alternative splice events, two distinct isoforms were defined and quantified.  Isoform 1 and 
isoform 2 are operationally defined as the shorter and longer isoforms, respectively.  Thus, 
isoform 1 corresponds to the TE-derived isoform for exon skipping, whereas isoform 2 
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corresponds to the TE-derived isoform for intron retention, alternate 3’ splicing, and 
alternate 5’ splicing.  
Genomic coordinates for individual alternative splice sites and their corresponding 
isoforms are defined by the presence of overlapping RNA-seq reads for at least three 
individuals.  Individual alternative splice events were characterized across all COSMIC 
genes, and each individual event was quantified as the number of reads mapping to the 
alternatively spliced exon.  This was done for all genes from individual samples 
corresponding to each cancer type and its corresponding matched normal-tumor sample 
pair.  Overlapping alternative splice event isoforms were clustered using single linkage 
clustering based on ≥75% overlap of splice site genomic coordinates, and cluster 
coordinates were defined as the minimum and maximum start and stop sites for the 
individual constituent splice sites.  Alternative splice site cluster counts for all isoforms 
were calculated as the average counts across all individual constituent splice sites within 
any given tissue type.   
 
3.3.3 Differential Expression (Splicing) 
The program DESeq2 was used to normalize alternative splice site cluster counts 
using the variance stabilizing transformation (VST) technique [131].  Differential 
alternative splice isoform expression, between matched normal-tumor sample pairs, was 
measured using relative expression change (REC) and via a 2 x 2 contingency table with 
the G-test.  For each alternative splice event, cluster average count values were computed 
across four conditions: (1) non-TE isoform normal, (2) TE isoform normal, (3) non-TE 
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isoform tumor, and (4) TE isoform tumor.  The relative expression change (REC) value for 
individual alternative splice events are calculated as the normalized difference of the TE 





















 is the average normalized cluster count for the TE-derived isoform 
across all individuals in normal tissue.  The statistical significance of normal-tumor 
differential expression (splicing), i.e. differences in average alternative splice site cluster 
counts, was evaluated using a 2 x 2 contingency table with the G-test: 
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3.3.4 Visualization 
Individual cases TE-derived and differentially expressed alternative splice sites of 
interest were visualized using the UCSC Genome Browser.  Locations of RNA-seq 
characterized alternative splice site clusters were compared to the locations of TE 
sequences and COSMIC gene exon/intron boundaries.  Genomic coordinates of the TE-
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induced alternatively spliced exons characterized here are distributed as a UCSC Genome 
Brower Track hub. 
 
3.4 Results and Discussion 
3.4.1 TE-derived Alternative Splice Sites and Cancer 
We analyzed RNA-seq data for matched normal-tumor sample pairs from 
individual patients in order to characterize the genomic landscape of alternative splicing in 
cancer.  A total of 678 patient samples among 22 different cancer types were considered 
for preliminary analysis; cancer types with <10 patient samples were subsequently 
excluded, yielding a final data set of 614 patients across 13 cancer types (Figure 25) (Table 
3).  We relied on a recently published approach to the characterization of alternative 
splicing in cancer, which has been shown to yield reliable results in terms of both 
characterizing and quantifying individual alternative splice sites and their corresponding 
isoforms [122].  We focused on four distinct types of alternative splicing events – intron 
retention, exon skipping, alterative 3’ splicing, and alterative 5’ splicing (Figure 26) – and 
modified the existing approach to yield tissue-specific counts of alternative splice site 
isoforms for individual patients (see Methods).  








Breast invasive carcinoma BRCA 220 110 
Kidney renal clear cell carcinoma KIRC 144 72 
Thyroid carcinoma THCA 116 58 
Lung adenocarcinoma LUAD 114 57 
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Prostate adenocarcinoma PRAD 104 52 
Liver hepatocellular carcinoma LIHC 100 50 
Lung squamous cell carcinoma LUSC 98 49 
Head and Neck squamous cell 
carcinoma 
HNSC 84 42 
Kidney renal papillary cell 
carcinoma 
KIRP 62 31 
Stomach adenocarcinoma STAD 54 27 
Colon adenocarcinoma COAD 48 24 
Kidney Chromophobe KICH 46 23 
Bladder Urothelial Carcinoma BLCA 38 19 
We then narrowed our analysis to a catalog of 723 known cancer-associated genes 
and focused on alternative splice sites in those genes that are derived from TE sequences.  
TE-derived splice sites were delineated by searching for canonical splice donor and 
acceptor site sequence motifs, located at 3’ and 5’ exon boundaries, that overlap with 
annotated TE sequences (Figure 27).  Human TE sequences were divided into their four 
major classes – SINEs, LINEs, LTR, and DNA (Figure 28) – and the overall extent of their 
contribution to alternative splicing in cancer was evaluated.  TE sequences contribute 
thousands of distinct alternative splice sites genome-wide, ranging from 10.5% of 
alternative 5’ splice events to 14.0% of exon skipping events (Figure 29).  TEs also 
contribute a substantial minority of the of alternative splice sites to cancer-associated 
genes.  Across the 13 cancer types, TE-derived isoforms are a consistent minority, and the 
numbers of alternative splice sites are more similar for TE- versus non-TE-derived 
isoforms, compared to the relatively small differences seen for normal versus cancer 
samples (Figure 7A).   
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Figure 7 Overall landscape of TE-derived alternative splicing in cancer. 
(A) Dot-and-whisker plot comparing the distribution of TE and non-TE isoforms in cancer-
associated genes in normal (blue and light blue) and tumor (red and light-red) tissues 
across all samples within each cancer type.  The median number of events are shown as 
dots and the outliers (defined classically as 1.5 x interquartile range) are shown as 
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whiskers.  (B) Counts of the total number of unique TE and non-TE isoforms in cancer-
associated genes is shown by the event type and TE class.  (C) The observed counts of TE 
isoforms in cancer-associated genes for each event type and TE class is compared to 
expected counts. 
At first glance, the overall landscape of TE-derived splicing isoforms in cancer-
associated genes suggests the possibility that TE contributions to alternative splicing in 
cancer may not be very biologically significant.  However, when alternative splicing events 
in cancer-associated genes are broken down by event type and TE-class, the potential 
contribution of TEs becomes more apparent.  This is because for any given splice site where 
a TE is present, the numbers of TE-derived splice isoforms tend to outnumber the non-TE-
derived isoforms (Figure 7B).  This holds true for three out of the four alternative splice 
event types; for intron retention, the non-TE-derived isoforms are more common.  Finally, 
it is interesting to note that there is no particular enrichment for the contributions of any 
given TE class to any of the four kinds alternative splice site events.  The observed numbers 
of TEs from each class that contribute to these events are very similar to the expected 
numbers based on their background frequencies within cancer-associated genes (Figure 
7C). 
 
3.4.2 Differential Expression of TE-derived Splice Sites 
We analyzed differences in the expression levels of alternative splice sites between 
matched normal-tumor sample pairs in an effort to evaluate the effects of individual TE-
derived splice sites on cancer.  The expression levels of individual alterative splice sites, 
and their corresponding isoforms, were quantified via normalized counts of mapped RNA-
seq reads as detailed in the Methods section.  For any given TE-derived splice site, there 
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are four possible expression counts for any individual patient: (1) non-TE isoform normal, 
(2) TE isoform normal, (3) non-TE isoform tumor, and (4) TE isoform tumor.  Expression 
counts for these four conditions can be averaged across individuals to measure the relative 
expression changes (REC) of TE-derived isoforms in tumor compared to normal tissue and 
to evaluate the significance of this difference (Figure 30).  Distributions of REC values for 
the four types of TE-derived splice sites across the 13 cancer types are shown in Figure 8.  
For the most part, these distributions are tightly clustered around the median value of 0, or 
no relative change, with sparsely populated tails that contain individual cases of potential 
interest.  We evaluated a number of these outlier genes, with highly differentially expressed 
alternative splice isoforms in matched normal-cancer samples (Table 4), in an effort to 
explore potential functional implications of TE-derived splice sites in cancer. 
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Figure 8 Differential expression of TE-derived alternative splice isoforms in tumor 
versus normal samples. 
Distributions of the relative expression counts (REC) comparing TE-derived to non TE-
derived alternative splice isoforms in tumor versus normal samples.  The formula for REC 
is described in the Methods and in Figure 30.  Data are shown for 13 cancer types and 4 
alternative splice event types.  Each dot represents an REC value derived from the average 
normalized expression counts of the TE- and non TE-derived isoforms in normal and 
cancer samples.  Higher expression (counts) of the TE-derived isoform in tumor are shown 
on the right side of the panels, whereas lower expression is shown to the left. 
 
3.4.3 Potential Functional Implications of TE-derived Splice Sites in Cancer 
One particular result that stood out from this analysis was the observation that a 
few cancer-associated genes have extremely high counts of TE-derived alternative splicing 
events (Figure 9).  The Kallikrein Related Peptidase 2 encoding gene KLK2 shows more 
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than twice as many TE-derived alternative splice sites compared to the second rank gene 
on this list.  The KLK2 protein is primarily expressed in the prostate and has been shown 
to promote prostate cancer cell growth [132]. The connection between TE-derived 
alternative splicing and cancer is supported by the fact that all of the TE-derived isoforms 
observed here were identified in prostate adenocarcinoma samples.  Alternative splicing of 
the KLK2 gene results in fusions with ETV1 and ETV4 in prostate cancer, and all of the 
known fusion transcripts for these genes are missing exon 3 of KLK2 [133, 134].  
Interestingly, exon skipping events are by far the most abundant TE-derived splice 
isoforms seen for this gene (Figure 9).  The large number of putative TE induced alternative 
splicing events in KLK2, specifically exon skipping, suggests TEs could play an important 
role in the manifestation of KLK2 fusion transcripts and their contribution to prostate 
cancer.  Given their dispersed repetitive nature, it is possible that TE sequences serve as 
hotspots for the generation of fusion transcripts in cancer.  We further explore this potential 
model for transcriptome diversification by TE sequences in the Conclusion section.     
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Figure 9 Frequency of TE-derived alternative splice events for individual genes. 
The total numbers of alternative splice counts per exon are shown for each cancer-
associated gene, broken down by the four alternative splice event types.  Genes with the 
highest counts of TE-derived alternative splice events across all cancer types are shown. 




Cancer Type %NT %TT 
Event 
Type 
467 MYH11 2 Lung squamous cell carcinoma 6.5 51.8 Alt3 
412 CANT1 2 Stomach adenocarcinoma 67.3 37.4 Exon 
132 WHSC1 1 Stomach adenocarcinoma 73.1 42.8 Exon 
412 CANT1 2 Breast invasive carcinoma 53.5 32.1 Exon 
154 KMT2D 1 Stomach adenocarcinoma 21.3 31.8 Alt5 
397 POLG 4 Stomach adenocarcinoma 34.8 54.6 Alt3 
397 POLG 4 Bladder Urothelial Carcinoma 34.8 47.6 Alt3 
261 PML 2 
Kidney renal papillary cell 
carcinoma 
57.2 70.3 Intron 
261 PML 2 Breast invasive carcinoma 47.0 59.6 Intron 
261 PML 2 Kidney Chromophobe 65.5 75.8 Intron 
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The Myosin Heavy Chain 11 gene MYH11 encodes part of a hexameric protein that 
functions as a major contractile complex, converting chemical energy into mechanical 
energy through the hydrolysis of ATP.  MYH11 has been shown to contribute to 
tumorigenesis in both leukemia and non-small cell lung cancer (NSCLC) [135].  MYH11 
undergoes alternative splicing, yielding isoforms that are differentially expressed in tumor 
samples [136].  MYH11 is also implicated in cancer-associated gene fusion events; for 
example, the CBFB-MYH11 gene fusion plays an important role in leukemogenesis [137-
139].  Here, we observe differential isoform expression of MYH11 across 49 paired normal-
tumor lung squamous cell carcinoma tissues, whereby a SINE (Alu) induces an alternative 
3' splicing event that yields a longer version of exon 41 (Figure 10a).  The longer SINE-
derived isoform makes up 6.5% of the transcript population in normal samples compared 
to 51.8% in tumor samples (Figure 10b-c). 
 44 
 
Figure 10 TE-derived alternative splicing in the MYH11 gene. 
(A) The location of MYH11 on the short arm of chromosome 16 is shown along with the 
specific location of its TE-derived alternative splicing event.  A SINE (Alu) sequence 
provides an alternate 3’ splice site resulting in an extended exon 41.  (B) Distributions of 
the non-TE (blue) and TE-derived (red) isoforms are shown for matched normal (left) and 
lung squamous cell carcinoma samples (right).  (C) Relative expression change (REC) 
values are plotted against the corresponding G-test P-values (see Methods and Figure 30) 
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for the matched normal and lung squamous cell carcinoma samples.  The MYH11 TE-
derived isoform values are shown as a red square. 
The Wolf-Hirschhorn Syndrome Candidate 1 Protein gene WHSC1, also known as 
the Nuclear Receptor Binding SET Domain Protein 2 gene (NSD2), encodes a histone 
methyltransferase that catalyzes the dimethylation of histone 3 lysine 36 (H3K36).  WHSC1 
expression is important for the epithelial-mesenchymal transition and metastasis in gastric 
cancer [140], and it is overexpressed in a number of different cancer types [141]. WHSC1 
has been shown to undergo complex alternative splicing.  Most of the primary transcripts 
of WHSC1 initiate from exon 3, which contains the proper translation initiation site, 
although a small fraction of transcripts retain upstream non-coding sequences including 
exons 1 and 2 [142].  Here, we identified a LINE (L1) element apparently responsible for 
an exon skipping event in exon 3, which occurs much more frequently in stomach 
adenocarcinoma primary tumor tissues (57%) when compared to matched normal tissues 
(27%) (Figure 11).       
 46 
 
Figure 11 TE-derived alternative splicing in the WHSC1 gene. 
(A) The location of WHSC1 on the short arm of chromosome 4 is shown along with the 
specific location of its TE-derived alternative splicing event.  A LINE (L1) sequence results 
in an exon skipping event.  (B) Distributions of the non-TE (blue) and TE-derived (red) 
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isoforms are shown for matched normal (left) and stomach adenocarcinoma samples 
(right).  (C) Relative expression change (REC) values are plotted against the 
corresponding G-test P-values (see Methods and Figure 30) for the matched normal and 
stomach adenocarcinoma samples.  The WHSC1 TE-derived isoform values are shown as 
a red square. 
The Calcium Activated Nucleotidase 1 encoding gene CANT1 is overexpressed in 
prostate cancer and thought to be involved in proliferation, DNA synthesis, cell cycle, and 
migration of prostate cancer cells [143].  CANT1 is known to undergo alternative splicing, 
with three well-defined isoforms.  Here, we observe a novel exon skipping event, which 
appears to be induced by both SINE and LINE elements and results in a differentially 
expressed isoform, found at 32.7% in normal samples and 62.6% in stomach 
adenocarcinoma tumor samples (Figure 31).   
 
3.5 Conclusions 
Our global survey of TE-induced alternative splicing in cancer revealed that TE 
sequences contribute widely to alternate splice sites in cancer-associated genes, including 
cases where the TE isoforms are relatively overexpressed in tumor tissue.  We hope that 
the landscape of TE-derived splice sites uncovered by our study can serve as a resource for 
further investigations into the role of TEs in tumorigenesis, and we have created a database 
of the TE-derived splice sites discovered here to facilitate follow-up studies on TE-induced 
alternative splicing.  The data are distributed as a ‘Track data hub’ [144] on the UCSC 




The tracks show the genomic locations of the TE-induced alternative splicing events, 
with a separate track for each of the four splicing event types.  The tracks can be used for 
visual inspection of individual events of interest or for more large-scale studies via 
download with the Table Browser. 
One of the more intriguing results uncovered by our study was the potential 
connection between TE-induced alternative splicing and cancer fusion genes.  
Tumorigenesis is often characterized by large-scale genome rearrangements, and cancer 
fusion genes are thought to result from translocations, which bring genes that are normally 
far apart in the genome into close physical proximity.  Our results showed numerous 
alternatively spliced exons that correspond to gene fusion junctions, particularly for the 
KLK2 gene that experiences both promiscuous alternative splicing and several gene fusion 
events, and these exons have previously been implicated in gene fusion events.  We 
propose a model whereby apparent gene fusions actually occur at the transcript level via 
trans-splicing facilitated by TE sequences. 
Pre-mRNA sequences destined for splicing are bound by heterogeneous 
ribonucleoprotein particle (hnRNP) proteins, which prevent the formation of short 
secondary structures caused by base pairing of complementary regions in the pre-mRNAs.  
In this way, the bound hnRNPs ensure that pre-mRNAs remain accessible for the assembly 
of the spliceosome.  It occurs to us that hnRNP bound pre-mRNAs will also be open to 
trans interactions with pre-mRNAs from different loci, if they possess complementary 
sequences.  Trans-splicing is the phenomenon whereby the splicing machinery joins splice 
donor and acceptor sites from different pre-mRNAs that are co-bound in the same 
spliceosome, yielding fused mature mRNAs.  We propose that TE dispersed repeats 
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provide complementary sequences for binding between pre-mRNAs from different loci, 
thereby serving as hot spots for trans-splicing.  We envision this mechanism as an RNA 
level analog of ectopic recombination between dispersed TE DNA sequences and a 
potential driver of transcriptome diversity. 
It is important to note that our model of TE-induced trans-splicing for the generation 
of fusion transcripts is speculative and only suggested by our data.  A number of additional 
analyses would need to be conducted to validate this model.  DNA sequence analysis is 
needed to distinguish genome level rearrangements in cancer tissue from transcript fusions.  
TE homology (i.e. sequence complementarity) between transcript fusion partners, co-
located with fusion junctions, would need to be confirmed.  Explicit reconstruction of entire 
fusion transcript models, as opposed to individual alternative splice event analysis as was 
done here, needs to be performed to fully characterize observed gene fusions.  Finally, it 
will be important to avoid RNA-seq experimental artifacts caused by template switching 




CHAPTER 4. TUMOR SUPPRESSOR GENES AND ALLELE-
SPECIFIC EXPRESSION: MECHANISMS AND SIGNIFICANCE 
4.1 Abstract 
LoF TSG alleles are shown to be segregating in world-wide populations of 
normal/healthy individuals at remarkably high frequencies, thereby establishing the 
potential importance of these genes in pre-disposing otherwise healthy individuals to 
cancer. To directly evaluate the possible contribution of the ASE of tumor suppressor LoF 
alleles in cancer onset/progression, matched sets of normal and tumor tissues isolated from 
233 cancer patients representing 4 diverse tumor types were analyzed. The results indicate 
that there are functionally important changes in patterns of ASE in individuals 
heterozygous for LoF TSG alleles associated with cancer onset/progression. While a 
variety of molecular mechanisms were identified as potentially contributing to changes in 
ASE patterns in cancer, changes in DNA copy number and allele-specific alternative 
splicing mediated by anti-sense RNA emerged as a predominant factors. 
 
4.2 Introduction 
The long-standing belief that cancer is a genetic disease driven by mutations in a 
select set of oncogenes and/or tumor suppressor genes (aka, "cancer driver" genes) [145-
149], has been augmented in recent years to incorporate the auxiliary contribution of 
changes in a variety of regulatory controls [150-152]. Recent findings indicate that these 
 51 
additional regulatory controls may, in at least some instances, manifest as allele-specific 
expression (ASE) at specific cancer driver gene loci [153, 154]. ASE is the phenomenon 
whereby two or more gene alleles are differentially expressed with respect to one another 
[155, 156]. The potential clinical consequences of ASE have been previously documented 
[157, 158] including emerging evidence for the potential contribution of ASE to cancer 
[154, 159]. 
 If cancer driver mutations can be transcriptionally repressed/de-repressed in an 
allele-specific manner, it follows that cancer driver mutations may be necessary but not 
always sufficient for onset and progression of the disease.  For example, cancer driver 
mutations may, to a greater or lesser extent, be repressible and thus segregating at higher 
than expected frequencies in populations of normal healthy individuals. In addition, 
regulatory modulations in the ASE of cancer driver mutations may themselves, in at least 
some instances, be a significant contributor to cancer onset and progression. Of particular 
interest, in this regard, are those genes where loss-of-function (LoF) mutations have been 
shown to drive cancer onset/progression. This class of cancer driver genes is commonly 
known as tumor suppressor genes (TSGs) because a functional wild-type allele is 
considered sufficient to "suppress" the cancer driver effect of LoF alleles in heterozygotes.  
While LoF tumor suppressor mutations are typically considered to be recessive [160, 161], 
if these mutant alleles can be significantly differentially expressed relative to wild-type 
alleles in heterozygotes, the clinical consequences could be significant.  
 In this study, we first demonstrate that LoF TSG alleles are segregating in world-
wide populations of normal/healthy individuals at remarkably high frequencies, thereby 
establishing the potential importance of these genes in pre-disposing otherwise healthy 
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individuals to cancer. To directly evaluate the possible contribution of ASE of tumor 
suppressor LoF alleles in cancer onset/progression, we analyzed matched sets of normal 
and tumor tissues isolated from 233 cancer patients representing four diverse tumor types. 
The results indicate that there are functionally important changes in ASE in individuals 
heterozygous for LoF TSG alleles associated with cancer onset/progression. While a 
variety of molecular mechanisms were identified as potentially contributing to changes in 
ASE in cancer, changes in DNA copy number and allele-specific alternative splicing 
mediated by anti-sense RNA emerged as a predominant factor. 
 
4.3 Results 
4.3.1 Tumor Suppressor Mutations are Abundant in Human Populations  
The Catalogue Of Somatic Mutations In Cancer (COSMIC) is the world’s largest 
database of somatic mutations associated with cancer onset and progression [72].  To 
determine the extent to which cancer associated mutations are segregating in the general 
human population, the genomic locations of all coding mutations in COSMIC census genes 
were intersected with sequence variants identified in individuals comprising the Phase 3 
release of the One Thousand Genomes Project (1KGP) .  The Phase 3 release catalogues 
all of the genetic variants present in 2504 putatively healthy individuals, representing a 
diversity of racial and ethnic groups randomly selected from 26 human populations around 
the world.  
 53 
 Remarkably, all individuals in the 1KGP were found to contain at least 31 
homozygous and 68 heterozygous COSMIC census mutations (Figure 32). In total, 2,296 
and 3,123 COSMIC census mutations were found in oncogenes and tumor suppressor 
genes, respectively, in healthy individuals. However, since the functional significance of 
all COSMIC mutations is not yet known and the fact that gain-of-function (dominant) 
mutations are difficult to unambiguously identify [162, 163], we focused our subsequent 
analyses on COSMIC mutations in TSGs that could be definitively classified as deleterious 
(i.e., non-sense, frame-shift, deletion mutations), along with all missense mutations 
predicted to be damaging by both The Sorting Intolerant from Tolerant (SIFT) [164] and 
Polymorphism Phenotyping v2 (PolyPhen-2) [165] algorithms. Employing this more 
conservative metric, 448 LoF COSMIC census mutations (Table 11) in TSGs were 
identified, of which ~93% of individuals carried at least one (Figure 12a). These 448 LoF 
mutations mapped to 137 different TSGs in at least one individual and 4 of these TSGs: 
Cbl Proto-Oncogene C (CBLC), Cadherin 11 (CDH11), Leucine Zipper Like Transcription 
Regulator 1 (LZTR1), and Tet Methylcytosine Dioxygenase 2 (TET2) had LoF mutations 
in >25% of the population (Figure 12b). Collectively, these findings indicate that genetic 
variants previously characterized as "cancer driver" mutations are segregating at relatively 
high frequencies in populations of individuals not afflicted with the disease. 
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Figure 12 Distribution of LoF COSMIC census mutations in TSGs of the 1KGP. 
Cancer associated mutations were identified in the 1000 genomes population (1KGP) as 
detailed in the Materials and Methods. a, Pie chart depicting the percent of the 1KGP 
containing deleterious cancer associated mutations in at least one TSG. b, Four TSGs most 
frequently mutated (LoF) in 1KGP. 
 
4.3.2 A Minority (<20%) of TSGs Display Genetic Profiles in Cancer Consistent with 
Knudson’s Two-Hit Hypothesis 
Given the relative abundance of TSG LoF alleles in human populations, we utilized 
the The Cancer Genome Atlas (TCGA) database [166] to explore the possible contribution 
of these genes to cancer onset and/or progression by examining matched sets of cancer and 
normal tissues collected from 233 cancer patients representative of four diverse cancer 
types (breast invasive carcinoma, head and neck squamous cell carcinoma, lung 
adenocarcinoma, and thyroid carcinoma). According to a model first proposed by Alfred 
Knudson in 1971 [167], newly arising LoF TSG mutant alleles, being recessive, can be 
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carried by normal cells with little significant negative effect. According to this model, 
acquisition of a second LoF mutation in the alternate wild-type allele is pre-requisite for 
tumor onset. 
 To test this hypothesis in our dataset, we genotyped all samples and identified TSGs 
that were heterozygous for a LoF mutation in normal tissues but that have acquired a 
secondary LoF mutation in the wild-type allele in the tumor samples. In total we found that 
only 46 of the 233 cancer patients (19.7%) were associated with acquisition of 
homozygosity in cancer for LoF alleles at TSG loci consistent with Knudson’s "two-hit" 
hypothesis. These results indicate that the vast majority of TSGs heterozygous for wild-
type and LoF alleles in normal tissues remain heterozygous in tumor tissue. However, if 
recessive LoF alleles can be significantly overexpressed relative to the wild-type alleles in 
an ASE fashion, LoF TSGs may be significant contributors to cancer onset/progression 
even in the heterozygous state. 
 
4.3.3 The Proportion of LoF Mutations Displaying ASE is Significantly Elevated in 
Cancer Tissues 
To explore the possible contribution of ASE in matched sets of normal and cancer 
tissues, we employed DNA-seq data from the TCGA database to identify all heterozygous 
sites in the exome and subsequently leveraged complementary RNA-seq data to compare 
the expression of wild-type or "reference" (ref) vs LoF mutant or "alternative" (alt) alleles 
at those loci (Figure 33). 
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 The proportion of COSMIC census mutations (SNPs-single nucleotide 
polymorphisms) in TSGs displaying ASE was found to be significantly higher in the cancer 
relative to normal tissues for breast invasive carcinoma, head and neck squamous cell 
carcinoma, and lung adenocarcinoma (P < 3.11 x 10-10) (Figure 13). Thyroid carcinoma 
was the only cancer type not displaying a significant difference, perhaps because these 
cancers are typically associated with a relatively low mutation rate [168]. To determine if 
this regulatory change was limited to TSG loci, we computed ASE for all heterozygous 
SNPs (het-SNPs) exome-wide. We found that all genes, on average, contain a significantly 
higher proportion of het-SNPs displaying ASE in breast, lung, head & neck (P < 3.46 x 10-
15) and thyroid (P < 0.005) tumors than normal samples (Figure 13). Thus, dysregulation 
in cancer, at least as manifest by ASE, is not limited to TSGs but extends to genes not 
previously identified as being implicated in tumorigenesis. 
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Figure 13 Distribution of the Proportion of ASE Loci. 
Allele counts were generated for normal and primary tumor tissue pairs for breast invasive 
carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma and thyroid 
carcinoma via analysis of RNA-Seq as described in the Materials and Methods section. 
Boxplots show the distribution of the of the proportion of COSMIC Census mutations in 
TSGs (left), all heterozygous SNPs in Non-TSGs (center) and all het-SNPs (right) with 
significant ASE (FDR = 5%, P < 0.005) in normal (blue) and tumor (red) samples. 
 
4.3.4 Differences in Patterns of ASE Between Normal and Tumor Tissues Includes but is 
not Limited to TSGs 
Changes in the relative expression of wild-type (ref) alleles vs. mutant (alt) alleles 
between normal and cancer tissues may manifest in one of six alternative ASE patterns: 
Pattern 1: No significant difference in ASE (ref=alt) in normal tissues but significant ASE 
(ref<alt) in cancer tissues; Pattern 2:  Significant ASE in normal tissues  (ref>alt) but no 
significant ASE (ref=alt) in cancer tissues; Pattern 3: Significant ASE in normal sample 
(ref>alt) and significant ASE in tumor sample (ref<alt); Pattern 4: No significant ASE in 
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normal tissues (ref=alt) but significant ASE in cancer tissues (ref>alt); Pattern 5: 
Significant ASE (ref<alt) in normal tissues but no significant ASE in cancer tissues 
(ref=alt); Pattern 6: Significant ASE in normal (ref<alt) and in cancer tissues (ref>alt) 
(Figure 14a). Patterns 1-3 are potentially of the most significance to cancer 
onset/progression because, in each case, the expression of the cancer driver LoF mutant 




Figure 14 ASE SNP Patterns. 
Allele counts were generated for normal and primary tumor tissue pairs for breast invasive 
carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma and thyroid 
carcinoma via analysis of RNA-Seq as described in the Materials and Methods section. 
Sites demonstrating significantly different ASE ratios (P < 0.05) between normal and 
tumor sample pairs that follow a tumorigenesis model are color coded by expression 
pattern as demonstrated in panel a. a, Six ASE patterns of interest were analyzed; Pattern 
1: no significant ASE in normal sample and significant ASE (ref<alt) in tumor; Pattern 2:  
significant ASE (ref>alt) in normal sample and no significant ASE in tumor; Pattern 3: 
significant ASE in normal sample (ref>alt) and significant ASE in tumor sample (ref<alt); 
Patterns 4-6 mirror Patterns 1-3 with the opposite allele over expressed. Significant ASE 
(FDR = 5%, P < 0.005) was determined using a binomial test within samples in order to 
group loci into patterns. b, Reference allele ratios (ref/total) for all COSMIC Census loci 
in TSGs intersecting normal and tumor sample pairs, for 233 TCGA participants are shown 
here. c, Reference allele ratios (ref/total) for all loci intersecting normal and tumor sample 
pairs, for 233 TCGA participants are shown here.  
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 The observed changes in ASE between matched sets of normal and cancer tissues 
for each of our 233 patients grouped into their respective Patterns, is presented in Table 5. 
A significant percentage of mutations in TSGs were found to display various patterns of 
ASE (FDR = 5%, P < 0.005; breast 14.9%, head and neck 16.0% and lung 19.6%) with 
Patterns 1 and 4 being the most predominant (see also Figure 14b). Thyroid cancer again 
stood out as an outlier where only 4.1% of mutations in TSGs were found to display ASE 
with Patterns 1 (2.3%) and 5 (1.3%) being nearly equally abundant. 
Table 5 Percent of SNPs displaying ASE in 233 TCGA patients. 






1 7.3 7.6 7.3 7.0 8.3 
2 0.4 0.8 0.3 0.4 1.4 
3 0.1 0.2 0.0 0.0 0.3 
4 3.8 4.1 3.7 3.4 4.8 
5 2.6 2.5 2.8 2.2 2.7 
6 0.5 0.5 0.8 0.4 0.4 






1 8.7 9.7 10.5 10.1 8.3 
2 0.4 0.4 0.0 0.0 0.9 
3 0.2 0.3 0.0 0.0 0.6 
4 4.6 4.5 3.7 4.2 4.7 
5 2.1 1.7 1.3 1.2 2.0 
6 0.7 1.0 0.5 0.9 1.0 






1 9.7 10.7 9.2 9.8 12.0 
2 0.3 1.0 0.1 0.0 2.0 
3 0.2 1.0 0.0 0.0 1.9 
4 5.4 6.8 7.0 6.5 6.9 
5 1.9 2.3 2.2 1.6 2.7 
6 0.7 0.8 1.1 0.6 0.9 






1 2.1 2.3 2.3 1.7 2.6 
2 0.2 0.5 0.0 0.1 1.0 
3 0.0 0.0 0.0 0.0 0.0 
4 0.5 0.8 0.5 0.4 1.1 
5 1.6 1.9 1.3 2.0 2.1 
6 0.1 0.0 0.0 0.0 0.0 
No ASE 95.5 94.5 95.9 95.8 93.2 
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 When the analysis was extended to include all transcribed genes (“%Total SNPs” 
in Table 5), a similar trend was observed, where 14.8%, 16.6% and 18.3% of all het-SNPs 
were found to display ASE in breast, head and neck and lung cancers, respectively. Thyroid 
cancer was again an outlier with only 4.5% of all transcribed genes displaying ASE (Figure 
14c). Collectively these results indicate that changes in ASE in cancer are widespread and 
not limited to TSGs. 
To explore this apparent dysregulation of COSMIC census mutations in TSGs 
further, we aggregated our SNP ASE data to quantify ASE of the entire allele of a gene by 
employing the Meta-analysis Based Allele-Specific Expression Detection (MBASED) 
protocol [154]. We found 14.4%, 17.9%, 20.4% and 5.7% of all TSGs show ASE in breast, 
head and neck, lung and thyroid cancers, respectively (Table 22). These results are 
consistent with the relative levels of ASE detected within SNPs in these cancers with 
Pattern 1 again emerging as a predominant pattern (9.1%, 11.1%, 13.2%, and 2.8%) (Table 
22). 
One example of those TSGs displaying changes in patterns of ASE in cancer is the 
Human Leukocyte Antigen A1 gene (HLA-A).  HLA-A has been previously identified as 
a hotspot for ASE activity [169], likely due to the high genetic variability that is well-
documented in the major histocompatibility complex [170, 171]. We detected changes in 
ASE in the HLA-A gene in 20% of our patients including nucleotide positions not 
previously reported to display ASE [172].  
Another example is Tumor Protein P53 (TP53) that displayed the highest level of 
ASE in our breast cancer patients (57.9% of all patients) displaying Pattern 4 63.6% of the 
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time (Figure 15). Additionally, breast cancer implicated TSGs Breast cancer type 1 
susceptibility protein (BRCA1) and Cadherin 1 (CDH1) were found to display changes in 
ASE in 15.4% and 32.4% of breast tumors, respectively, frequently displaying Pattern 1 
(Figure 15). Interestingly, Zinc Finger Protein 331 (ZNF331) was the only TSG 
predominately displaying Pattern 2 (Figure 15). A previous study [173] has shown ZNF331 
to display large amounts of ASE in breast cancer, citing genomic imprinting as a possible 
explanation [174]. 
 
Figure 15 Tumor suppressor genes with ASE in breast cancer patients. 
Gene level ASE was computed as described in the Materials and Methods section.  The 
proportion of breast cancer patients with ASE in 115 TSGs. 
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The four TSGs: CBLC, CDH11, LZTR1, and TET2 previously shown to be most 
frequently mutated in 1KGP (Figure 12b) were also observed to display changes in ASE 
in breast cancer (Figure 15). Similar trends in the frequency of ASE Patterns among TSGs 
were observed in head and neck, lung, and thyroid cancers, with thyroid again sporting the 
least amount of ASE (Figure 34). 
 
4.3.5 Changes in DNA Allelic Ratios May Explain up to 35% of the Observed Changes 
in ASE Between Normal and Cancer 
Perhaps the most straight-forward explanation of the observed changes in ASE in 
cancer is that it is a reflection of underlying changes in allele counts on the DNA level. For 
example, it is known that the duplication or deletion of alleles on the DNA level can 
contribute to ASE in cancer [153, 175]. In addition, the polyclonal heterogeneity of most 
tumors can manifest as an imbalance in DNA allele counts and associated ASE changes in 
analyses carried out on bulk tumor samples. 
 To explore the extent to which changes in DNA copy number may be contributing 
to the observed ASE in our samples, we downloaded whole-exome sequencing data (WXS) 
for nine randomly selected patients representing each of the three cancer types displaying 
the highest level of ASE (breast invasive carcinoma, lung adenocarcinoma, and head & 
neck squamous cell carcinoma) (Table 23). We ensured these individuals displayed ASE 
in COSMIC genes (Figure 35) and that their ASE was evenly spread throughout the 
genome (Figure 36). We found that, on average, 35.2% (45.7% Breast, 25.8% Head and 
Neck, and 20.5% Lung) of ASE genes displayed DNA allele counts that correlated with 
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RNA allele counts (Table 6). Further, investigation of these samples revealed that only 
10% of these genes displayed copy number duplications potentially accounting for their 
ASE (Figure 16a). Collectively these findings indicate that while, on average, a large 
fraction of our observed changes in ASE may be accounted for by corresponding changes 
in DNA allele counts, a significant fraction of ASE in cancer is likely attributable to allele-
specific changes in gene regulation. 
 
Figure 16 Mechanisms of ASE. 
Potential underlying mechanisms for ASE were explored as outlined in the Materials and 
Methods.  Pie chart depicts amount of ASE which could be attributed to a, tumor 
heterogeneity and copy number variation (CNV) b, cis-eQTLs, c, DNA methylation and d, 
exon-skipping via computational analysis. 
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Table 6 ASE patterns potentially explained by DNA counts. 
Patient 
ASE SNPs explained 
by DNA counts 
Total ASE SNPs 
Percentage of ASE 
correlated 
Breast 1 526 1336 39.4 
Breast 2 719 1411 51.0 
Breast 3 177 367 48.2 
Head & Neck 1 275 930 29.6 
Head & Neck 2 179 674 26.6 
Head & Neck 3 217 993 21.9 
Lung 1 56 233 24.0 
Lung 2 47 155 30.3 
Lung 3 11 167 6.6 
Total 2207 6266 35.2 
 
4.3.6 Allele-specific cis-Regulatory Variation may Account for a Small Fraction of 
Observed Changes in ASE Between Normal and Cancer 
Allele-specific regulatory changes in gene expression could be explained by 
sequence variation mapping to cis-regulatory regions located up- or down-stream of 
affected genes [20, 176, 177].  To explore the extent to which allele-specific cis-regulatory 
variation may account for ASE in cancer, we identified expression-quantitative trait loci 
(eQTLs) present in six of our nine patients’ normal and tumor samples using the Genotype-
Tissue Expression Project’s (GTEx) single tissue cis-eQTL data available for breast and 
lung tissue [178]. eQTLs are regions of the genome containing DNA sequence variants 
previously established to regulate gene expression levels [179]. Genes previously 
established to be regulated by at least one eQTL are classified as eGenes [180, 181].  
 Genes displaying ASE in our study were found to be significantly enriched for 
eGenes relative to genes not displaying ASE (P = 0.018) (Figure 37). This finding was 
pronounced for breast (P = 2.56 x 10-6) and lung cancer (P = 6.22 x 10-4) patients (Figure 
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37). However, collectively only 24% of genes displaying ASE in our dataset are eGenes 
and just 3% of ASE eQTLs are ASE-specific (i.e., found only in genes o ASE). Moreover, 
we found that the expression slope of an eQTL is not often correlated with the allelic 
expression of a gene (1.8%; Figure 16b; Table 25). For example, consider the heterozygous 
eQTL variant (rs10654) mapping to the 3' UTR of the NUP54 gene in both normal and 
tumor samples of breast cancer patient 2 (TCGA-BH-A0BW). Despite being heterozygous, 
this eQTL is not associated with ASE in the normal tissue but is associated with ASE in 
cancer tissue where the alternative haplotype is overexpressed and in phase with the highly 
expressed alternative eQTL allele (Figure 38a). 
 We also pursued the eQTLs differing in genotype between normal and tumor 
samples for specific evidence of cis-regulation. While infrequent, we did find several 
notable cases where eQTL genotypes correlated with ASE. Shown in Figure 38b, is a 
model for how cis-eQTLs may be responsible for the intragenic ASE we observed. In this 
particular example, three separate eQTLs within a 50bp region (rs34176173, rs12085114, 
rs34016668) are found ~4.8k base pairs from the 3’ UTR of the gene NME7 in breast 
invasive carcinoma patient 3 (TCGA-BH-A0DT). The eQTL is homozygous for the ref 
allele in the normal sample that does not show ASE, and heterozygous in the tumor sample. 
The eQTL alternative allele that is associated with high expression of NME7 is present on 
the alt haplotype being overexpressed. Further, all three eQTLs are in linkage 
disequilibrium with the ASE SNP (r > 0.42) suggesting they segregate together. We found 
four additional cases where cis-eQTLs could account for ASE but none of these were 
associated with COSMIC census genes. 
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Collectively, the above findings indicate that while allele-specific cis-regulatory 
variation may account for some instances of ASE, it alone does not explain the vast 
majority (>75%) of instances of ASE in our dataset. 
 
4.3.7 Changes in Methylation may Account for a Small Fraction of Changes in ASE 
Between Normal and Cancer 
Another possibility is that ASE is regulated epigenetically. For example, it has been 
previously suggested that epigenetic inactivation of one of the two alleles could result in 
ASE [182]. Epigenetic effects across chromosomes are often regionally associated with 
CpG repeats or "CpG islands" [183-185]. To determine if genes displaying ASE in our 
dataset display evidence of regional chromosomal clustering, we visualized the genomic 
locations of ASE for nine patients on a genome ideogram (Figure 36). The results provide 
no evidence for regional chromosomal clustering indicative of regional epigenetic effects.  
To further search for evidence of epigenetic involvement in ASE in our dataset, we 
analyzed global DNA methylation sites in normal and cancer tissues since this is a common 
mechanism by which gene transcription can be repressed epigenetically [186-188]. 
Methylation data were downloaded from TCGA for seven of the nine patients described 
above and used to compare genes that had a significant change in methylation with genes 
showing a significant change in ASE.  We found that only 10.2% of genes displaying ASE 
also displayed significant differences (>1.3-fold) in methylation between normal and tumor 
tissues (Figure 16c; Table 25). Although these results indicate that changes in methylation 
are not likely to be playing a significant role in the ASE detected in our patient samples, 
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the analysis cannot be considered definitive because the methylation data provided by 
TCGA are not allele specific. 
 
4.3.8 A Significant Fraction of Changes in ASE Between Normal and Cancer may be a 
Reflection of Underlying Alternative Splicing Events Induced by Anti-sense RNA 
A recent study has implicated allele-specific alternative splicing as a potentially 
significant factor in ASE [189]. For example, consider a scenario where an allele-specific 
exon-skipping event occurs more frequently in a cancer tissue than normal (Figure 39).  
This would result in a negligible difference in the level of transcripts containing the wild-
type (ref) and LoF mutant (alt) allele in normal but significantly fewer transcripts 
containing the wild-type allele ("T allele" in Figure 39) in cancer. 
 To explore the possibility that allele-specific alternative splicing may be 
contributing to the observed ASE in our patient samples, we leverage previously computed 
isoform counts for TCGA patient data [122]. Specifically, we sought to determine if there 
is a significant increase in exon skipping in genes displaying ASE. The results indicate that 
70% of SNPs displaying changes in ASE between normal and cancer correlate with an 
increased frequency of exon-skipping events (i.e., >1.5-fold increase in expression of reads 
consistent with exon-skipping events) (Table 3; Figure 16d).  
 While these results suggest that allele-specific alternative splicing may be a 
significant contributor to ASE, it does not provide a mechanism as to how two variant 
alleles from the same gene may be alternatively spliced. One possibility is that the point 
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mutations or indels that distinguish mutant LoF (alt) alleles from wild-type (ref) alleles 
map to consensus splice sites or other cis-regulatory locations known to be involved in the 
splicing process [111, 121]. However, of the 100,852 SNPs associated with changes in 
ASE between normal and tumor, only 1.4% (1,418/100,852) map to consensus splice sites 
(716 in acceptor G, 702 in donor AG). 
 A second possible mechanism that may explain how two variant alleles from the 
same gene may be alternatively spliced emerges from previous studies showing that 
splicing events can be experimentally induced in vivo by exposing primary transcripts to 
even small fragments of anti-sense RNAs that pair with known splice sites in the primary 
transcript [14, 190].  We reasoned that if such allele-specific anti-sense RNAs are being 
differentially produced in normal and cancer tissues, it may explain observed differences 
in allele-specific splicing and consequent differences in ASE.  
 To test this hypothesis, we quantified the levels of anti-sense RNAs mapping to 
splice sites adjacent to allele-specific alternative-splice events. The results presented in 
Table 3 demonstrate a significant increase in levels of anti-sense RNA in genes displaying 
allele-specific alternative-splice events associated with ASE. For example, Figure 17a 
depicts a case where the ADAM15 gene displays ASE in breast cancer patient 3 (TCGA-
BH-A0DT). The ADAM15 protein is known to display tumor suppressive activities when 
it is released as an exosomal component [191], and abnormal expression and dysregulation 
of alternative splicing in ADAM15 has been previously associated with breast cancer [192-
194]. Previous studies have also shown that four ADAM15 isoforms varying by the 
sequence of the cytoplasmic domains, display variable effects in vitro. The shortest 
isoform, ADAM-15D, arises due to loss of exons 19 to 21 causing a reading frame shift in 
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exons 22 and 23 when compared with the other three isoforms. The variant lacks proline-
rich modules and has a distinct sequence of 37 amino acids.  As shown in Figure 17b, we 
observe an increase in anti-sense RNA mapping to acceptor (1.7x) and donor (1.8x) sites 
in this patient’s tumor. We have identified an exon skipping event (exon 19), consistent 
with the ADAM-15D isoform. The increase in anti-sense RNA correlates with this 
isoform's expression, which is substantially higher (3.8x) in the patient's tumor sample 
when compared to normal and could explain ASE at this locus (Figure 21c). 
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Figure 17 ADAM15 exon skipping correlates with ASE in a breast adenocarcinoma 
patient. 
a, An exon skipping event in exon 19 of ADAM15 in a breast cancer patient (TCGA-BH-
A0DT). b, Antisense reads mapping to donor and acceptor sites are quantified, alongside 
the ASE locus within the exon. c, Quantification of reads supporting the isoform missing 
exon 19.  Relative expression plots are shown for antisense RNA, ASE and isoforms below. 
 Another example is illustrated in Figure 40a, where the Lysyl Oxidase Like 2 
(LOXL2) gene displays ASE at the rs1051146 locus in breast cancer patient 1 (TCGA-BH-
A0B3) which overlaps with an exon skipping event. LOXL2 has accumulated numerous 
reports that document its role in cancer formation and proliferation of breast cancer [195-
197]. Further, research has shown that a short isoform of LOXL2 missing exon 13 can 
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regulate cancer cell migration and invasion through a dissimilar mechanism compared to 
its canonical form [198]. Here, we observe more anti-sense RNA mapping to acceptor 
(8.7x) and donor (9.2x) sites (Figure 40b) and increased skipping of exon 6 (9.9x) (Figure 
40c) in breast cancer patient 1’s tumor sample, both correlated with an increase in ASE.  
 Tenascin C (TNC) is a gene belonging to a family of extracellular matrix (ECM) 
glycoproteins that is known to be overexpressed in cancer cells. Studies have shown that 
remodeling of ECM in cancer can affect cellular interaction as ECM influences behavior 
of the cells [199, 200]. One specific study has shown that a TNC isoform containing exons 
14 and 16 but not 15 is upregulated in breast cancer which leads to increased cell invasion 
and proliferation [201]. In breast cancer patient 3, TNC displays changes in ASE at 
rs17819466 inside exon 15 (Figure 41a). Anti-sense RNA mapping to acceptor (2.1x) and 
donor (2.6x) sites are elevated in the tumor sample (Figure 41b), as are split-reads spanning 
exons 14 and 16 (5.5x) (Figure 41c). 
 Collectively, these results suggest that anti-sense mediated alternative splicing is a 
significant factor in accounting for our observed changes in ASE between normal and 
cancer and may be contributing to tumorigenesis. 
 
4.4 Discussion 
Cancer is a complex disease not only from the perspective of the number and 
diversity of genes involved but also because of the existence of extensive regulatory 
variation controlling the expression of these genes. One manifestation of these regulatory 
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controls is allele-specific expression (ASE) at specific cancer driver gene loci [153]. If 
cancer driver mutations can be transcriptionally repressed/de-repressed in an allele-specific 
manner, they may be segregating at higher than expected frequencies in populations of 
normal healthy individuals. In an initial effort to explore this possibility, we conducted a 
computational analysis of functionally significant cancer driver mutations in a sampling of 
normal healthy human populations across the world (2.5 thousand genomes comprising the 
1000 Genome Project (1KGP) [59] ). While relatively few confirmed dominant oncogene 
mutations were found to be segregating in these populations, a remarkable 93% of healthy 
individuals sampled were found to carry functionally significant loss-of-function (LoF) 
cancer driver mutations at one or more tumor suppressor gene loci (21% of individuals 
carry 1 mutant allele; 28% carry 2, 24% carry 3, 13% carry 4, 5% carry 5, 2% carry >6). 
While these frequencies are higher than what have been generally reported for specific 
TSGs [202, 203], they are not unprecedented. Among the most intensively studied TSGs 
is the RB1 gene that is associated with inherited childhood retinoblastoma [167]. Although 
the frequency of individuals heterozygous for LoF RB1 alleles ("carriers") in human 
populations is generally reported to be  5% [203], considerable variability exists among 
ethnic groups/populations. For example, in a study of select Asian populations, the 
frequency of carriers of LoF RB1 alleles was reported to be as high as 34% in specific 
ethnic populations [204].  Collectively, our findings serve to confirm the potential 
importance of TSGs in pre-disposing a significant fraction of otherwise healthy individuals 
to cancer. 
 The fact that LoF TSG alleles are typically recessive to their "partner" functional 
or "wild-type" allele lead to the "two-hit" hypothesis first proposed by Alfred Knudson in 
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1971 [167]. The "two-hit" hypothesis proposes that individuals heterozygous for a LoF 
tumor suppressor allele will not typically develop cancer unless an additional LoF mutation 
occurs in the gene's functional partner allele.  While the two-hit hypothesis has been 
successfully employed to account for many instances of inherited cancers associated with 
tumor suppressor genes [205-207], a number of examples have been identified in recent 
years that are inconsistent with Knudson's "two-hit" hypothesis [208-211]. For example, it 
is now known that not all children afflicted with retinoblastoma are homozygous for the 
LoF RB1 allele [212, 213] and this condition has, in several cases, been associated with 
aberrant expression of unlinked regulatory genes [214].   
 To evaluate the "two-hit" model in our dataset, we computed the frequency of 
patients heterozygous for a LoF (alt) mutation in normal tissues that acquired a secondary 
LoF mutation in the partner wild-type (ref) allele in matched sets of cancer and normal 
samples. We found that < 20 % of patients acquired a second LoF mutation in cancer tissues 
as predicted by the "two-hit" model. This finding is consistent with a growing body of 
evidence that the mechanisms underlying the contribution of TSGs to cancer onset and 
progression are often more complex than originally envisioned [215, 216].  
 A primary goal of our current study was an evaluation of the potential significance 
of changes in ASE of TSGs between normal and cancer, and to explore the molecular 
mechanisms that may underly this process. Towards this end, we searched the TCGA 
database for evidence of ASE in matched sets of normal and tumor tissue samples isolated 
from 233 randomly selected cancer patients representing four diverse tumor types. We 
found that COSMIC census mutations in TSGs display significantly (P < 3.11 x 10-10) 
more ASE in tumors compared to matched normal tissues in breast, head and neck, and 
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lung cancers. Our finding that this change is not limited to COSMIC genes but extends to 
genes not previously associated with cancer, implies a general loss of regulatory control in 
cancer. Evidence for such a global loss in regulatory control in cancer has been previously 
reported [217-219]. Although the mechanisms underlying these global changes in 
regulatory control in cancer remain largely unknown, epigenetic changes are emerging as 
one potentially important player in the process [220]. 
 In a preliminary effort to explore the possible contribution of epigenetics to the 
global changes in ASE observed between our normal and cancer samples, we downloaded 
methylation data for our patient samples from TCGA. We found that only 10% of genes 
displaying ASE also displayed significant differences (>1.3-fold) in methylation between 
our normal and tumor tissue samples. While changes in methylation are generally 
considered to be a reliable indicator of epigenetic-associated changes in gene expression 
[221], our results suggest that changes in methylation are not likely to be playing a 
significant role in the regulation of ASE in our patient samples.  
 Of the six possible Patterns of change in ASE between normal and cancer tissues, 
we found that Pattern 1 (i.e., no ASE in normal tissue but expression of mutant allele (alt) 
> expression of wild-type (ref) allele in cancer tissue) was one of the most commonly 
observed Patterns across cancer types. This finding is consistent with the hypothesis that 
LoF TSG alleles may be contributing significantly to cancer onset/progression even in the 
heterozygous state. 
One possible explanation of the observed changes in ASE between normal and 
cancer tissue is that it is structural in nature, i.e., the consequence of differences in allele 
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counts attributable to, for example, loss of heterozygosity (LOH) or the polyclonal 
heterogeneity characteristic of most tumors [175]. To test this possibility, we compared 
RNA allele counts with DNA allele counts in the same patient samples. We found that on 
average 35% of genes displaying ASE had DNA allele counts that correlated with RNA 
allele counts. These results are consistent with prior findings indicating that a significant 
fraction of ASE can be accounted for by underlying differences in DNA allelic content 
[175]. However, only 10% of these genes displayed copy number duplications consistent 
with their ASE. Thus, at least with respect to our patient samples, differences in ASE 
between normal and cancer tissues is not merely structurally based but likely attributable 
to allele-specific differences in gene expression. 
Allele-specific differences in gene expression may be attributable to variant cis-
regulatory sequences located up- or down-stream from the respective alleles' coding 
regions. Such cis-regulatory variation is commonplace and is often identified by utilizing 
QTL mapping methodologies [222]. We employed the Genotype-Tissue Expression 
Project’s (GTEx) single tissue cis-eQTL database to explore the extent to which allele-
specific cis-regulatory variation may account for ASE in our patient samples. We found 
that only 24% of genes displaying ASE are eGenes, more of which explain ASE in normal 
(38%) than tumor (21.8%) samples. Moreover, only 1.8% of ASE haplotypes were found 
to be in phase with an eQTL indicating that cis-regulatory variation is not a likely 
explanation of the majority of instances of ASE in our dataset. 
Having failed to identify a mechanism of transcriptional level regulation that could 
explain the majority of observed instances of ASE in our dataset, we turned our attention 
to the potential influence of post-transcriptional regulation on ASE. One post-
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transcriptional mechanism of growing prominence in cancer biology is alternative splicing 
(AS) [12, 223]. The primary RNA products of genes are processed at the post-
transcriptional level by alternative RNA splicing resulting in multiple RNA isoforms per 
gene. If alternate RNA isoforms are generated on an allele-specific basis (allele-specific 
alternative splicing), it could manifest itself as differences in ASE. To explore the 
possibility that allele-specific alternative splicing could be contributing to changing 
patterns of ASE in cancer, we examined isoform counts associated with our TCGA patient 
data [122]. We found that almost half (46%) of SNPs displaying ASE in our patient 
samples were indeed associated with exon skipping.  
 While the potential functional significance of alternative splicing in cancer has been 
long noted [123], the mechanisms underlying the phenomenon remain poorly understood. 
Because the genes displaying changes in ASE are not associated with cis-regulatory 
mutations in splice acceptor/donor sites, we focused our attention on possible trans-
regulatory mechanisms. One possibility is that one or more of the regulatory proteins or 
RNAs associated with the spliceosome could be mutated or otherwise dis-regulated in 
cancer resulting in aberrant splicing patterns [120]. However, the fact that our observed 
allele-specific alternative splicing was limited to only a subset of genes suggested that the 
underlying mechanism was of a more targeted nature. 
 One possibility was suggested from previous studies showing that splicing events 
can be experimentally induced in vivo by exposing primary transcripts to anti-sense RNAs 
that pair with known splice sites in the primary transcript [16, 17, 224]. Indeed, there is 
growing evidence that de novo expression of anti-sense RNAs may play a significant role 
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in the induction of alternate splice variants [225] and that this may be a significant factor 
in cancer onset/progression. 
 
4.5 Summary and Conclusions 
We have shown that LoF TSGs are segregating in human populations at significant 
frequencies suggesting that many otherwise healthy individuals are at elevated risk of 
developing cancer. Changes in ASE between normal and cancer tissues indicates that LoF 
TSG alleles may contribute to cancer onset/progression even when heterozygous with wild-
type functional alleles.  While a variety of molecular mechanisms were identified as 
potentially contributing to changes in ASE between normal and cancer, differences in DNA 
counts and allele-specific alternative splicing mediated by anti-sense RNA emerged as 
predominant factors. 
 
4.6 Materials and Methods 
4.6.1 Cancer Associated Mutation Identification in 1000 Genomes Population 
Using the BEDTools program [226], the genomic locations of all coding mutations 
in COSMIC census genes (v82) [130] were intersected with a vcf file containing all 
sequence variants called from the 2504 individuals of the Phase 3 release of the 1000 
Genomes Project (1KGP) [59]. The distribution of these cancer associated mutations was 
determined for all intersecting mutations including the subset of deleterious mutations. 
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Variant effects were annotated using Variant Effect Predictor (VEP) using the Ensembl 91 
release [227]. Mutations were considered to be deleterious if they were non-sense, 
frameshift, splice acceptor/donor mutations, or whole gene deletion mutations. Missense 
mutations predicted deleterious by both SIFT [164] and Polyphen2 [165] were also scored 
as deleterious mutations. Moreover, we removed any mutation that had been labeled as 
benign or likely benign by clinvar [228]. 
 
4.6.2 Sequencing Data Acquisition 
Whole exome sequencing (WXS) and transcriptome sequencing (RNA-Seq) data 
for matched sets of normal and primary tumor samples collected from 233 cancer patients 
were downloaded from The Cancer Genome Atlas (TCGA) via Genomic Data Commons 
(GDC) (89 Breast Cancer (BRCA) patients, 52 Lung Adenocarcinoma (LUAD) patients, 
39 Head and Neck Squamous Cell Carcinoma (HNCSC) patients and 28 Thyroid Cancer 
(THCA) patients; Table 26). The data consisted of paired-end reads generated from 
Illumina platforms. As per the harmonization pipeline of GDC all WXS samples were 
aligned to GRCh38 reference genome [229], indels were locally realigned and base quality 
scores were recalibrated. RNA-Seq samples were also aligned to GRCh38 by the GDC. 
Autosomes were subsequently extracted for downstream analysis using SAMtools [63]. To 
investigate the mechanisms of ASE Whole Genome Sequencing data (WGS) for nine of 
these patients (three breast invasive carcinoma, three head and neck squamous cell 
carcinoma and three lung adenocarcinoma) were downloaded. The BAM files for WGS 
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were checked for quality using FASTQC, lifted over to GRCh38 and local realignment of 
indels was performed using GATK [69]. 
 
4.6.3 Genotyping and Variant Calling with WXS and Variant Annotation 
Genotyping was implemented from WXS. SAMtools mpileup output was fed to 
VarScan’s mpileup2snp function in order to call variants [230]. Only reads with mapping 
quality > 14 were counted. Further, to call a variant, a position must have met a minimum 
read depth of 8, minimum allelic depth of 2 and variant allele frequency threshold of 0.2. 
The default p-value of 0.01 was used for calling variants. Variants were annotated using 
VEP with the same criteria mentioned as above. 
 
4.6.4 Allele Specific Expression Analysis 
4.6.4.1 Counting Allele-Specific Reads 
Indexed RNA-Seq BAM files along with filtered heterozygous variants were 
passed to GATK’s ASEReadCounter tool [69]. At this step, only reads with minimum 
mapping quality and base quality scores of 20 and 30, respectively, were counted. Also, 
minimum depths of 20 reads per site and four reads per allele were applied. With the aim 
of inferring biological significance, resulting allele counts were annotated with rsid using 
Kaviar. Subsequently, gene names associated with particular SNPs were fetched from 
dbSNP using EDirect [231]. The fraction of reads containing the reference allele over the 
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total number of reads at a given position (Ref Ratio) was calculated for all heterozygous 
SNPs. Custom scripts were written to perform allele specific expression analysis. 
 
4.6.4.2 Accounting for Mapping Bias 
When mapping RNA-seq reads to the reference genome, reads overlapping a SNP 
that contain the alternative allele tend to map less frequently than those reads containing 
the reference allele. This allelic mapping bias has been well documented and presents 
challenges in ASE analysis [232]. Degner et al. demonstrated that the reliability in ASE 
estimation is greatly dependent on the capability to control for reference mapping bias 
[233]. To limit this bias, we first removed sites known to be susceptible to mapping bias. 
We did so by removing all sites with 50bp mapability < 1 based on the UCSC mapability 
track [234]. To correct for any residual bias, we calculated the genome-wide allelic ratios 
for all nucleotide pairs and used them in place of 0.5 as the expected allelic ratio in the 
binomial test (Figure 42) as previously done by Lappalainen et al [235]. 
 
4.6.4.3 ASE Analysis 
Using the allele counts for every heterozygous position that met our filtering 
requirements, we performed a binomial test to identify whether the ratio of reference and 
alternative read counts differed significantly from the corresponding expected proportion 
between those alleles. Expected ratios were inflated slightly from 0.5 based on the observed 
allele counts within our population as described in the previous section. We classified a 
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site as an ASE SNP if its binomial p-value was less than 0.005 and corrected for a false 
discovery rate (FDR) of 5%. Gene level ASE was determined by aggregating ASE 
information from all heterozygous SNPs within a gene as outlined by the MBASED 
protocol [154]; ASE genes were classified with a major allele frequency (MAF) greater 
than 0.7 and p-value less than 0.05 (FDR 5%). To label significant ASE genes with Patterns 
we pseudo-phased them by creating a major haplotype consisting of the alleles with higher 
RNA read counts. If a haplotype contained more reference SNPs it was labelled as the 
reference haplotype and vice versa for the alternative. If the number of reference and 
alternative SNPs on each haplotype were the same, the haplotype was labelled as 
ambiguous. 
Differences in ASE between normal and cancer tissue groups, were evaluated by 
comparing the distributions of the proportion of SNPs with ASE within each collection. 
The statistical significance levels of the observed difference in ASE between normal and 
tumor tissues for both COSMIC census mutations and all heterozygous SNPs were 
evaluated by comparing these distributions using the non-parametric Mann-Whitney U 
test. 
When comparing SNPs intersecting paired normal and tumor samples, we applied 
a combined binomial-Fisher test to determine if ASE patterns were significant. Three ASE 
patterns of interest were analyzed; Pattern 1: No significant difference in ASE (ref=alt) in 
normal tissues but significant ASE (ref<alt) in cancer tissues; Pattern 2:  Significant ASE 
in normal tissues  (ref>alt) but no significant ASE (ref=alt) in cancer tissues; Pattern 3: 
Significant ASE in normal sample (ref>alt) and significant ASE in tumor sample (ref<alt); 
Pattern 4: No significant ASE in normal tissues (ref=alt) but significant ASE in cancer 
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tissues (ref>alt); Pattern 5: Significant ASE (ref<alt) in normal tissues but no significant 
ASE in cancer tissues (ref=alt); Pattern 6: Significant ASE in normal (ref<alt) and in cancer 
tissues (ref>alt). All Patterns are visualized in Figure 14a. Significant ASE (FDR = 5%, P 
< 0.005) was determined using a binomial test within samples and subsequently a Fisher’s 
exact test (P < 0.05) when comparing two samples. Both tests were applied to increase 
stringency and validity of results. 
 
4.6.5 Second Site Loss-of-Function Mutations 
Filtered heterozygous sites in tumor suppressor genes (TSGs) of all 233 patients in 
normal and tumor samples were phased using SHAPEIT [236]. Loss-of-function mutations 
were defined as stop gained, frameshift, splice acceptor/donor, start lost and stop lost 
mutations. Deleterious missense mutations predicted to be damaging/deleterious by SIFT 
[164] and Polyphen2 [165] were also considered loss of function in TSGs. Patients with a 
secondary site loss-of-function mutation were defined as having a heterozygous mutation 
in the normal sample and either: 1) the same mutation homozygous in the tumor sample, 
2) a new loss of function mutation on the opposite allele in the tumor sample (i.e. compound 
heterozygote), or 3) a DNA segment with loss of allele at the locus in the tumor sample. 





4.6.6 Analyses to Determine Mechanisms of ASE 
4.6.6.1 Cis Expression Quantitative Trait Loci (cis-eQTL) Analysis 
In order to investigate the possible contribution of upstream/downstream regulatory 
variation to ASE, cis-eQTL detection was performed. Variants were called, using 
SAMtools mpileup and bcftools [63], on the genomic sequence ± 1mb from the 
transcription start site (TSS) of each gene. Mono-allelic sites were phased using SHAPEIT 
[236] with the 1KGP reference panel of haplotypes for each participant’s super population. 
Indels and multi-allelic sites were phased using HapCUT [238]. Subsequently, the outputs 
of the two tools were merged to complete the phasing step. Correlated cis-eQTL-gene pairs, 
for lung and breast tissues, were downloaded from The Genotype Tissue Expression 
Project’s (GTEx) single tissue cis-eQTL data [181]. The eQTL-gene pairs were intersected 
with variants of the breast and lung cancer TCGA participant samples. We then created a 
list of all possible eQTL SNP – ASE SNP pairs, by pairing eQTL variants with all ASE 
SNPs in the corresponding eGene. We tested to see if there was a difference in the 
enrichment of eQTLs in ASE genes versus non-ASE genes using the Fisher’s exact test, 
across all individual samples. Resulting eQTL SNP – ASE SNP pairs were tested for 
linkage disequilibrium (LD) using PLINK [239] and the appropriate super population from 
1KGP (EUR or AFR) based on the patients’ reported race. Pairwise correlations (r) for all 
SNP pairs were computed. Finally, VEP [227] was used to find eQTLs in regulatory 
regions and genomic regions of interesting cases were visualized using the 
AllelicImbalance R package [240]. 
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4.6.6.2 Tumor Heterogeneity and Allele Specific Copy Number Variation 
To explore the possible contribution of DNA copy number variation to ASE, DNA 
read counts and allelic depths were generated for heterozygous sites in matched normal 
and tumor samples using the snp-pileup utility provided in the FACETS package [237]. A 
binomial test with an expected ratio of 0.5 and an FDR of 5% were used to select sites 
where the allelic depth of the reference and alternative allele were significantly different. 
These sites were overlapped with ASE SNPs to see how much of the observed ASE could 
be attributed to the heterogenous nature of tumor tissues and copy number variations. 
Segments with non-diploid copy number variations or evidence of loss of allele 
were identified using FACETS with a c value of 100. To calculate the amount of ASE 
associated with copy number variation, ASE SNPs were overlapped with non-diploid copy 
number variation segments to see if the copy number change supported the allelic 
imbalance observed in the RNA-Seq reads. 
 
4.6.6.3 Methylation 
To investigate the possible contribution of methylation to ASE, Illumina Infinium 
HumanMethylation450 (HM450) and Human Methylation 27 (HM27) Array data were 
downloaded from TCGA for six patients (TCGA-50-5932, TCGA-BH-A0B3, TCGA-BH-
A0BW, TCGA-BH-A0DT, TCGA-CV-6959, TCGA-CV-7255) for tumor and normal 
samples. Methylation intensity was quantified by a beta-value calculated as the ratio of the 
methylated probe intensity and the sum of the methylated and unmethylated probes. Fold 
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changes of the beta-values were calculated between the tumor and normal samples; a fold 
change of > 1.33 was considered significant. To estimate how many changes in ASE 
between tumor and normal samples could be accounted for by epigenetic changes in 
methylation we overlapped genes that had a significant change in methylation with genes 
showing a change in ASE. 
 
4.6.6.4 Alternative Splicing 
To explore the possible contribution of post-transcriptional alternative splicing to 
ASE, a compressed alternative splicing dataset from a study [122] containing over 8,000 
patients across 32 cancer types on TCGA was downloaded from GDC. Exon-skipping 
event data for 233 patients in this ASE study were matched and pulled from the dataset for 
further analyses.  
In order to compare the expression of a genelet that provides evidence for an exon-
skipping event that could be contributing to observed ASE in matched normal and tumor 
samples, the genomic coordinates of ASE SNPs were first intersected with the start and 
stop positions of all confirmed exon-skipping events using bedtools. Kahles et al. [122] 
define ISO1 and ISO2 genelets as isoforms with shorter and longer lengths, respectively. 
For exon-skipping events, the ISO1 genelet refers to the boundary connecting the exons 
adjacent to the one being skipped. For the filtered list of exon-skipping events that intersect 
with an ASE SNP, the difference in the number of multi-exon spanning reads (ISO1) 
between normal and its paired tumor sample were inspected for each of the ASE patterns. 
The isoform counts were normalized to counts per million (CPM) using the total number 
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of reads to account for sequencing depth. For ASE SNPs with Patterns 1 and 4, a SNP was 
counted as correlated with exon-skipping if a 1.5x fold increase in ISO1 CPM was observed 




Similarly, for ASE SNPs with Patterns 2 and 5, a SNP was counted as correlated 
with exon-skipping if a 1.5x fold increase in ISO1 CPM was observed from normal 
to tumor, i.e. (
𝑛𝑜𝑟𝑚𝑎𝑙 𝐼𝑆𝑂1 𝐶𝑃𝑀
𝑡𝑢𝑚𝑜𝑟 𝐼𝑆𝑂1 𝐶𝑃𝑀
≥ 1.5). For ASE SNPs with Patterns 3 and 6, evidence 
of exon-skipping was necessary in both samples, i.e. (𝑛𝑜𝑟𝑚𝑎𝑙 𝐼𝑆𝑂1 𝐶𝑃𝑀 > 0,
𝑡𝑢𝑚𝑜𝑟 𝐼𝑆𝑂1 𝐶𝑃𝑀 > 0). 
 
4.6.7 Splice Site Mutations 
Exonic regions of splice site motifs were first defined prior to examining ASE SNPs 
that could be contributing to the observed alternative splicing. These regions were defined 
as two bases downstream of the acceptor site (AG) and three bases upstream (5'-ward) of 
the donor site (GT). Strand information was taken into account while defining these exonic 
regions for genes on the minus strand. Using bedtools, ASE SNPs were intersected with 
the specified exonic regions. 
 
4.6.8 Antisense RNA 
Detecting antisense RNA requires the alignment to be performed with reads that 
have strand information available. The sequence alignment map (BAM) files available on 
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TCGA are missing such information as unstranded library kits were used to generate the 
reads. The CAFE [241] pipeline predicts the orientation of the unstranded reads using 
Markov chain models coupled with maximum likelihood estimation given a reference 
BAM file generated from strand-specific RNA-Seq reads. For the nine patients (3 LUAD: 
TCGA-44-6776, TCGA-50-5932, TCGA-55-6984; 3 BRCA: TCGA-BH-A0B3, TCGA-
BH-A0BW, TCGA-BH-A0DT; 3 HNSC: TCGA-CV-7255, TCGA-CV-7416, TCGA-CV-
6959), BAMs consisting of reads with predicted directions were generated using the 
pipeline and three cell lines with stranded RNA-Seq reads available for each cancer type 
(LUAD: HCC78 - SRR2050924; BRCA: MCF7 - SRR5048141; HNSC: neuroblastoma-
derived cell line – SRR4787038). 
Regions where antisense RNA could interfere with the splicing of an exon were 
determined using the canonical splicing motif for Homo sapiens [242] along with a gene’s 
strand. (+ strand: acceptor= -40bp AG +2bp, donor= -3bp GT +5bp; - strand: acceptor= -
2bp AG +40bp, donor= -5bp GT +3bp). Using bedtools, the reads that intersected these 
regions on the opposite strand of the coding gene were quantified in order to estimate the 
amount of antisense reads. The change in the number of antisense reads mapping to the 
splicing motif of genes between normal and tumor samples was quantified as a fold change 
in antisense expression. The read counts were normalized with CPM, using the total 
number of reads to account for sequencing depth. 
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CHAPTER 5. LEVERAGING TCGA GENE EXPRESSION DATA 




Machine learning has been utilized to predict cancer drug response from multi-
omics data generated from sensitivities of cancer cell lines to different therapeutic 
compounds. Here, we build machine learning models using gene expression data from 
patients’ primary tumor tissues to predict whether a patient will respond positively or 
negatively to two chemotherapeutics: 5-Fluorouracil and Gemcitabine. 
 
5.1.2 Results 
We focused on 5-Fluorouracil and Gemcitabine because based on our exclusion 
criteria, they provide the largest numbers of patients within TCGA. Normalized gene 
expression data were clustered and used as the input features for the study. We used 
matching clinical trial data to ascertain the response of these patients via multiple 
classification methods. Multiple clustering and classification methods were compared for 
prediction accuracy of drug response. Clara and random forest were found to be the best 
clustering and classification methods, respectively. The results show our models predict 
with up to 86% accuracy; despite the study’s limitation of sample size. We also found the 
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genes most informative for predicting drug response were enriched in well-known cancer 
signaling pathways and highlighted their potential significance in chemotherapy prognosis. 
 
5.1.3 Conclusions 
Primary tumor gene expression is a good predictor of cancer drug response. 
Investment in larger datasets containing both patient gene expression and drug response is 
needed to support future work of machine learning models. Ultimately, such predictive 
models may aid oncologists with making critical treatment decisions. 
 
5.2 Background 
The goal of personalized medicine is to tailor treatments for individuals based on 
unique characteristics of their genetic background.  Given the vast variety of cancers and 
the inherent molecular heterogeneity of the disease, personalized medicine in cancer can 
be particularly effective, [243].  By studying molecular profiles of tumors, one can 
potentially discover biomarkers for drug sensitivity, resistance, or adverse effects that may 
be helpful in predicting drug response [244, 245].  Recent successes demonstrated small 
molecule inhibitors which target pathways upregulated in cancer patients [246].  Further, 
breast cancer has long served as a model for successful personalized oncology, by 
¬administering treatments specific for HER2-positive patients [247].  
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While personalized oncology has shown signs of promise, not all cancers have such 
well-defined targetable pathways [23].  This has led to the recent emergence of machine 
learning for predicting cancer drug response.  This method, though promising, has had 
rather limited success.  Difficulties creating reliable predictive models have stemmed from 
a lack of clinical data to use for training, poorly annotated drug responses, and noise 
introduced by a large number of features [26].  In previous studies, the lack of patient data 
was offset by utilizing genomic and transcriptomic profiles of cancer cell lines as the 
features for predicting response to chemotherapy [25, 248-251].   Low interpretability and 
limited accuracy are the drawbacks of predicting in vivo response based on in vitro data.  
The high dimensionality of molecular data is prone to overfitting and can lead to deceptive 
associations from intrinsically multiplex gene networks.  Together, these challenges have 
muddled attempts to build informative and accurate patient drug predictive models. 
To address these complications, we applied several machine learning techniques. 
First, to reduce dimensionality we utilized optCluster [252], an R package for determining 
the optimal clustering algorithm and optimal number of clusters.  OptCluster identifies 
highly similar or repetitive expression patterns from genes and clusters them into gene 
modules.  This method reduces the number of features while also minimizing the amount 
of information loss.  Secondly, we predicted drug response using the random forest 
algorithm [253] in order to protect against overfitting; a common issue with many machine 
learning methods.  Random forest is an ensemble method which builds decision trees.  This 
approach deters overfitting by incorporating a variety of features and leveraging a majority 
vote when performing classification [230].  Perhaps, most importantly, we evade using 
cell-line data to extrapolate in vivo predictions by instead harnessing gene expression data 
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available from primary tumor tissues in The Cancer Genome Atlas (TCGA) [57].  We 
observe robust prediction using our model and we evaluate predictive gene modules that 
are implicated in biological pathways critical to drug response. 
 
5.3 Results 
5.3.1 Drug Selection Results 
Our study is based on data obtained from the National Cancer Institute's TCGA 
database [166].  TCGA provided both patients’ clinical trial data and transcriptomic data 
from patients’ primary tumor samples. This data included expression levels for 60,483 
genes including protein-coding genes, non-coding RNA genes and pseudogenes.  We used 
the Genomic Data Commons API to download the Upper-Quartile Normalized Fragments 
per Kilobase per Million mapped reads (UQ-FPKMs) from the patients’ primary tumor 
samples. The clinical trial data consisted of 12,051 records with data for 32 cancer types.  
Each record contains clinical trial data for an individual patient. There are multiple clinical 
trials in the database and a patient will have one record for each clinical trial of which they 
participated (i.e. a patient can have two records if they participated in different trials). Each 
record included information about: drugs administered, patient demographics, temporal 
data of the study, and response of the patient.  
For the purposes of classification, we defined a responder as a patient who had 
partial or complete response and a non-responder as a patient who had a clinical 
progressive disease or stable disease response. One pan-cancer model for each drug was 
created by including all the cancer types that the selected drug had treated.  Only patients 
 93 
on single drug therapy throughout the entire duration of treatment were retained in the 
study. 
Based on these criteria, Fluorouracil (5-FU) and Gemcitabine (GCB) were chosen 
because they provided the highest number of records.  Our study included two models: (1) 
5-FU pan-cancer and (2) GCB pan-cancer. See Table 7 for the counts of each model. 
Table 7 Patient counts for each model by response. 
Model Responder Count Non-responder Count Total Count 
Fluorouracil pan-cancer* 34 24 58 
Gemcitabine pan-
cancer** 37 55 92 
*Fluorouracil pan-cancer includes: colon adenocarcinoma, esophageal carcinoma, 
pancreatic adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma 
**Gemcitabine pan-cancer includes: bladder urothelial carcinoma, breast invasive 
carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, 
cholangiocarcinoma, head and neck squamous cell carcinoma, liver hepatocellular 
carcinoma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, pancreatic 
adenocarcinoma, pheochromocytoma and paraganglioma, sarcoma, skin cutaneous 
melanoma, testicular germ cell tumors, uterine corpus endometrial carcinoma 
 
5.3.2 OptCluster Results 
We report the results of the most accurate clustering algorithm from optCluster in 
Table 8.  Clara coupled with several classification algorithms provided the best gene 
modules with a cross-validation mean accuracy of 84.1% (sd:10.7%) for 5-FU and 82.3% 
(sd: 8.6%) for GCB.  In Figure 18, we see how accuracy changes relative to the number of 
selected clusters.  The peak accuracy was with 32 and 50 clusters for 5-FU and GCB, 
respectively.  We tested other classification methods, support vector machines and logistic 
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regression, but they yielded worse results. Cross-validation accuracy for support vector 
machine was 81% for 5-FU and 71.5% for GCB and logistic regression was 77.0% for 5-
FU and 73.0% for GCB.  There was minimal impact on accuracy when including 
demographic data of the patients (gender, age, cancer type and cancer stage) [5-FU: 83.6%; 
Gemcitabine: 79.1%]. Additional tuning improved the model validation accuracy, as seen 
in  
Table 8. 
Table 8 Number of clusters and mean accuracy for pan-cancer models. 











































204 32 52.9% 192 50 85.7% 
* RF is for random forest; SVM is for support vector machine 
**Number of considered clusters represents the number of clusters entered into random 
forest for variable importance ranking. 




Figure 18 Accuracy of random forest by number of clusters (using clara clustering 
algorithm). 
(A) Mean accuracy (200x cross-validation) was calculated using 1-204 clusters in order 
of importance from the 5-FU pan-cancer model. (B) Mean accuracy (200x cross-
validation) was calculated using 1-192 clusters in order of importance from the GCB pan-
cancer model. 
In Figure 19a-b, the cross-validation predicted probabilities for non-responders and 
responders are plotted.  The 5-FU model is particularly strong at identifying responders 




Figure 19 Random forest classifier performance for pan-cancer models. 
(A) Comparison of the cross-validation predicted probabilities between non-responders 
and responders for the 5-FU pan-cancer model. (B) Comparison of the cross-validation 
predicted probabilities between non-responders and responders for the GCB pan-cancer 
model. (C) ROC curve for 5-FU pan-cancer model; Cross-validation (Sensitivity: 0.97 
Specificity: 0.66 AUC: 0.98) Model-validation (Sensitivity: 0.64 Specificity: 0.33 AUC: 
0.56). (D) ROC curve for GCB pan-cancer model; Cross-validation (Sensitivity: 0.80 





5.3.3 Model Validation & ROC Curves 
The ROC curves in Figure 19c-d demonstrate the results of the sensitivity and 
specificity for the cross-validated accuracy of the training data and the model validation of 
the test data.  The results of the model validation showed an increase in the accuracy for 
GCB by 3 percentage points to 85.7%.  We did not see the same improvement in 5-FU, 
which dropped to 52.9% accuracy.  The training data for both models performed with AUC 
= 0.98. More interestingly, we see the GCB validation curve still classifies well with AUC 
= 0.71, while the 5-FU validation curve is barely above the random classifier line; showing 
it doesn’t perform much better than chance. This decrease in accuracy could be attributed 
to sample size and difficulty in predicting on the cancer type (stomach adenocarcinoma) 
used for this validation.        
 
5.3.4 Gene Set Enrichment Analysis 
Once we established a ranking of modules in terms of predictive importance, we 
performed a gene set enrichment analysis using PANTHER [254]. We analysed the genes 
that comprised the clara gene modules that the optimal models used for prediction (Table 
27).  The top 20 biological pathways by gene percent are shown for the pan-cancer models 
in  
Table 9.  In addition, Figure 20 shows the relationship of gene expression level 
between responders and non-responders for the each of these pathways.  A high positive 
number, such as in P00018 indicates that the mean gene expression for the responders in 
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pathway, P00018, are higher than that of the non-responders.  The opposite holds true for 
the negative values. 
 
Table 9 Top 20 PANTHER pathways in models by gene percent. 
Model Category name Accession # Genes 
Percent 




















Wnt signaling pathway  P00057 10 3.20% 11.80% 2.82E-02 4.60E+00 
Integrin signaling pathway  P00034 6 1.90% 7.10% 6.60E-02 3.59E+00 
Gonadotropin-releasing hormone 
receptor pathway  
P06664 5 1.60% 5.90% 4.06E-01 2.88E+00 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway  
P00031 4 1.30% 4.70% 7.91E-01 3.39E+00 
Huntington disease  P00029 4 1.30% 4.70% 1.70E-01 2.78E+00 
p53 pathway  P00059 3 1.00% 3.50% 1.49E-01 2.69E+00 
EGF receptor signaling pathway  P00018 3 1.00% 3.50% 4.66E-01 3.16E+00 
PDGF signaling pathway  P00047 3 1.00% 3.50% 4.88E-01 3.18E+00 
Cadherin signaling pathway  P00012 3 1.00% 3.50% 5.08E-01 3.18E+00 
CCKR signaling map  P06959 3 1.00% 3.50% 7.45E-01 3.28E+00 
Apoptosis signaling pathway  P00006 2 0.60% 2.40% 6.97E-01 3.34E+00 
Angiogenesis  P00005 2 0.60% 2.40% 1.00E+00 1.00E+00 
Ionotropic glutamate receptor 
pathway  
P00037 2 0.60% 2.40% 1.74E-01 2.36E+00 
FGF signaling pathway  P00021 2 0.60% 2.40% 7.03E-01 3.27E+00 
B cell activation  P00010 2 0.60% 2.40% 2.74E-01 2.80E+00 
DPP signaling pathway  P06213 1 0.30% 1.20% 1.10E-01 2.56E+00 
DPP-SCW signaling pathway  P06212 1 0.30% 1.20% 9.70E-02 2.64E+00 
BMP/activin signaling pathway-
drosophila  
P06211 1 0.30% 1.20% 1.10E-01 2.24E+00 
Axon guidance mediated by 
Slit/Robo  
P00008 1 0.30% 1.20% 1.10E-01 2.24E+00 
Metabotropic glutamate receptor 
group III pathway  
P00039 1 0.30% 1.20% 1.10E-01 2.24E+00 




 Inflammation mediated by 
chemokine and cytokine 
P00031 33 2.80% 6.70% 2.28E-05 9.27E-04 
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signaling pathway 
Wnt signaling pathway  P00057 28 2.40% 5.70% 1.85E-02 3.02E-01 
T cell activation  P00053 21 1.80% 4.30% 2.95E-07 2.40E-05 
Table 9 (continued). 
 Heterotrimeric G-protein 
signaling pathway-Gq alpha and 
Go alpha mediated pathway  
P00027 17 1.50% 3.50% 1.74E-03 5.68E-02 
B cell activation  P00010 17 1.50% 3.50% 1.82E-06 9.91E-05 
Integrin signaling pathway  P00034 16 1.40% 3.30% 1.12E-01 8.33E-01 
Angiogenesis  P00005 15 1.30% 3.10% 9.70E-02 7.91E-01 
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway  
P00026 15 1.30% 3.10% 6.25E-02 7.27E-01 
Cadherin signaling pathway  P00012 15 1.30% 3.10% 5.56E-02 6.97E-01 
Nicotinic acetylcholine receptor 
signaling pathway  
P00044 14 1.20% 2.90% 2.66E-03 7.22E-02 
Gonadotropin-releasing hormone 
receptor pathway  
P06664 13 1.10% 2.70% 1.00E+00 1.01E+00 
EGF receptor signaling pathway  P00018 13 1.10% 2.70% 9.59E-02 8.22E-01 
Apoptosis signaling pathway  P00006 10 0.90% 2.00% 2.29E-01 1.24E+00 
CCKR signaling map  P06959 11 0.90% 2.20% 6.17E-01 1.60E+00 
Parkinson disease  P00049 10 0.90% 2.00% 8.77E-02 8.41E-01 
Interleukin signaling pathway  P00036 11 0.90% 2.20% 1.98E-02 2.93E-01 
PDGF signaling pathway  P00047 9 0.80% 1.80% 7.21E-01 1.53E+00 
FGF signaling pathway  P00021 9 0.80% 1.80% 4.27E-01 1.42E+00 




Figure 20 Average t-statistics for PANTHER pathways enriched in final models. 
Plots show the average t-statistic for most prevalent pathways. Mean gene expression 
values for each gene in a given pathway were compared for non-responders vs responders. 
(A) 309 identified genes from 5-FU pan-cancer model across pathways with highest gene 
percentage. (B) 1158 identified genes from GCB pan-cancer model across pathways with 
highest gene percentage. 
 
5.4 Discussion 
In our study we have shown that primary tumor gene expression can be a good 
predictor of cancer drug response. By utilizing different clustering and classification 
methods we predicted cancer drug response with model validation accuracy of up to 86%.  
 Our model validation results show stronger performance for the GCB model than 
the 5-FU model. We attribute the GCB model’s high prediction accuracy to multiple facets. 
First, the GCB model had a more substantial sample size of 92 patients. This was 
undoubtedly beneficial, as the algorithm was able to take advantage of the increased 
diversity in the training data to build a more robust model. Secondly, when clustering the 
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gene expression levels using a similarity threshold, the GCB data was grouped into fewer 
clusters; an indication the dataset was more homogenous and adaptable to dimension 
reduction.  Further, random forest cross-validation accuracy was optimized at a higher 
number of clusters than 5-FU (73% more genes), leading us to believe the larger sample 
size helped the model to better differentiate informative features from noise.  Another 
important variable between models is the specific cancer type on which model validation 
was performed. Our 5-FU training model was only able to predict with 76% accuracy on 
STAD patients (see  
Table 45) compared to the 84.1% overall accuracy.  This provides evidence that the 
pan-cancer model was better at predicting drug response for some cancer types than others. 
We infer from our results that some drugs target mechanisms that are shared across 
a majority of cancers, while others may target mechanisms specific to certain cancer 
families.  Our GCB pan-cancer model predicts all cancer types at comparable levels to that 
of the overall accuracy. On the other hand, a much higher variation in accuracy is seen 
from the 5-FU model ( 
Table 45).  In the cases where the targeted mechanisms of a drug are different across 
cancer families, we would expect to see a reduction in the prediction accuracies of cancers 
with dissimilar mechanisms.  When more data becomes available, future work could test 
the performance of models built on molecularly similar cancers of the same histology or 
anatomy, as suggested by a recent study [255]. 
Our gene set enrichment analysis reveals that many biological pathways relevant to 
drug metabolism and cancer are present in our most predictive gene modules. Both 5-FU 
 102 
and GCB pan-cancer models' predictors were found to have a high percent of genes from 
the WNT signaling pathway, 11.8% and 5.7%, respectively. This pathway's contribution to 
tumorigenesis via cell fate determination and cell migration have already been proven 
[256]. Moreover, upregulation of the WNT pathway is involved in more than 30% of gastric 
cancer cases [257]. This is supported by our data since stomach adenocarcinoma is the 
most populous cancer type in the 5-FU pan-cancer model (Table 7). Both pan-cancer 
models were also enriched for genes from the “inflammation mediated by chemokine and 
cytokine signaling” pathway. Chemokines direct trafficking and migration of immune cells 
and inhibition of these proteins has been proven effective in preventing the accumulation 
of leukocytes near sites of inflammation [254]. Lastly, integrin signaling was found within 
the top seven pathways from  
Table 8. Integrins are adhesion receptors that allow cells to respond to signals from 
the surrounding microenvironment by interacting with the extracellular matrix [258].  They 
have been implicated in cell adhesion-mediated drug resistance, a pro-survival and anti-
apoptotic function [259]. We believe the presence of these pathways in our models 




The results of our final approach for prediction cancer drug responses were 
conclusively accurate and, more importantly, interpretable.  Our classifier selected genes 
that are integral parts of drug metabolism and cancer biology.  This combination of 
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accuracy and interpretability has been difficult to achieve in predictive models attempted 
in the past.  We attribute our success to the utilization of in-vivo gene expression data, 
which eliminates the need to extrapolate human drug responses from cell-line or other in-
vitro features.  Furthermore, our implementation of optCluster and random forest provided 
us with a method to perform dimension reduction in a biologically informative manner.  
Feature ranking, as we have shown, selects biologically relevant genes, that may yield new 
therapeutic targets.  While recent discussion has suggested machine learning can appear as 
"alchemy" [260], we encourage the continued effort in the field of personalized cancer 
medicine as it bears great potential for benefiting patients.  To conclude, predicting cancer 
drug response from patient RNA-seq data will be an important tool for personalized 
oncology.  We anticipate that predictive models, such as the ones we present, will continue 
to grow more powerful and will provide clinicians and patients with additional information 
to aid in selecting first or second-line therapies. 
 
5.6 Methods 
5.6.1 Clustering & Variable Selection 
Based on results from a previous study [25], which showed pan-cancer models out-
performed single cancer models, along with our own empirical analysis (see 
Supplementary Methods), our study focused on pan-cancer models. We relied on clustering 
methods for dimension reduction. We implemented six clustering algorithms (clara, 
hierarchical, k-means, model, pam, and sota) [261-265] to determine which would provide 
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the highest percentage of correct predictions (prediction accuracy).  We selected the top 
5,000 genes for clustering based on gene expression variability (Figure 43). 
To determine accuracy, we used the mean value for each gene module (cluster 
assignments) as a variable for prediction.  The number of observations were lower than the 
chosen number of clusters, so variable selection was performed. We used random forest to 
determine variable importance.  Random forest utilizes a forest of binary trees to split the 
data into multiple subsets based on predictive power.  To stabilize the ranked list of 
variable importance, we took the mean Gini value for each gene module after 200 random 
forest runs.  Mean decrease Gini was selected as it helped control for overfitting, an issue 
we were conscious of given the small sample size.  We determined the optimal number of 
variables for prediction by ranging the number of variables from one to the number of 
clusters and using random forest a second time to classify patients as responder or non-
responder.   
The accuracy obtained from the six clustering algorithms were computed and 
compared. We also attempted clustering with +/- 50% of the starting number of genes, but 
these yielded worse performances.  For the analysis, we used the R package, optCluster, 
and relied on internal validation to determine the stability of the clusters [252].  For each 
clustering method, we determined the best model by exploring the impact of the number 
of clusters on prediction accuracy. 
To find the best clustering algorithm for our study, we performed clustering and 
classification in a five-step process (Figure 44).    
1. The algorithm was run with N number of clusters (where N is in the range of 180-
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220; accuracies were observed to drop outside this cluster number range).    
2. Random forest was used to determine variable importance and perform variable 
selection. 
3. For each top n most important variables (where n is between 1 to N), random 
forest was used to classify each patient. 
4. The highest classification method was logged for the best value of N and n for 
each clustering method and for each drug model. 
5. The best model from the previous step was selected and the parameters were 
tuned to capture any additional accuracy.                 
To further validate the results, we assessed the accuracy rates of logistic regression and 
support vector machines when applied on our optimal random forest features. We also 
tested the impact of demographic data of the patients (gender, age, cancer type and cancer 
stage) on the accuracy of the model.   
 
5.6.2 Model Validation 
The final 5-FU and GCB models were trained on their respective pan-cancer data 
in which half of the patients from the most populous cancer, STAD or PAAD respectively, 
were held out as the validation sets.  To reduce the impact of small sample size in the pan-
cancer models, we used bootstrap as an up-sampling method to increase the size of the 
training set by 50%. The two validation sets consisted of 17 randomly selected STAD 
patients and 28 randomly selected PAAD patients for the 5-FU and GCB model 
respectively.   
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5.6.3 Statistical Methods: Gene Enrichment Analysis 
Our hypothesis was that the selected genes in our final model would be enriched 
for pathways involved in drug metabolism or cell signaling.  To test this hypothesis, we 
performed two statistical tests. First, we performed a PANTHER overrepresentation test. 
Using the results of the PANTHER analysis, we performed a t-test comparing the mean 
gene expression of responders and non-responders for the top twenty pathways based on 







SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
Figure 21 Scheme of the analysis pipeline used for this study. 
1) Matched normal and primary tumor sample data for three patients each from three 
cancer types were obtained from TCGA.  2) Transcriptome (RNA-seq) and whole genome 
sequence (DNA-seq) data were compared for normal versus tumor tissue samples.  3) RNA-
seq and DNA-seq data were analyzed to characterize TE expression levels and TE 
insertional activity for normal versus tumor tissue samples as shown.  4) Genomic features 




Figure 22 Scheme of the TE insertion detection analysis pipeline used for this study. 
Steps used to merge predictions from the MELT and Mobster programs are shown along 
with the post-processing steps used to ensure that accurate TE insertion predictions were 
chosen for subsequent analysis. 
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Figure 23 Density distributions for the numbers of mapped reads supporting TE 
insertion calls. 
Read depth distributions are shown for TE insertion calls made with the MELT (blue) and 
Mobster (orange) programs for all 18 of the matched normal and primary tumor tissue samples 
analyzed here. The locations of the lower read depth threshold of 5 reads are indicated for 
each distribution with a gray line, and the distributions are all bounded by the upper read 
depth threshold corresponding to 4X the average sequencing depth of the sample. 
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Figure 24 Population frequencies of observed TE insertions in matched normal 
versus tumor tissue pairs are shown for all of the TEs analyzed here and for L1s 
alone. 
Frequencies are represented as in Figure 4, but data are shown for each individual sample 
across the three cancer types analyzed here.  
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Table 10 Data sources, programs, and statistical methods used in this study. 
 
Name Description Reference 
Data Sources 
TCGA RNA-seq data from matched normal-tumor patient 
samples from 13 cancer types 
[166] 
COSMIC Cancer Gene Census (CGC) annotations for 723 cancer-
associated genes 
[266] 
RepeatMasker Genomic coordinates and annotations for human TEs [129] 
NCBI RefSeq Genomic coordinates (exon/intron boundaries) for human 
genes 
[127] 





Coordinates and event counts of alternative splicing 
events in TCGA samples 
[122] 
Programs 
SplAdder Detection and quantification of alternative splicing events [268] 
BEDTools Identification of alternative splicing events colocated near 
TE sequences 
[71] 
DESeq2 Normalization of alternative splice isoform expression 












Blind transformation used to remove the experiment-wide 
trend of variance over mean, normalize alternative splice 




Algorithm to merge overlapping alternative splice 
isoforms based on >75% overlap of isoform genomic 




Quantification of the normalized change in expression 
levels of TE-derived alternative splice isoforms in tumor 
versus normal tissue 
 
G-test Maximum likelihood statistical significance test for 2x2 




Figure 25 Number of patient samples per cancer type analyzed here. 
RNA-seq data for matched normal-tumor sample pairs were taken from The Cancer 








Figure 26 Alternative splicing event types analyzed here. 
Four kinds of alternative splice events were analyzed for this study: intron retention, exon 
skipping, alternate 3’ splicing, and alternate 5’ splicing.  Splicing events were identified 
and characterized based on the mapping of RNA-seq reads to gene models, using the 
program SplAdder as previously described [268]. For each type of splicing event, its 
corresponding RNA-seq read mapping pattern is shown adjacent to a schematic of the 
inferred splicing event type.   
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Figure 27 Scheme for the identification TE-derived splice sites. 
The top panel shows 3’ and 5’ exon boundaries along with their canonical splice donor 
and acceptor site sequence motifs [242]. Potential TE-derived splice donor and acceptor 
sites were identified where TE sequences were found to overlap the canonical splice site 





Figure 28 Counts of human transposable element (TE) sequences in the human 
genome. 
TE names and counts are taken from RepeatMakser annotations.  TEs are grouped into 
four major classes, and TE family names are shown for each class.  The four major classes 
are: SINE – short interspersed nuclear element, LINE – long interspersed nuclear element, 
LTR – long terminal repeat containing element, and DNA – DNA-type element.  SINEs, 
LINEs, and LTRs are retrotransposons that transpose via a copy and paste mechanism 
catalyzed by reverse transcriptase; DNA-type elements transpose via a cut and paste 








Figure 29 Number of alternative splice events seen for human genes. 
Counts for the four different alternative splice event types are shown for TE-derived (white) 







Figure 30 Quantification and statistical testing for differential expression of TE-
derived alternative splice events. 
(A) The relative Expression Change (REC) metric quantifies the normalized change in 
expression levels of TE-derived alternative splice isoforms in tumor versus normal tissue.  
This metric accounts for the expression of TE and non-TE isoform in both normal and 
tumor issues.  Higher REC values indicate relatively higher expression of TE isoform in 
tumor tissue and vice versa.  Details on the expression counts and formulas can be found 
in the Methods section.  (B) Formulation of the 2x2 contingency matrix used for the G-test 




Figure 31 TE-derived alternative splicing in the CANT1 gene. 
(A) The location of CANT1 on the long arm of chromosome 17 is shown along with the 
specific location of its TE-derived alternative splicing event.  The presence of LINE and 
SINE sequences result in an exon skipping event.  (B) Distributions of the non-TE (blue) 
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and TE-derived (red) isoforms are shown for matched normal (left) and stomach 
adenocarcinoma samples (right).  (C) Relative expression change (REC) values are plotted 
against the corresponding G-test P-values (see Methods and Figure 30) for the matched 
normal and stomach adenocarcinoma samples.  The CANT1 TE-derived isoform values 
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Figure 32 Distribution of COSMIC census mutations in the 1KGP. 
The distribution of cancer associated mutations (all coding mutations in COSMIC Census 
Genes) within the 1KGP, color-coded by homozygous and heterozygous mutation as shown 
in the key. 
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Table 11 448 LoF COSMIC census mutations in TSGs of 1KGP. 
cosmicIds GeneName Description RoleInCancer Hets Homs 1KG_AF 
COSM44637 TP53 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM6458552 APOBEC3B Deletion - Frameshift oncogene, TSG 87 4 0.0189696 
COSM4766174 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM4040370 POLE Substitution - Missense TSG 2 0 3.99E-04 
COSM6357161 ARNT Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM912247 CAMTA1 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM302197 FANCA Substitution - Missense TSG 1 0 2.00E-04 
COSM3692861 CBLC Substitution - Missense oncogene, TSG 62 1 0.0127796 
COSM96955 SUFU Substitution - Missense TSG 1 0 2.00E-04 
COSM3528373 TMED1 Substitution - Missense TSG 1 0 2.00E-04 
COSM3152880 SGSM3 Substitution - Missense oncogene, TSG, fusion 3 0 5.99E-04 
COSM2152381 PPARG Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1738822 TP63 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1740190 CASC5 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM898756 SPEN Substitution - Missense TSG 1 0 2.00E-04 
COSM97174 PRDM1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1709781 PER1 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1222525 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM13713 
RP11-
145E5.5 Substitution - Missense TSG 1 0 2.00E-04 
COSM3279826 PALB2 Substitution - Missense TSG 4 0 7.99E-04 
COSM4707624 NOTCH2 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1471274 ERBB4 Substitution - Nonsense oncogene, TSG 1 0 2.00E-04 
COSM4525688 FAT1 Substitution - Missense TSG 3 0 5.99E-04 
COSM4852474 KAT6B Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1375475 FES Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM6469471 FAT1 Substitution - Missense TSG 17 0 0.00339457 
COSM5945710 ASXL1 Substitution - Missense TSG 4 0 7.99E-04 
COSM3117280 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM1051055 FAT4 Substitution - Missense TSG 2 0 3.99E-04 
COSM1321925 ATM Substitution - Missense TSG 5 0 9.98E-04 
COSM861 RB1 Substitution - Missense TSG 1 0 2.00E-04 
COSM6002376 ZFHX3 Substitution - Missense TSG 1 0 2.00E-04 
COSM1162368 KMT2C Substitution - Missense TSG 1 0 2.00E-04 
COSM1581248 KMT2C Substitution - Missense TSG 4 0 7.99E-04 
COSM3665212 AXIN2 Substitution - Missense TSG 2 0 3.99E-04 
COSM3291839 PTPRT Substitution - Missense TSG 1 0 2.00E-04 
COSM2911748 DNMT3A Substitution - Missense TSG 1 0 2.00E-04 
COSM5979811 NOTCH1 Substitution - Missense oncogene, TSG, fusion 2 0 3.99E-04 
COSM5981687 ASXL1 Substitution - Missense TSG 2 0 3.99E-04 
COSM403987 BCOR Substitution - Missense TSG, fusion 1 0 2.00E-04 
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Table 12 (continued). 
COSM1035959 CBLB Substitution - Missense TSG 1 0 2.00E-04 
COSM205536 ATR Substitution - Missense TSG 1 0 2.00E-04 
COSM87161 TET2 Substitution - Missense TSG 2 0 3.99E-04 
COSM50512 NOTCH1 Substitution - Missense oncogene, TSG, fusion 3 0 5.99E-04 
COSM1058511 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM5989825 RAD21 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM87153 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM1702652 KAT6B Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM5792284 BIRC3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM925 RB1 Substitution - Missense TSG 4 0 7.99E-04 
COSM4555574 TNFAIP3 Substitution - Missense TSG 1 0 2.00E-04 
COSM13463 
RP11-
145E5.5 Substitution - Missense TSG 11 0 0.00219649 
COSM1172017 NOTCH2 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1015967 ERBB4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM29723 MLH1 Unknown TSG 1 0 2.00E-04 
COSM485085 KMT2C Substitution - Nonsense TSG 1 0 2.00E-04 
COSM21828 ATM Substitution - Missense TSG 3 0 5.99E-04 
COSM5602899 BCL9L Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM6203207 KMT2D Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM2135245 RAD51B Substitution - Missense TSG, fusion 9 0 0.00179712 
COSM975877 NCOR1 Substitution - Missense TSG 5 0 9.98E-04 
COSM4990375 N4BP2L1 Substitution - Missense TSG 1 0 2.00E-04 
COSM6023789 MLH1 Substitution - Missense TSG 6 0 0.00119808 
COSM4171872 NOTCH1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM332031 FAT4 Substitution - Missense TSG 9 0 0.00179712 
COSM1197389 FAT1 Substitution - Missense TSG 7 0 0.00139776 
COSM3899739 NRG1 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM5981818 LZTR1 Substitution - Missense TSG 3 0 5.99E-04 
COSM1241437 KMT2C Substitution - Missense TSG 2 0 3.99E-04 
COSM4015501 PRF1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5940810 SMAD2 Substitution - Missense TSG 1 0 2.00E-04 
COSM5762836 ASXL1 Substitution - Missense TSG 1 0 2.00E-04 
COSM289289 MED12 Substitution - Missense TSG 1 0 2.00E-04 
COSM241285 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM368041 NCOR2 Substitution - Missense TSG 1 0 2.00E-04 
COSM41644 TET2 Substitution - Nonsense TSG 2 0 3.99E-04 
COSM4682092 EXT2 Substitution - Missense TSG 2 0 3.99E-04 
COSM990606 KEAP1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5945587 PHF6 Substitution - Missense TSG 0 0 0 
COSM3733340 FAT4 Substitution - Missense TSG 2 0 3.99E-04 
COSM4698764 LRIG3 Substitution - Missense TSG, fusion 6 0 0.00119808 
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Table 13 (continued). 
COSM3084735 PMS2 Substitution - Missense TSG 1 0 2.00E-04 
COSM1709385 ZFHX3 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3284349 TCF3 Substitution - Missense oncogene, TSG, fusion 3 0 5.99E-04 
COSM3732749 LRP1B Substitution - Missense TSG 2 0 3.99E-04 
COSM3967980 SH2B3 Substitution - Missense TSG 1 0 2.00E-04 
COSM5376647 BRCA2 Substitution - Missense TSG 1 0 2.00E-04 
COSM4383892 TET2 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM36249 TNFAIP3 Substitution - Missense TSG 63 1 0.0129792 
COSM6025620 PML Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1033838 MYH9 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4830573 SLC34A2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM186809 MLH1 Substitution - Missense TSG 3 0 5.99E-04 
COSM5020249 TET2 Substitution - Missense TSG 383 40 0.0924521 
COSM1054236 FAT1 Substitution - Missense TSG 4 0 7.99E-04 
COSM6469473 FAT1 Substitution - Missense TSG 3 0 5.99E-04 
COSM3417538 N4BP2L1 Substitution - Missense TSG 1 0 2.00E-04 
COSM3740582 NOTCH2 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM327337 TET2 Substitution - Missense TSG 12 0 0.00239617 
COSM99653 NOTCH1 Substitution - Missense oncogene, TSG, fusion 2 0 3.99E-04 
COSM279944 CLTCL1 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM404245 CD274 Substitution - Missense TSG, fusion 3 0 5.99E-04 
COSM224982 EXT2 Substitution - Missense TSG 2 0 3.99E-04 
COSM1006985 LRP1B Substitution - Missense TSG 9 1 0.00219649 
COSM1637799 FHIT Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM2796667 AXIN2 Substitution - Missense TSG 1 0 2.00E-04 
COSM1035875 VHL Substitution - Missense TSG 1 0 2.00E-04 
COSM42084 TET2 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM5357611 ARID1B Substitution - Missense TSG 1 0 2.00E-04 
COSM1351719 BCL9L Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM142703 PTPRT Substitution - Missense TSG 1 0 2.00E-04 
COSM1714395 APOBEC3B Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM4039331 ETV6 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM6329722 POLE Substitution - Missense TSG 1 0 2.00E-04 
COSM947808 RB1 Substitution - Missense TSG 1 0 2.00E-04 
COSM4139978 PER1 Substitution - Missense TSG, fusion 16 0 0.00319489 
COSM4989668 CBLC Substitution - Missense oncogene, TSG 3 0 5.99E-04 
COSM5020556 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM303861 
RP11-
145E5.5 Substitution - Missense TSG 1 0 2.00E-04 
COSM6413439 CBFA2T3 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM278449 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM4596715 FAT4 Substitution - Missense TSG 11 0 0.00219649 
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Table 14 (continued). 
COSM5712841 TCF3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM6229984 NTRK1 Substitution - Missense oncogene, TSG, fusion 12 0 0.00239617 
COSM1050869 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM1581234 KMT2C Substitution - Missense TSG 3 0 5.99E-04 
COSM3639951 PMS2 Substitution - Missense TSG 5 0 9.98E-04 
COSM4733147 TET2 Substitution - Missense TSG 2 0 3.99E-04 
COSM5020081 TYW1 Unknown TSG 8 0 0.00159744 
COSM4126516 PTPN13 Substitution - Missense TSG 2 0 3.99E-04 
COSM5979034 
CTC-
554D6.1 Substitution - Missense TSG 2 0 3.99E-04 
COSM4040376 POLE Substitution - Missense TSG 1 0 2.00E-04 
COSM3505442 FES Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM3291831 PTPRT Substitution - Missense TSG 1 0 2.00E-04 
COSM3687129 ARHGEF12 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1195213 ETNK1 Substitution - Missense TSG 2 0 3.99E-04 
COSM6289411 CHEK2 Substitution - Missense TSG 1 0 2.00E-04 
COSM3793095 ERCC5 Substitution - Missense TSG 21 1 0.00459265 
COSM6023913 CDH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5576878 NOTCH2 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM5748604 NTRK1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4928397 CLTCL1 Substitution - Missense TSG, fusion 3 0 5.99E-04 
COSM4799369 DDX10 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4415590 FANCA Substitution - Missense TSG 279 37 0.0704872 
COSM1087645 KMT2C Substitution - Missense TSG 1 0 2.00E-04 
COSM245482 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM21637 ATM Substitution - Missense TSG 1 0 2.00E-04 
COSM5462513 PKD1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5507365 TERT Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM3042197 ERCC3 Substitution - Missense TSG 13 0 0.00259585 
COSM1408311 MSH6 Substitution - Missense TSG 2 0 3.99E-04 
COSM6035524 ARHGEF12 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1221785 PPP2R1A Substitution - Missense TSG 1 0 2.00E-04 
COSM4899601 PALB2 Substitution - Missense TSG 1 0 2.00E-04 
COSM6466277 LRP1B Substitution - Missense TSG 24 0 0.00479233 
COSM14367 VHL Substitution - Missense TSG 2 0 3.99E-04 
COSM1496821 WRN Substitution - Missense TSG 2 0 3.99E-04 
COSM5020362 SUFU Substitution - Missense TSG 3 0 5.99E-04 
COSM3672430 CDK12 Substitution - Missense TSG 1 0 2.00E-04 
COSM4538895 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM3968227 ARID2 Substitution - Missense TSG 1 0 2.00E-04 
COSM4748966 CREBBP Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4665561 BCORL1 Substitution - Nonsense oncogene, TSG 1 0 2.00E-04 
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Table 15 (continued). 
COSM1256743 LRP1B Substitution - Missense TSG 10 0 0.00199681 
COSM1039402 ATR Substitution - Missense TSG 1 0 2.00E-04 
COSM248836 APC Substitution - Missense TSG 0 0 0 
COSM262336 NCOR1 Substitution - Missense TSG 12 0 0.00239617 
COSM5990008 CDH11 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4672963 CLTCL1 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM3591209 TP63 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM3009860 FAT4 Substitution - Missense TSG 2 0 3.99E-04 
COSM4720948 RECQL4 Substitution - Missense oncogene, TSG 3 0 5.99E-04 
COSM3968387 WIF1 Substitution - Nonsense TSG, fusion 1 0 2.00E-04 
COSM93978 BRCA1 Substitution - Missense TSG 1 0 2.00E-04 
COSM4749447 TP53 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4606547 SETD2 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM5879023 TET2 Unknown TSG 1 0 2.00E-04 
COSM3740792 SPEN Substitution - Missense TSG 1 0 2.00E-04 
COSM5021138 CLTCL1 Substitution - Missense TSG, fusion 5 0 9.98E-04 
COSM5899948 PBRM1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1716814 PTPN13 Substitution - Missense TSG 40 1 0.00838658 
COSM1058526 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM1216588 NAB2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM3364915 VHL Substitution - Missense TSG 5 0 9.98E-04 
COSM3392822 FAT1 Substitution - Missense TSG 1 0 2.00E-04 
COSM2871917 RECQL4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM22487 ATM Substitution - Missense TSG 1 0 2.00E-04 
COSM4589981 LZTR1 Unknown TSG 893 2 0.179113 
COSM5989823 FAT4 Substitution - Missense TSG 2 0 3.99E-04 
COSM4683689 FAT4 Substitution - Missense TSG 4 0 7.99E-04 
COSM133736 DNMT3A Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3724370 NOTCH1 Substitution - Missense oncogene, TSG, fusion 2 0 3.99E-04 
COSM1471496 EP300 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM87012 DNMT3A Substitution - Missense TSG 0 0 0 
COSM473150 BRIP1 Substitution - Missense TSG 1 0 2.00E-04 
COSM2871931 RECQL4 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM6338144 BCL9L Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM1297701 BCL9L Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM231547 DNMT3A Substitution - Missense TSG 1 0 2.00E-04 
COSM42076 TET2 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3131780 FAT1 Substitution - Missense TSG 2 0 3.99E-04 
COSM5494125 PTK6 Substitution - Missense oncogene, TSG 4 0 7.99E-04 
COSM4893689 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM1204277 DNM2 Substitution - Missense TSG 1 0 2.00E-04 
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Table 16 (continued). 
COSM5985274 KMT2C Substitution - Missense TSG 14 0 0.00279553 
COSM1679262 ZFHX3 Substitution - Missense TSG 2 0 3.99E-04 
COSM2739084 NCOR1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1194722 FAT1 Substitution - Missense TSG 5 0 9.98E-04 
COSM21938 ATM Substitution - Missense TSG 1 0 2.00E-04 
COSM4383801 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM1050971 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM3699056 NRG1 Substitution - Missense TSG, fusion 167 15 0.0393371 
COSM922707 ATM Substitution - Missense TSG 2 0 3.99E-04 
COSM4382532 BMPR1A Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM6461750 CARS Substitution - Missense TSG, fusion 10 0 0.00199681 
COSM6324495 FAT1 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3443164 ATM Substitution - Missense TSG 1 0 2.00E-04 
COSM3100110 ELL Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM986144 PER1 Substitution - Missense TSG, fusion 3 0 5.99E-04 
COSM20674 NTRK1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5428669 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM5764815 PBRM1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5980437 POLE Substitution - Missense TSG 1 0 2.00E-04 
COSM3600130 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM1058546 PTPN13 Substitution - Missense TSG 2 0 3.99E-04 
COSM4384332 KMT2C Substitution - Missense TSG 1 0 2.00E-04 
COSM947376 FOXO1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4129165 CDH11 Substitution - Missense TSG, fusion 673 118 0.18151 
COSM3520127 RNF43 Substitution - Missense TSG 10 0 0.00199681 
COSM4103837 MYH9 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM3559467 ATP2B3 Substitution - Missense TSG 1 0 2.00E-04 
COSM1243234 EXT2 Substitution - Missense TSG 1 0 2.00E-04 
COSM3279882 DCTN5 Substitution - Missense TSG 3 0 5.99E-04 
COSM601786 PMS2 Substitution - Missense TSG 16 0 0.00319489 
COSM1184281 AXIN2 Substitution - Missense TSG 4 0 7.99E-04 
COSM6339935 TGFBR2 Substitution - Missense TSG 2 0 3.99E-04 
COSM4018618 ARHGEF12 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4440896 RUNX1T1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM43680 TP53 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5369878 
RP11-
145E5.5 Substitution - Missense TSG 1 0 2.00E-04 
COSM3513236 CBFA2T3 Substitution - Missense TSG, fusion 6 0 0.00119808 
COSM3402556 GRIN2A Substitution - Missense TSG 1 0 2.00E-04 
COSM4419889 DNM2 Substitution - Missense TSG 11 0 0.00219649 
COSM4716121 PMS2 Substitution - Missense TSG 22 0 0.00439297 
COSM6229194 KMT2C Substitution - Missense TSG 1 0 2.00E-04 
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Table 17 (continued). 
COSM5880093 NOTCH1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4588060 WRN Substitution - Missense TSG 6 0 0.00119808 
COSM5851889 NCOR1 Substitution - Missense TSG 1 0 2.00E-04 
COSM11606 TP53 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4999323 SLC25A1 Deletion - Frameshift TSG, fusion 20 1 0.00439297 
COSM1032073 CLTCL1 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM1642075 PPARG Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM5870389 ZBTB22 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM4584283 MLH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1039312 XPC Substitution - Missense TSG 1 0 2.00E-04 
COSM5548996 NOTCH1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM1375971 ERCC4 Substitution - Missense TSG 1 0 2.00E-04 
COSM4980437 ATP2B3 Substitution - Missense TSG 0 0 0 
COSM3879563 KMT2C Substitution - Missense TSG 2 0 3.99E-04 
COSM1199596 CARS Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM2226965 NCOR2 Substitution - Missense TSG 1 0 2.00E-04 
COSM144596 KMT2D Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM4986919 PALB2 Substitution - Missense TSG 43 0 0.00858626 
COSM211728 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM1718902 FOXO3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5980256 CDKN1B Substitution - Missense TSG 1 0 2.00E-04 
COSM1394499;COSM1683551 CBLC Insertion - Frameshift oncogene, TSG 360 37 0.0866613 
COSM4383607 DNMT3A Substitution - Nonsense TSG 1 0 2.00E-04 
COSM4923010 DICER1 Substitution - Missense TSG 1 0 2.00E-04 
COSM5019704 BRCA2 Substitution - Missense TSG 6 0 0.00119808 
COSM4059146 TSC2 Substitution - Missense TSG 1 0 2.00E-04 
COSM4406524 SPEN Substitution - Missense TSG 1 0 2.00E-04 
COSM719370 ERBB4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM4416035 MSH6 Substitution - Missense TSG 14 0 0.00279553 
COSM41741 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM5008355 FAT4 Substitution - Missense TSG 44 2 0.00958466 
COSM5020989 ATM Substitution - Missense TSG 2 0 3.99E-04 
COSM4039895 NCOR2 Substitution - Missense TSG 1 0 2.00E-04 
COSM5940326 PTPRB Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3390954 LRP1B Substitution - Missense TSG 2 0 3.99E-04 
COSM1691126 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM5341968 POLE Substitution - Missense TSG 1 0 2.00E-04 
COSM3765996 NCOR1 Substitution - Missense TSG 20 0 0.00399361 
COSM3151672 APOBEC3B Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM5765556 LEF1 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM5749277 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
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Table 18 (continued). 
COSM5985218 FAT1 Substitution - Missense TSG 1 0 2.00E-04 
COSM4988714 SDHB Substitution - Missense TSG 1 0 2.00E-04 
COSM5515797 MKL1 Substitution - Missense oncogene, TSG, fusion 2 0 3.99E-04 
COSM5711936 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM5019598 LRP1B Substitution - Missense TSG 20 0 0.00399361 
COSM4119165 PBRM1 Substitution - Missense TSG 1 0 2.00E-04 
COSM2813147 DNM2 Substitution - Missense TSG 1 0 2.00E-04 
COSM4698822 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM441184 LRP1B Substitution - Missense TSG 2 0 3.99E-04 
COSM5019975 NTRK1 Substitution - Missense oncogene, TSG, fusion 108 7 0.024361 
COSM1212595 KLF6 Substitution - Missense TSG 2 0 3.99E-04 
COSM1232948 XPC Substitution - Missense TSG 6 1 0.00159744 
COSM197777 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM5019884 CLTCL1 Substitution - Missense TSG, fusion 40 1 0.00838658 
COSM471318 ERCC4 Substitution - Missense TSG 1 0 2.00E-04 
COSM5042148 MKL1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM4575243 POLE Substitution - Missense TSG 2 0 3.99E-04 
COSM181752 SPEN Substitution - Missense TSG 2 0 3.99E-04 
COSM4992716 ZBTB22 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1222582 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
COSM6412981 ELL Substitution - Missense TSG, fusion 3 0 5.99E-04 
COSM36205 ASXL1 Substitution - Missense TSG 26 0 0.00519169 
COSM3152897 MKL1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM6284223 EPAS1 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM1235467 NOTCH1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5020963 ATM Substitution - Missense TSG 7 0 0.00139776 
COSM3009627 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM2871902 RECQL4 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM145584 LRIG3 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM923664 BCL9L Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM6475880 TGFBR2 Unknown TSG 1 0 2.00E-04 
COSM1321166 BMPR1A Substitution - Missense oncogene, TSG 5 0 9.98E-04 
COSM13385 MSH6 Substitution - Missense TSG 1 0 2.00E-04 
COSM446120 MAP3K13 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM5920788 BLM Substitution - Missense TSG 1 0 2.00E-04 
COSM6352341 CDH1 Substitution - Missense TSG 6 0 0.00119808 
COSM5967258 CHEK2 Deletion - Frameshift TSG 5 0 9.98E-04 
COSM220521 EP300 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM3186044 MSH6 Insertion - Frameshift TSG 40 0 0.00798722 
COSM5020928 HPDL Substitution - Missense TSG 12 0 0.00239617 
COSM3983748 NRG1 Substitution - Missense TSG, fusion 5 0 9.98E-04 
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Table 19 (continued). 
COSM5776518 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM3133345 SLC34A2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM85140 RSPO2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM3786996 ARHGEF12 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4950062 EXT2 Substitution - Missense TSG 2 0 3.99E-04 
COSM5008803 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM3398773 KMT2D Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM5694461 DNM2 Substitution - Missense TSG 1 0 2.00E-04 
COSM5575916 ATRX Substitution - Missense TSG 1 0 2.00E-04 
COSM5020013 TET2 Substitution - Missense TSG 413 23 0.0916534 
COSM5989864 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM4984943 ERCC5 Substitution - Missense TSG 86 4 0.01877 
COSM1026894 PTPRT Substitution - Missense TSG 1 0 2.00E-04 
COSM3365254 BAP1 Substitution - Missense TSG 1 0 2.00E-04 
COSM145832 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
COSM6023987 CDH1 Substitution - Missense TSG 2 0 3.99E-04 
COSM12507 
RP11-
145E5.5 Substitution - Missense TSG 1 0 2.00E-04 
COSM898730 SPEN Substitution - Missense TSG 1 0 2.00E-04 
COSM4989562 PTPRT Substitution - Missense TSG 2 0 3.99E-04 
COSM3235559 ATP2B3 Substitution - Missense TSG 1 0 2.00E-04 
COSM4117131 MLH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1362025 KMT2D Substitution - Missense oncogene, TSG 41 1 0.00858626 
COSM3766291 TCF3 Substitution - Missense oncogene, TSG, fusion 42 0 0.00838658 
COSM1391233 TCF3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5008349 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM2716441 ERBB4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM5903691 WRN Substitution - Missense TSG 1 0 2.00E-04 
COSM5945045 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM2111018 DDX10 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM2923605 FANCA Substitution - Missense TSG 1 0 2.00E-04 
COSM28777 KDM6A Substitution - Nonsense oncogene, TSG 0 0   
COSM4718596 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM907737 ARID1A Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1007064 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM202922 NCOR2 Substitution - Missense TSG 1 0 2.00E-04 
COSM3133335 SLC34A2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM5612735 POLE Substitution - Missense TSG 1 0 2.00E-04 
COSM6405476 AXIN1 Substitution - Missense TSG 3 0 5.99E-04 
COSM6200068 CAMTA1 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM1213728 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM4122123 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
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Table 20 (continued). 
COSM4912352 FAT1 Substitution - Missense TSG 2 0 3.99E-04 
COSM4851464 BCL9L Substitution - Missense oncogene, TSG 6 0 0.00119808 
COSM5019549 BLM Substitution - Missense TSG 237 10 0.0513179 
COSM5981146 NCOR1 Substitution - Missense TSG 1 0 2.00E-04 
COSM1750941 PAFAH1B3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM5995709 PTPN13 Substitution - Missense TSG 2 0 3.99E-04 
COSM5869076 FOXO3 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM242616 RECQL4 Substitution - Missense oncogene, TSG 2 0 3.99E-04 
COSM3952512 NOTCH1 Substitution - Missense oncogene, TSG, fusion 2 0 3.99E-04 
COSM5415553 PTPRK Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM1685386 SH2B3 Substitution - Missense TSG 1 0 2.00E-04 
COSM3567190 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM3899655 WRN Substitution - Missense TSG 3 0 5.99E-04 
COSM914244 SUFU Substitution - Missense TSG 1 0 2.00E-04 
COSM2922693 CBFA2T3 Substitution - Missense TSG, fusion 3 0 5.99E-04 
COSM899738 SDHB Substitution - Missense TSG 1 0 2.00E-04 
COSM4588244 NBN Substitution - Missense TSG 1 0 2.00E-04 
COSM5981750 PTK6 Substitution - Missense oncogene, TSG 6 0 0.00119808 
COSM97172 PRDM1 Substitution - Missense TSG 2 0 3.99E-04 
COSM968803 PALB2 Substitution - Missense TSG 1 0 2.00E-04 
COSM6467686 PTPRT Substitution - Missense TSG 2 0 3.99E-04 
COSM1235622 MYH9 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM6455249 WRN Substitution - Nonsense TSG 1 0 2.00E-04 
COSM24635 ATM Substitution - Missense TSG 6 0 0.00119808 
COSM3172222 PTPRK Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM22499 ATM Substitution - Missense TSG 13 0 0.00259585 
COSM3754971 CDH11 Substitution - Missense TSG, fusion 738 175 0.217252 
COSM5743825 PER1 Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM5019671 RANBP2 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM219132 CBL Substitution - Nonsense oncogene, TSG, fusion 1 0 2.00E-04 
COSM943175 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
COSM1736534 PML Substitution - Missense TSG, fusion 2 0 3.99E-04 
COSM3235547 ATP2B3 Substitution - Missense TSG 0 0 0 
COSM4986833 ERCC4 Substitution - Missense TSG 131 6 0.0285543 
COSM5784452 ZFHX3 Substitution - Missense TSG 1 0 2.00E-04 
COSM1579580 FANCA Substitution - Missense TSG 109 4 0.0233626 
COSM982272 BRIP1 Substitution - Missense TSG 1 0 2.00E-04 
COSM232262 ERBB4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM3663500 EIF3E Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM4582279 CHEK2 Substitution - Missense TSG 2 0 3.99E-04 
COSM3304542 KMT2C Substitution - Missense TSG 2 0 3.99E-04 
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Table 21 (continued). 
COSM3466980 ERCC5 Substitution - Missense TSG 5 0 9.98E-04 
COSM3753566 ERCC5 Substitution - Missense TSG 1118 346 0.361422 
COSM5587819 FES Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1049765 TET2 Substitution - Missense TSG 1 0 2.00E-04 
COSM5537808 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
COSM17485 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM3909209 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM4605861 NOTCH2 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM163645 POT1 Substitution - Missense TSG 1 0 2.00E-04 
COSM3772152 TSC2 Substitution - Missense TSG 1 0 2.00E-04 
COSM48575 MSH6 Substitution - Missense TSG 1 0 2.00E-04 
COSM4606482 KMT2C Substitution - Missense TSG 1 0 2.00E-04 
COSM4169988 NOTCH1 Substitution - Missense oncogene, TSG, fusion 1 0 2.00E-04 
COSM282501 LRP1B Substitution - Missense TSG 1 0 2.00E-04 
COSM4631416 PTCH1 Substitution - Missense TSG 1 0 2.00E-04 
COSM21301 ATM Substitution - Missense TSG 2 0 3.99E-04 
COSM977450 NF1 Substitution - Missense TSG, fusion 1 0 2.00E-04 
COSM430330 SH2B3 Substitution - Missense TSG 1 0 2.00E-04 
COSM4987639 ERCC4 Substitution - Missense TSG 29 0 0.00579073 
COSM1131275 FAT4 Substitution - Missense TSG 1 0 2.00E-04 
COSM5019066 TSC2 Substitution - Missense TSG 4 0 7.99E-04 
COSM1222520 PTPN13 Substitution - Missense TSG 1 0 2.00E-04 
COSM3639952 PMS2 Substitution - Missense TSG 1 0 2.00E-04 
COSM3457812 NCOR2 Substitution - Missense TSG 1 0 2.00E-04 
COSM2716452 ERBB4 Substitution - Missense oncogene, TSG 1 0 2.00E-04 
COSM1979240 EXT2 Substitution - Missense TSG 4 0 7.99E-04 
COSM249142 DNMT3A Substitution - Missense TSG 1 0 2.00E-04 
COSM5005948 ERCC4 Substitution - Missense TSG 4 0 7.99E-04 
COSM3756940 CBLC Substitution - Missense oncogene, TSG 449 24 0.0992412 
COSM5627064 BLM Substitution - Missense TSG 1 0 2.00E-04 
COSM6376158 KMT2C Substitution - Missense TSG 2 0 3.99E-04 
COSM922745 ATM Substitution - Missense TSG 1 0 2.00E-04 
COSM4606553 SH2B3 Substitution - Missense TSG 6 0 0.00119808 
COSM3399055 PTPRB Substitution - Missense TSG 1 0 2.00E-04 
COSM5569099 ZFHX3 Substitution - Missense TSG 0 0 0 
COSM5016779 BRIP1 Substitution - Missense TSG 1 0 2.00E-04 
COSM6357850 LZTR1 Substitution - Nonsense TSG 1 0 2.00E-04 
COSM3149630 MYH9 Substitution - Missense TSG, fusion 2 0 3.99E-04 




Figure 33 ASE workflow used in this study. 
Matched normal and primary tumor samples for four cancer types were analyzed for allele-
specific expression using whole exome (DNA-seq) and transcriptome (RNA-seq) data.  
DNA-seq data was used to identify heterozygous sites in the exome and RNA-seq data was 
analyzed to compare expression of reference vs alternative alleles at those sites. The core 






Table 22 Percent of genes displaying ASE in 233 TCGA patients. 






1 9.6 9.3 9.1 8.3 9.3 
2 0.5 0.5 0.4 0.3 0.7 
3 0.0 0.0 0.0 0.0 0.0 
4 3.4 3.3 2.8 3.4 3.7 
5 2.7 2.2 2.1 2.5 2.1 
6 0.1 0.1 0.0 0.0 0.1 





1 12.4 12.5 11.1 13.6 13.1 
2 0.4 0.3 0.1 0.6 0.6 
3 0.1 0.1 0.1 0.0 0.2 
4 4.2 4.1 4.5 3.9 3.8 
5 2.6 2.0 2.0 2.1 1.7 
6 0.1 0.2 0.1 0.1 0.3 





1 13.4 13.1 13.2 12.5 14.0 
2 0.3 0.3 0.1 0.4 0.4 
3 0.0 0.1 0.0 0.0 0.1 
4 5.2 5.7 5.6 5.5 5.8 
5 1.7 1.3 1.4 1.6 1.4 
6 0.1 0.0 0.0 0.1 0.0 





1 3.3 2.9 2.8 3.3 3.8 
2 0.3 0.3 0.1 0.2 0.6 
3 0.0 0.0 0.0 0.0 0.0 
4 0.5 0.5 0.2 0.5 1.0 
5 2.6 2.2 2.6 2.3 2.2 
6 0.0 0.0 0.0 0.0 0.0 




Figure 34 Frequency of ASE in tumor suppressor genes. 
Gene level ASE was computed as described in the Materials and Methods section. a, The 
proportion of head and neck cancer patients with ASE in 64 TSGs b, The proportion of 
lung cancer patients with ASE in 89 TSGs c, The proportion of thyroid cancer patients with 
ASE in 55 TSGs. 
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Table 23 DNA-sequencing (DNA-seq) and RNA-sequencing (RNA-seq) data sources 
for the nine TCGA patients analyzed for mechanism of ASE in this study. 
ID TCGA Barcode 
Cancer 
Type 






























F 53 White 
NT-G 42.4 100 
TCGA-BH-A0B3-11B-21R-A089-07 NT-R 5.5 50 
TCGA-BH-A0B3-11B-21W-A100-09 NT-X 8.1 100 
TCGA-BH-A0B3-01A-11D-A128-09 TP-G 40.2 100 
TCGA-BH-A0B3-01B-21R-A089-07 TP-R 5.4 50 








F 71 Black 
NT-G 54.1 100 
TCGA-BH-A0BW-11A-12R-A115-07 NT-R 7 50 
TCGA-BH-A0BW-11A-12D-A10Y-
09 
NT-X 14.7 100 
TCGA-BH-A0BW-01A-11D-A10Y-
09 
TP-G 46.1 100 
TCGA-BH-A0BW-01A-12R-A115-07 TP-R 7.3 50 
TCGA-BH-A0BW-01A-11D-A10Y-
09 








F 41 White 
NT-G 63.3 100 
TCGA-BH-A0DT-11A-12R-A12D-07 NT-R 7.7 50 
TCGA-BH-A0DT-11A-12D-A12B-09 NT-X 22.7 100 
TCGA-BH-A0DT-01A-21D-A12B-09 TP-G 79.9 100 
TCGA-BH-A0DT-01A-21R-A12D-07 TP-R 6.6 50 

































F 32 White 
NT-G 6.9 101 
TCGA-CV-7255-11A-01R-2016-07 NT-R 7.5 48 
TCGA-CV-7255-11A-01D-2012-08 NT-X 27.3 76 
TCGA-CV-7255-01A-11D-2276-10 TP-G 5.8 101 
TCGA-CV-7255-01A-11R-2016-07 TP-R 7.1 48 







F 29 White 
NT-G 7.7 101 
TCGA-CV-7416-11A-01R-2081-07 NT-R 5.9 48 
TCGA-CV-7416-11A-01D-2078-08 NT-X 23.9 76 
TCGA-CV-7416-01A-11D-2334-08 TP-G 28.6 101 
TCGA-CV-7416-01A-11R-2081-07 TP-R 6 48 







M 48 White 
NT-G 38.3 51 
TCGA-CV-6959-11A-01R-1915-07 NT-R 8.5 48 
TCGA-CV-6959-11A-01D-1912-08 NT-X 26.8 76 
TCGA-CV-6959-01A-11D-1911-02 TP-G 31.4 51 
TCGA-CV-6959-01A-11R-1915-07 TP-R 6.6 48 























F 60 White 
NT-G 38.9 51 
TCGA-44-6776-11A-01R-1858-07 NT-R 5.4 48 
TCGA-44-6776-11A-01D-1855-08 NT-X 29.1 76 
TCGA-44-6776-01A-11D-1853-02 TP-G 6.9 51 
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TP-R 7.4 48 








M 75 White 
NT-G 34.6 101 
TCGA-50-5932-11A-01R-1755-07 NT-R 4.2 48 
TCGA-50-5932-11A-01D-1753-08 NT-X 29.3 76 
TCGA-50-5932-01A-11D-1753-08 TP-G 44.5 101 
TCGA-50-5932-01A-11R-1755-07 TP-R 7.4 48 








F NA White 
NT-G 36.2 101 
TCGA-55-6984-11A-01R-1949-07 NT-R 4.9 48 
TCGA-55-6984-11A-01D-1945-08 NT-X 23.1 76 
TCGA-55-6984-01A-11D-1945-08 TP-G 41 101 
TCGA-55-6984-01A-11R-1949-07 TP-R 5.2 48 
TCGA-55-6984-01A-11D-1945-08 TP-X 17.8 76 
aNT-G=Normal tissue WGS, NT-R=Normal tissue RNA-seq, NT-X=Normal tissue 
WXS, TP-G=Tumor primary WGS, TP-R=Tumor primary RNA-seq, TP-X=Tumor 





Figure 35 Heatmap of COSMIC genes across 9 patients analyzed for mechanism of 
ASE. 
Rows are genes and columns are samples. Genes are sorted by genomic location. Samples 
are grouped by tissue type, tumor (left) and normal (right) and by cancer (lung, breast, 
head & neck). Significant ASE (P < 0.05) genes are shown in red (alt > ref) and blue (ref 
> alt). Note some genes have significant ASE however their direction is ambiguous 




Figure 36 Distribution of ASE SNPs in the genome from 9 patients studied for 
mechanism. 
Genome Ideogram showing locations of ASE SNPs marked in red; TSGs denoted with 




Figure 37 ASE eGenes. 
Heterozygous eQTLs associated with protein coding genes (eGenes) were identified in 
patient samples using whole genome sequencing (WGS). a, Percentages of ASE genes 
associated with eQTLs in breast and lung cancer patient samples combined. b, Percentages 
of ASE genes associated with eQTLs broken down by individual patient sample. 
 















ASE Genes w 
beta value | 




Breast 1 845 8 0.9% 113 13.4 
Breast 2 834 6 0.7% 25 3.0 
Breast 3 296 5 1.7% 9 3.4 
Head & Neck 1 447 eQTLs not available 87 19.5 
Head & Neck 2 NA eQTLs not available Methylation data not available 
Head & Neck 3 540 eQTLs not available 65 12.0 
Lung 1 458 25 5.4% Methylation data not available 
Lung 2 131 1 5.1% 15 13.0 
Lung 3 201 4 5.4% Methylation data not available 





Figure 38 eQTLs in cis and trans with ASE genes. 
Specific genomic regions spanning eQTLs and ASE SNPs were plotted using 
AllelicImbalance as described in the Materials and Methods. The top panels contain GTEx 
single tissue eQTL box plots and the relative expression of alleles for linked SNPs. The 
grey lines in the middle panel show where the SNP locations lie in relation to the 
appropriate genome track shown beneath in yellow. a, A heterozygous eQTL present in the 
3’ UTR of NUP54 in both the normal and tumor samples of a breast invasive carcinoma 
patient. b, Three eQTLs present downstream from NME7 which are homozygous reference 





Figure 39 Model for antisense induced allele-specific exon skipping and its 
contribution to ASE. 
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Figure 40 LOXL2 exon skipping correlates with ASE in a breast adenocarcinoma 
patient. 
a, An exon skipping event in exon 6 of TNC in a breast cancer patient (TCGA-BH-A0B3). 
b, Antisense reads mapping to donor and acceptor sites are quantified, alongside the ASE 
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locus within the exon. c, Quantification of reads supporting the isoform missing exon 6.  




Figure 41 TNC exon skipping correlates with ASE in a breast adenocarcinoma 
patient. 
a, An exon skipping event in exon 15 of TNC in a breast cancer patient (TCGA-BH-A0DT). 
b, Antisense reads mapping to donor and acceptor sites are quantified, alongside the ASE 
locus within the exon. c, Quantification of reads supporting the isoform missing exon 15.  
Relative expression plots are shown for antisense RNA, ASE and isoforms below. 
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Figure 42 Allelic ratios for all possible nucleotide combinations. 
Distribution of proportion of sites where reference allele count is greater than alternative 
allele count in normal samples for a, breast cancer patients. b, head and neck cancer 
patients. c, lung cancer patients. d, thyroid cancer patients. 
Table 26 Metadata for 233 TCGA patients analyzed in this study. 
TCGA Barcode Cancer Type Sex Age Race 
TCGA-A7-A0CE BRCA female 57 white 
TCGA-A7-A0D9 BRCA female 37 white 
TCGA-A7-A0DB BRCA female 56 white 
TCGA-A7-A13E BRCA female 62 white 
TCGA-A7-A13F BRCA female 44 white 
TCGA-A7-A13G BRCA female 79 white 
TCGA-AC-A23H BRCA female 90 white 
TCGA-AC-A2FB BRCA female 65 white 
TCGA-AC-A2FF BRCA female NA asian 
TCGA-AC-A2FM BRCA female 87 white 
TCGA-BH-A0AU BRCA female 45 white 
TCGA-BH-A0AY BRCA female 62 white 
TCGA-BH-A0AZ BRCA female 47 white 
TCGA-BH-A0B3 BRCA female 53 white 
TCGA-BH-A0B5 BRCA female 40 white 
TCGA-BH-A0B7 BRCA female 42 white 
TCGA-BH-A0B8 BRCA female 64 white 
TCGA-BH-A0BA BRCA female 51 white 
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Table 15 (continued). 
TCGA-BH-A0BC BRCA female 60 white 
TCGA-BH-A0BJ BRCA female 41 white 
TCGA-BH-A0BM BRCA female 54 white 
TCGA-BH-A0BQ BRCA female 39 white 
TCGA-BH-A0BT BRCA female 56 white 
TCGA-BH-A0BV BRCA female 78 white 
TCGA-BH-A0BW BRCA female 71 black or african american 
TCGA-BH-A0BZ BRCA female 59 white 
TCGA-BH-A0C0 BRCA female 63 white 
TCGA-BH-A0C3 BRCA female 47 white 
TCGA-BH-A0DD BRCA male 58 white 
TCGA-BH-A0DG BRCA female 30 black or african american 
TCGA-BH-A0DH BRCA female 64 white 
TCGA-BH-A0DK BRCA female 49 white 
TCGA-BH-A0DL BRCA female 64 white 
TCGA-BH-A0DP BRCA female 60 white 
TCGA-BH-A0DQ BRCA female 42 white 
TCGA-BH-A0DT BRCA female 41 white 
TCGA-BH-A0DV BRCA female 54 white 
TCGA-BH-A0DZ BRCA female 43 white 
TCGA-BH-A0E0 BRCA female 38 white 
TCGA-BH-A0E1 BRCA female 52 white 
TCGA-BH-A0H5 BRCA female 45 white 
TCGA-BH-A0H7 BRCA female 65 white 
TCGA-BH-A0H9 BRCA female 69 white 
TCGA-BH-A0HA BRCA female 31 white 
TCGA-BH-A0HK BRCA female 81 white 
TCGA-BH-A18J BRCA female 56 white 
TCGA-BH-A18K BRCA female 46 white 
TCGA-BH-A18L BRCA female 50 white 
TCGA-BH-A18M BRCA female 39 white 
TCGA-BH-A18N BRCA female 88 white 
TCGA-BH-A18P BRCA female 60 white 
TCGA-BH-A18Q BRCA female 56 white 
TCGA-BH-A18S BRCA female 79 white 
TCGA-BH-A18U BRCA female 72 white 
TCGA-BH-A18V BRCA female 48 white 
TCGA-BH-A1EN BRCA female 78 white 
TCGA-BH-A1EO BRCA female 68 white 
TCGA-BH-A1ET BRCA female 55 white 
TCGA-BH-A1EV BRCA female 45 white 
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Table 15 (continued). 
TCGA-BH-A1EW BRCA female 38 white 
TCGA-BH-A1F0 BRCA female 80 white 
TCGA-BH-A1F2 BRCA female 53 white 
TCGA-BH-A1F6 BRCA female 51 white 
TCGA-BH-A1F8 BRCA female 90 white 
TCGA-BH-A1FC BRCA female 78 black or african american 
TCGA-BH-A1FD BRCA female 68 white 
TCGA-BH-A1FE BRCA female 31 white 
TCGA-BH-A1FG BRCA female 88 white 
TCGA-BH-A1FH BRCA female 47 white 
TCGA-BH-A1FJ BRCA female 66 white 
TCGA-BH-A1FM BRCA female 44 white 
TCGA-BH-A1FN BRCA female 34 white 
TCGA-BH-A1FR BRCA female 73 white 
TCGA-BH-A1FU BRCA female 44 white 
TCGA-BH-A203 BRCA female 78 white 
TCGA-BH-A204 BRCA female 80 white 
TCGA-BH-A208 BRCA female 48 white 
TCGA-BH-A209 BRCA female 77 black or african american 
TCGA-E2-A153 BRCA female 51 white 
TCGA-E2-A158 BRCA female 43 white 
TCGA-E2-A15I BRCA female 44 white 
TCGA-E2-A15K BRCA female 58 white 
TCGA-E2-A15M BRCA female 66 white 
TCGA-E2-A1BC BRCA female 63 not reported 
TCGA-E2-A1LB BRCA female 41 black or african american 
TCGA-E2-A1LH BRCA female 59 white 
TCGA-E2-A1LS BRCA female 46 white 
TCGA-GI-A2C8 BRCA female 63 white 
TCGA-GI-A2C9 BRCA female 58 black or african american 
TCGA-CV-6933 HNSC male 53 white 
TCGA-CV-6934 HNSC female 66 white 
TCGA-CV-6935 HNSC male 67 white 
TCGA-CV-6936 HNSC male 68 white 
TCGA-CV-6938 HNSC male 87 white 
TCGA-CV-6939 HNSC male 60 white 
TCGA-CV-6943 HNSC male 74 white 
TCGA-CV-6955 HNSC female 74 white 
TCGA-CV-6956 HNSC male 67 white 
TCGA-CV-6959 HNSC male 48 white 
TCGA-CV-6960 HNSC male 49 black or african american 
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Table 15 (continued). 
TCGA-CV-6961 HNSC male 61 white 
TCGA-CV-6962 HNSC male 66 white 
TCGA-CV-7091 HNSC male 54 white 
TCGA-CV-7097 HNSC male 53 white 
TCGA-CV-7101 HNSC male 80 white 
TCGA-CV-7103 HNSC male 49 white 
TCGA-CV-7177 HNSC female 82 white 
TCGA-CV-7178 HNSC female 64 white 
TCGA-CV-7183 HNSC male 53 white 
TCGA-CV-7235 HNSC male 67 white 
TCGA-CV-7238 HNSC female 69 white 
TCGA-CV-7242 HNSC female 60 white 
TCGA-CV-7245 HNSC male 62 white 
TCGA-CV-7250 HNSC male 64 white 
TCGA-CV-7252 HNSC female 62 black or african american 
TCGA-CV-7255 HNSC female 32 white 
TCGA-CV-7261 HNSC male 57 white 
TCGA-CV-7406 HNSC male 50 white 
TCGA-CV-7416 HNSC female 29 white 
TCGA-CV-7423 HNSC male 65 white 
TCGA-CV-7424 HNSC male 67 asian 
TCGA-CV-7425 HNSC female 77 white 
TCGA-CV-7432 HNSC male 79 white 
TCGA-CV-7434 HNSC male 64 white 
TCGA-CV-7437 HNSC male 77 not reported 
TCGA-CV-7438 HNSC female 87 white 
TCGA-CV-7440 HNSC male 38 white 
TCGA-HD-8635 HNSC female 61 white 
TCGA-22-4593 LUAD male 77 white 
TCGA-22-4609 LUAD male 81 white 
TCGA-22-5471 LUAD male 76 white 
TCGA-22-5478 LUAD male 79 not reported 
TCGA-22-5481 LUAD female 72 white 
TCGA-22-5482 LUAD male 81 white 
TCGA-22-5483 LUAD male 74 white 
TCGA-22-5489 LUAD male 64 white 
TCGA-22-5491 LUAD male 74 white 
TCGA-33-4587 LUAD female 63 white 
TCGA-33-6737 LUAD male 71 white 
TCGA-38-4625 LUAD female 66 white 
TCGA-38-4626 LUAD female 57 white 
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Table 15 (continued). 
TCGA-38-4627 LUAD female 64 white 
TCGA-38-4632 LUAD male 42 black or african american 
TCGA-39-5040 LUAD male 59 white 
TCGA-43-6771 LUAD male 85 white 
TCGA-44-2655 LUAD female 65 white 
TCGA-44-2657 LUAD female 74 white 
TCGA-44-2662 LUAD male 65 white 
TCGA-44-5645 LUAD female 61 black or african american 
TCGA-44-6777 LUAD female 85 white 
TCGA-44-6778 LUAD male 59 black or african american 
TCGA-49-4490 LUAD female 45 white 
TCGA-49-6745 LUAD male 82 white 
TCGA-49-6761 LUAD female 68 white 
TCGA-50-5930 LUAD male 47 white 
TCGA-50-5931 LUAD female 75 white 
TCGA-50-5932 LUAD male 75 white 
TCGA-50-5933 LUAD male 72 white 
TCGA-50-5935 LUAD female 86 white 
TCGA-50-5936 LUAD male 58 white 
TCGA-50-5939 LUAD male 85 white 
TCGA-50-6595 LUAD female 74 white 
TCGA-51-4079 LUAD female 73 black or african american 
TCGA-55-6970 LUAD female 67 white 
TCGA-55-6972 LUAD male 72 white 
TCGA-55-6975 LUAD male NA white 
TCGA-55-6978 LUAD male NA white 
TCGA-55-6982 LUAD female NA white 
TCGA-55-6984 LUAD female NA white 
TCGA-55-6986 LUAD female NA white 
TCGA-56-7580 LUAD male 84 white 
TCGA-56-7582 LUAD male 84 white 
TCGA-77-7138 LUAD male 67 not reported 
TCGA-77-8007 LUAD male 68 not reported 
TCGA-85-7710 LUAD female 59 white 
TCGA-90-7767 LUAD male 56 white 
TCGA-91-6829 LUAD male 79 white 
TCGA-91-6831 LUAD male 66 white 
TCGA-91-6836 LUAD female 52 white 
TCGA-92-7340 LUAD female 45 white 
TCGA-BJ-A28R THCA female 38 white 
TCGA-BJ-A28X THCA female 32 white 
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Table 15 (continued). 
TCGA-BJ-A290 THCA male 70 white 
TCGA-BJ-A2N7 THCA female 30 white 
TCGA-BJ-A2N8 THCA female 30 white 
TCGA-BJ-A2N9 THCA female 42 white 
TCGA-BJ-A2NA THCA male 77 white 
TCGA-BJ-A3PR THCA female 70 white 
TCGA-BJ-A3PU THCA male 52 white 
TCGA-DO-A1JZ THCA female 23 black or african american 
TCGA-E8-A2JQ THCA female 18 white 
TCGA-EL-A3GZ THCA female 34 white 
TCGA-EL-A3H1 THCA female 66 black or african american 
TCGA-EL-A3H2 THCA male 58 white 
TCGA-EL-A3H7 THCA female 36 white 
TCGA-EL-A3MW THCA female 55 white 
TCGA-EL-A3MX THCA female 66 white 
TCGA-EL-A3MY THCA male 81 white 
TCGA-EL-A3N3 THCA female 53 white 
TCGA-EL-A3T0 THCA female 46 white 
TCGA-EL-A3T1 THCA female 38 black or african american 
TCGA-EL-A3T2 THCA female 55 white 
TCGA-EL-A3T3 THCA male 63 white 
TCGA-EL-A3T7 THCA female 47 white 
TCGA-EL-A3T8 THCA male 36 asian 
TCGA-EL-A3TA THCA male 42 white 
TCGA-EL-A3TB THCA female 47 white 
TCGA-EL-A3ZG THCA male 15 asian 
TCGA-EL-A3ZH THCA female 42 white 
TCGA-EL-A3ZK THCA female 41 white 
TCGA-EL-A3ZL THCA female 34 white 
TCGA-EL-A3ZM THCA male 60 not reported 
TCGA-EL-A3ZO THCA female 79 white 
TCGA-EL-A3ZP THCA male 19 white 
TCGA-EL-A3ZR THCA female 46 white 
TCGA-EL-A3ZS THCA female 22 white 
TCGA-EL-A3ZT THCA male 35 white 
TCGA-EM-A1CS THCA female 55 not reported 
TCGA-EM-A1CT THCA male 76 not reported 
TCGA-EM-A1CU THCA male 31 not reported 
TCGA-EM-A1CV THCA female 32 not reported 
TCGA-EM-A1CW THCA female 39 not reported 
TCGA-EM-A1YC THCA female 71 not reported 
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Table 15 (continued). 
TCGA-ET-A2MX THCA male 27 white 
TCGA-ET-A2N5 THCA female 46 black or african american 
TCGA-ET-A3DP THCA female 43 black or african american 
TCGA-ET-A3DW THCA male 64 asian 
TCGA-FY-A3TY THCA female 61 white 
TCGA-GE-A2C6 THCA female 33 white 
TCGA-H2-A2K9 THCA male 25 white 
TCGA-KS-A41I THCA female 47 white 
TCGA-KS-A41J THCA female 28 white 





SUPPLEMENTARY INFORMATION FOR CHAPTER 5 
 










Table 27 Genes selected by random forest variable importance. 








ENSG00000137275 P00006 Apoptosis signaling pathway       
ENSG00000169413 P00005 Angiogenesis         
ENSG00000067900 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000067900 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000067900 P06959 CCKR signaling map       
ENSG00000187764 P00007 Axon guidance mediated by semaphorins     
ENSG00000101144 P00052 TGF-beta signaling pathway       
ENSG00000101144 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000079215 P00037 Ionotropic glutamate receptor pathway      
ENSG00000079215 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000130821 P00043 
Muscarinic acetylcholine receptor 2 and 4 signaling 
pathway  
ENSG00000130821 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000080503 P00057 Wnt signaling pathway       
ENSG00000099956 P00057 Wnt signaling pathway       
ENSG00000275837 P00057 Wnt signaling pathway       
ENSG00000073584 P00057 Wnt signaling pathway       
ENSG00000132639 P00001 Adrenaline and noradrenaline biosynthesis      
ENSG00000132639 P00002 Alpha adrenergic receptor signaling pathway     
ENSG00000132639 P00037 Ionotropic glutamate receptor pathway      
ENSG00000132639 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000132639 P00040 Metabotropic glutamate receptor group II pathway    
ENSG00000132639 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000132639 P00043 
Muscarinic acetylcholine receptor 2 and 4 signaling 
pathway  
ENSG00000132639 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000132639 P04373 5HT1 type receptor mediated signaling pathway    
ENSG00000132639 P04374 5HT2 type receptor mediated signaling pathway    
ENSG00000132639 P04375 5HT3 type receptor mediated signaling pathway    
ENSG00000132639 P04376 5HT4 type receptor mediated signaling pathway    
ENSG00000132639 P04377 Beta1 adrenergic receptor signaling pathway     
ENSG00000132639 P04378 Beta2 adrenergic receptor signaling pathway     
ENSG00000132639 P04379 Beta3 adrenergic receptor signaling pathway     
ENSG00000132639 P04380 
Cortocotropin releasing factor receptor signaling 
pathway    
ENSG00000132639 P04391 Oxytocin receptor mediated signaling pathway     
ENSG00000132639 P04394 
Thyrotropin-releasing hormone receptor signaling 
pathway     
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Table 28 (continued). 
 
ENSG00000132639 P05734 Synaptic_vesicle_trafficking         
ENSG00000132639 P05912 Dopamine receptor mediated signaling pathway     
ENSG00000132639 P05915 Opioid proenkephalin pathway       
ENSG00000132639 P05916 Opioid prodynorphin pathway       
ENSG00000132639 P05917 Opioid proopiomelanocortin pathway       
ENSG00000057252 P02727 Androgen/estrogene/progesterone biosynthesis        
ENSG00000167780 P02727 Androgen/estrogene/progesterone biosynthesis        
ENSG00000100485 P00005 Angiogenesis         
ENSG00000100485 P00010 B cell activation       
ENSG00000100485 P00018 EGF receptor signaling pathway      
ENSG00000100485 P00021 FGF signaling pathway       
ENSG00000100485 P00032 
Insulin/IGF pathway-mitogen activated protein 
kinase kinase/MAP kinase cascade  
ENSG00000100485 P00034 Integrin signalling pathway       
ENSG00000100485 P00036 Interleukin signaling pathway       
ENSG00000100485 P00047 PDGF signaling pathway       
ENSG00000100485 P00048 PI3 kinase pathway       
ENSG00000100485 P00053 T cell activation       
ENSG00000100485 P04393 Ras Pathway        
ENSG00000100485 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000066336 P00036 Interleukin signaling pathway       
ENSG00000104549 P00014 Cholesterol biosynthesis        
ENSG00000010671 P00010 B cell activation       
ENSG00000278195 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000278195 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000138378 P00018 EGF receptor signaling pathway      
ENSG00000138378 P00036 Interleukin signaling pathway       
ENSG00000138378 P00038 JAK/STAT signaling pathway       
ENSG00000138378 P00047 PDGF signaling pathway       
ENSG00000126561 P00018 EGF receptor signaling pathway      
ENSG00000126561 P00036 Interleukin signaling pathway       
ENSG00000126561 P00038 JAK/STAT signaling pathway       
ENSG00000126561 P00047 PDGF signaling pathway       
ENSG00000079950 P00001 Adrenaline and noradrenaline biosynthesis      
ENSG00000079950 P00049 Parkinson disease        
ENSG00000196628 P06959 CCKR signaling map       
ENSG00000148737 P00004 Alzheimer disease-presenilin pathway       
ENSG00000148737 P00005 Angiogenesis         
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Table 29 (continued). 
 
ENSG00000148737 P00012 Cadherin signaling pathway       
ENSG00000148737 P00057 Wnt signaling pathway       
ENSG00000148516 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000028137 P00006 Apoptosis signaling pathway       
ENSG00000133107 P00004 Alzheimer disease-presenilin pathway       
ENSG00000105397 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000170142 P00060 Ubiquitin proteasome pathway       
ENSG00000154277 P00049 Parkinson disease        
ENSG00000141968 P00010 B cell activation       
ENSG00000141968 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000141968 P00047 PDGF signaling pathway       
ENSG00000141968 P00053 T cell activation       
ENSG00000015285 P00053 T cell activation       
ENSG00000106299 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000106299 P00029 Huntington disease        
ENSG00000115085 P00053 T cell activation       
ENSG00000171700 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000171700 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000136286 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000067191 P00003 Alzheimer disease-amyloid secretase pathway      
ENSG00000067191 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000067191 P00040 Metabotropic glutamate receptor group II pathway    
ENSG00000067191 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000067191 P04374 5HT2 type receptor mediated signaling pathway    
ENSG00000067191 P04377 Beta1 adrenergic receptor signaling pathway     
ENSG00000067191 P04378 Beta2 adrenergic receptor signaling pathway     
ENSG00000067191 P04391 Oxytocin receptor mediated signaling pathway     
ENSG00000067191 P04394 
Thyrotropin-releasing hormone receptor signaling 
pathway     
ENSG00000110031 P00005 Angiogenesis         
ENSG00000110031 P00056 VEGF signaling pathway       
ENSG00000123329 P00047 PDGF signaling pathway       
ENSG00000008516 P00004 Alzheimer disease-presenilin pathway       
ENSG00000152689 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000149260 P00029 Huntington disease        
ENSG00000170075 P00049 Parkinson disease        
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Table 30 (continued). 
 
ENSG00000118514 P04372 5-Hydroxytryptamine degredation        
ENSG00000164674 P05734 Synaptic_vesicle_trafficking         
ENSG00000196664 P00054 Toll receptor signaling pathway      
ENSG00000174123 P00054 Toll receptor signaling pathway      
ENSG00000166664 P00003 Alzheimer disease-amyloid secretase pathway      
ENSG00000166664 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000275917 P00003 Alzheimer disease-amyloid secretase pathway      
ENSG00000275917 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000118971 P00013 Cell cycle        
ENSG00000118971 P00048 PI3 kinase pathway       
ENSG00000112576 P00013 Cell cycle        
ENSG00000163823 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000121807 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000183813 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000112486 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000173585 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000100024 P02771 Pyrimidine Metabolism        
ENSG00000012124 P00010 B cell activation       
ENSG00000178562 P00053 T cell activation       
ENSG00000172215 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000004468 P06959 CCKR signaling map       
ENSG00000167286 P00053 T cell activation       
ENSG00000198851 P00053 T cell activation       
ENSG00000160654 P00053 T cell activation       
ENSG00000198821 P00053 T cell activation       
ENSG00000198373 P00060 Ubiquitin proteasome pathway       
ENSG00000019582 P00053 T cell activation       
ENSG00000166225 P00005 Angiogenesis         
ENSG00000166225 P00021 FGF signaling pathway       
ENSG00000105369 P00010 B cell activation       
ENSG00000007312 P00010 B cell activation       
ENSG00000062598 P00034 Integrin signalling pathway       
ENSG00000160219 P00018 EGF receptor signaling pathway      
ENSG00000140044 P00006 Apoptosis signaling pathway       
ENSG00000113361 P00012 Cadherin signaling pathway       
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ENSG00000113361 P00057 Wnt signaling pathway       
ENSG00000144837 P05726 2-arachidonoylglycerol biosynthesis        
ENSG00000100568 P00001 Adrenaline and noradrenaline biosynthesis      
ENSG00000198001 P00054 Toll receptor signaling pathway      
ENSG00000099365 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000099365 P00040 Metabotropic glutamate receptor group II pathway    
ENSG00000099365 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000099365 P00043 
Muscarinic acetylcholine receptor 2 and 4 signaling 
pathway  
ENSG00000099365 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000099365 P05734 Synaptic_vesicle_trafficking         
ENSG00000213658 P00053 T cell activation       
ENSG00000104951 P04372 5-Hydroxytryptamine degredation        
ENSG00000132718 P05734 Synaptic_vesicle_trafficking         
ENSG00000114737 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000114737 P00035 Interferon-gamma signaling pathway       
ENSG00000196405 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000189007 P02739 
De novo pyrimidine deoxyribonucleotide 
biosynthesis     
ENSG00000189007 P02774 Salvage pyrimidine deoxyribonucleotides       
ENSG00000189007 P02775 Salvage pyrimidine ribonucleotides       
ENSG00000137171 P00003 Alzheimer disease-amyloid secretase pathway      
ENSG00000136280 P00018 EGF receptor signaling pathway      
ENSG00000197410 P00012 Cadherin signaling pathway       
ENSG00000197410 P00057 Wnt signaling pathway       
ENSG00000284227 P00012 Cadherin signaling pathway       
ENSG00000284227 P00057 Wnt signaling pathway       
ENSG00000165323 P00012 Cadherin signaling pathway       
ENSG00000165323 P00057 Wnt signaling pathway       
ENSG00000282908 P00012 Cadherin signaling pathway       
ENSG00000282908 P00057 Wnt signaling pathway       
ENSG00000169118 P00049 Parkinson disease        
ENSG00000169118 P00057 Wnt signaling pathway       
ENSG00000146094 P00005 Angiogenesis         
ENSG00000278259 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000278372 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000128271 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
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ENSG00000128271 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000123454 P00001 Adrenaline and noradrenaline biosynthesis      
ENSG00000123454 P05912 Dopamine receptor mediated signaling pathway     
ENSG00000276231 P00018 EGF receptor signaling pathway      
ENSG00000276231 P00019 Endothelin signaling pathway       
ENSG00000120907 P00002 Alpha adrenergic receptor signaling pathway     
ENSG00000120907 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000150594 P00002 Alpha adrenergic receptor signaling pathway     
ENSG00000150594 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000180096 P00049 Parkinson disease        
ENSG00000118363 P04395 Vasopressin synthesis        
ENSG00000239900 P02738 De novo purine biosynthesis      
ENSG00000114841 P00029 Huntington disease        
ENSG00000140795 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000140795 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000172667 P00059 p53 pathway        
ENSG00000184845 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000184845 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000184845 P05912 Dopamine receptor mediated signaling pathway     
ENSG00000158050 P00046 Oxidative stress response       
ENSG00000128951 P02739 
De novo pyrimidine deoxyribonucleotide 
biosynthesis     
ENSG00000161202 P00004 Alzheimer disease-presenilin pathway       
ENSG00000161202 P00005 Angiogenesis         
ENSG00000161202 P00057 Wnt signaling pathway       
ENSG00000124126 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000111674 P00024 Glycolysis         
ENSG00000088367 P05912 Dopamine receptor mediated signaling pathway     
ENSG00000088367 P06587 Nicotine pharmacodynamics pathway       
ENSG00000181104 P00005 Angiogenesis         
ENSG00000181104 P00011 Blood coagulation        
ENSG00000137714 P04396 Vitamin D metabolism and pathway     
ENSG00000129682 P00021 FGF signaling pathway       
ENSG00000000938 P00049 Parkinson disease        
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ENSG00000187474 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000010810 P00007 Axon guidance mediated by semaphorins     
ENSG00000010810 P00012 Cadherin signaling pathway       
ENSG00000010810 P00034 Integrin signalling pathway       
ENSG00000010810 P00049 Parkinson disease        
ENSG00000204681 P05731 GABA-B_receptor_II_signaling         
ENSG00000206466 P05731 GABA-B_receptor_II_signaling         
ENSG00000206511 P05731 GABA-B_receptor_II_signaling         
ENSG00000232569 P05731 GABA-B_receptor_II_signaling         
ENSG00000232632 P05731 GABA-B_receptor_II_signaling         
ENSG00000237051 P05731 GABA-B_receptor_II_signaling         
ENSG00000237112 P05731 GABA-B_receptor_II_signaling         
ENSG00000154727 P00047 PDGF signaling pathway       
ENSG00000258643 P00006 Apoptosis signaling pathway       
ENSG00000132965 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000112699 P02752 Mannose metabolism        
ENSG00000167083 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000167083 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000167083 P00028 
Heterotrimeric G-protein signaling pathway-rod 
outer segment phototransduction   
ENSG00000167083 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000167083 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000167083 P00040 Metabotropic glutamate receptor group II pathway    
ENSG00000167083 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000167083 P00043 
Muscarinic acetylcholine receptor 2 and 4 signaling 
pathway  
ENSG00000167083 P00048 PI3 kinase pathway       
ENSG00000167083 P00057 Wnt signaling pathway       
ENSG00000167083 P04373 5HT1 type receptor mediated signaling pathway    
ENSG00000167083 P04374 5HT2 type receptor mediated signaling pathway    
ENSG00000167083 P04376 5HT4 type receptor mediated signaling pathway    
ENSG00000167083 P04377 Beta1 adrenergic receptor signaling pathway     
ENSG00000167083 P04378 Beta2 adrenergic receptor signaling pathway     
ENSG00000167083 P04379 Beta3 adrenergic receptor signaling pathway     
ENSG00000167083 P04380 
Cortocotropin releasing factor receptor signaling 
pathway    
ENSG00000167083 P04385 Histamine H1 receptor mediated signaling pathway    
ENSG00000167083 P04386 Histamine H2 receptor mediated signaling pathway    
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ENSG00000167083 P04391 Oxytocin receptor mediated signaling pathway     
ENSG00000167083 P04394 
Thyrotropin-releasing hormone receptor signaling 
pathway     
ENSG00000167083 P05730 Endogenous_cannabinoid_signaling         
ENSG00000167083 P05731 GABA-B_receptor_II_signaling         
ENSG00000167083 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000167083 P05913 Enkephalin release        
ENSG00000167083 P05915 Opioid proenkephalin pathway       
ENSG00000167083 P05916 Opioid prodynorphin pathway       
ENSG00000167083 P05917 Opioid proopiomelanocortin pathway       
ENSG00000186810 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000198055 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000198055 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000198055 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000198055 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000177885 P00005 Angiogenesis         
ENSG00000177885 P00010 B cell activation       
ENSG00000177885 P00018 EGF receptor signaling pathway      
ENSG00000177885 P00021 FGF signaling pathway       
ENSG00000177885 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000177885 P00032 
Insulin/IGF pathway-mitogen activated protein 
kinase kinase/MAP kinase cascade  
ENSG00000177885 P00034 Integrin signalling pathway       
ENSG00000177885 P00036 Interleukin signaling pathway       
ENSG00000177885 P00047 PDGF signaling pathway       
ENSG00000177885 P00048 PI3 kinase pathway       
ENSG00000177885 P00053 T cell activation       
ENSG00000177885 P04393 Ras Pathway        
ENSG00000177885 P05912 Dopamine receptor mediated signaling pathway     
ENSG00000177885 P06587 Nicotine pharmacodynamics pathway       
ENSG00000177885 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000177885 P06959 CCKR signaling map       
ENSG00000164418 P00029 Huntington disease        
ENSG00000164418 P00037 Ionotropic glutamate receptor pathway      
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ENSG00000164418 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000179603 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000179603 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000179603 P00039 Metabotropic glutamate receptor group III pathway    
ENSG00000163739 P06959 CCKR signaling map       
ENSG00000152402 P00019 Endothelin signaling pathway       
ENSG00000143774 P02738 De novo purine biosynthesis      
ENSG00000101336 P00049 Parkinson disease        
ENSG00000168384 P00053 T cell activation       
ENSG00000206291 P00053 T cell activation       
ENSG00000224103 P00053 T cell activation       
ENSG00000228163 P00053 T cell activation       
ENSG00000229685 P00053 T cell activation       
ENSG00000231389 P00053 T cell activation       
ENSG00000235844 P00053 T cell activation       
ENSG00000236177 P00053 T cell activation       
ENSG00000196735 P00053 T cell activation       
ENSG00000206305 P00053 T cell activation       
ENSG00000225890 P00053 T cell activation       
ENSG00000228284 P00053 T cell activation       
ENSG00000232062 P00053 T cell activation       
ENSG00000236418 P00053 T cell activation       
ENSG00000204287 P00053 T cell activation       
ENSG00000206308 P00053 T cell activation       
ENSG00000226260 P00053 T cell activation       
ENSG00000227993 P00053 T cell activation       
ENSG00000228987 P00053 T cell activation       
ENSG00000230726 P00053 T cell activation       
ENSG00000234794 P00053 T cell activation       
ENSG00000277263 P00053 T cell activation       
ENSG00000189403 P00059 p53 pathway        
ENSG00000086696 P02727 Androgen/estrogene/progesterone biosynthesis        
ENSG00000211899 P00010 B cell activation       
ENSG00000282657 P00010 B cell activation       
ENSG00000110324 P00036 Interleukin signaling pathway       
ENSG00000095752 P00036 Interleukin signaling pathway       
ENSG00000081985 P00036 Interleukin signaling pathway       
ENSG00000100385 P00036 Interleukin signaling pathway       
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ENSG00000163464 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000163464 P00036 Interleukin signaling pathway       
ENSG00000180871 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000180871 P00036 Interleukin signaling pathway       
ENSG00000171105 P00032 
Insulin/IGF pathway-mitogen activated protein 
kinase kinase/MAP kinase cascade  
ENSG00000171105 P00033 
Insulin/IGF pathway-protein kinase B signaling 
cascade    
ENSG00000171105 P00048 PI3 kinase pathway       
ENSG00000171105 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000156886 P00034 Integrin signalling pathway       
ENSG00000083457 P00034 Integrin signalling pathway       
ENSG00000169896 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000169896 P00034 Integrin signalling pathway       
ENSG00000140678 P00034 Integrin signalling pathway       
ENSG00000160255 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000160255 P00034 Integrin signalling pathway       
ENSG00000123104 P00010 B cell activation       
ENSG00000123104 P00019 Endothelin signaling pathway       
ENSG00000123104 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000123104 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000123104 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000123104 P00047 PDGF signaling pathway       
ENSG00000123104 P00057 Wnt signaling pathway       
ENSG00000123104 P04385 Histamine H1 receptor mediated signaling pathway    
ENSG00000123104 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000123104 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000101384 P00005 Angiogenesis         
ENSG00000101384 P00045 Notch signaling pathway       
ENSG00000120457 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000120457 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
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ENSG00000120457 P00043 
Muscarinic acetylcholine receptor 2 and 4 signaling 
pathway  
ENSG00000143761 P00029 Huntington disease        
ENSG00000143761 P00034 Integrin signalling pathway       
ENSG00000043462 P00053 T cell activation       
ENSG00000165527 P00029 Huntington disease        
ENSG00000165527 P00034 Integrin signalling pathway       
ENSG00000107798 P02727 Androgen/estrogene/progesterone biosynthesis        
ENSG00000079435 P02782 Triacylglycerol metabolism        
ENSG00000155366 P00005 Angiogenesis         
ENSG00000155366 P00007 Axon guidance mediated by semaphorins     
ENSG00000155366 P00008 Axon guidance mediated by Slit/Robo     
ENSG00000155366 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000155366 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000155366 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000155366 P00034 Integrin signalling pathway       
ENSG00000155366 P04393 Ras Pathway        
ENSG00000155366 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000070018 P00004 Alzheimer disease-presenilin pathway       
ENSG00000070018 P00057 Wnt signaling pathway       
ENSG00000281324 P00004 Alzheimer disease-presenilin pathway       
ENSG00000281324 P00057 Wnt signaling pathway       
ENSG00000204487 P00006 Apoptosis signaling pathway       
ENSG00000206437 P00006 Apoptosis signaling pathway       
ENSG00000223448 P00006 Apoptosis signaling pathway       
ENSG00000227507 P00006 Apoptosis signaling pathway       
ENSG00000231314 P00006 Apoptosis signaling pathway       
ENSG00000236237 P00006 Apoptosis signaling pathway       
ENSG00000236925 P00006 Apoptosis signaling pathway       
ENSG00000238114 P00006 Apoptosis signaling pathway       
ENSG00000137834 P00052 TGF-beta signaling pathway       
ENSG00000006062 P00006 Apoptosis signaling pathway       
ENSG00000006062 P00018 EGF receptor signaling pathway      
ENSG00000006062 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000006062 P06959 CCKR signaling map       
ENSG00000282637 P00006 Apoptosis signaling pathway       
ENSG00000282637 P00018 EGF receptor signaling pathway      
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ENSG00000282637 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000282637 P06959 CCKR signaling map       
ENSG00000198909 P00010 B cell activation       
ENSG00000198909 P00018 EGF receptor signaling pathway      
ENSG00000198909 P00021 FGF signaling pathway       
ENSG00000198909 P00034 Integrin signalling pathway       
ENSG00000198909 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000104814 P00006 Apoptosis signaling pathway       
ENSG00000104814 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000282928 P00006 Apoptosis signaling pathway       
ENSG00000282928 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000198625 P00033 
Insulin/IGF pathway-protein kinase B signaling 
cascade    
ENSG00000198625 P00059 p53 pathway        
ENSG00000198625 P04392 P53 pathway feedback loops 1     
ENSG00000198625 P04398 p53 pathway feedback loops 2     
ENSG00000137486 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000137486 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000137486 P00057 Wnt signaling pathway       
ENSG00000137486 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000141480 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000141480 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000141480 P00057 Wnt signaling pathway       
ENSG00000141480 P05911 
Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin  
ENSG00000141480 P06959 CCKR signaling map       
ENSG00000215914 P00004 Alzheimer disease-presenilin pathway       
ENSG00000167508 P00014 Cholesterol biosynthesis        
ENSG00000070669 P02730 Asparagine and aspartate biosynthesis      
ENSG00000091536 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000128641 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000176658 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000142347 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000197535 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000169994 P00044 Nicotinic acetylcholine receptor signaling pathway     
ENSG00000099331 P00044 Nicotinic acetylcholine receptor signaling pathway     
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ENSG00000107954 P00045 Notch signaling pathway       
ENSG00000196712 P00018 EGF receptor signaling pathway      
ENSG00000101096 P00009 Axon guidance mediated by netrin     
ENSG00000101096 P00010 B cell activation       
ENSG00000101096 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000101096 P00053 T cell activation       
ENSG00000101096 P00057 Wnt signaling pathway       
ENSG00000101096 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000101096 P06959 CCKR signaling map       
ENSG00000007171 P00048 PI3 kinase pathway       
ENSG00000099250 P00007 Axon guidance mediated by semaphorins     
ENSG00000133961 P00045 Notch signaling pathway       
ENSG00000125510 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000125510 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000277044 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000277044 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000124507 P00029 Huntington disease        
ENSG00000113555 P00012 Cadherin signaling pathway       
ENSG00000113555 P00057 Wnt signaling pathway       
ENSG00000255408 P00012 Cadherin signaling pathway       
ENSG00000255408 P00057 Wnt signaling pathway       
ENSG00000204967 P00012 Cadherin signaling pathway       
ENSG00000204967 P00057 Wnt signaling pathway       
ENSG00000204965 P00012 Cadherin signaling pathway       
ENSG00000204965 P00057 Wnt signaling pathway       
ENSG00000204963 P00012 Cadherin signaling pathway       
ENSG00000204963 P00057 Wnt signaling pathway       
ENSG00000187372 P00012 Cadherin signaling pathway       
ENSG00000187372 P00057 Wnt signaling pathway       
ENSG00000120327 P00012 Cadherin signaling pathway       
ENSG00000120327 P00057 Wnt signaling pathway       
ENSG00000113212 P00012 Cadherin signaling pathway       
ENSG00000113212 P00057 Wnt signaling pathway       
ENSG00000253846 P00012 Cadherin signaling pathway       
ENSG00000253846 P00057 Wnt signaling pathway       
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ENSG00000253767 P00012 Cadherin signaling pathway       
ENSG00000253767 P00057 Wnt signaling pathway       
ENSG00000185527 P00028 
Heterotrimeric G-protein signaling pathway-rod 
outer segment phototransduction   
ENSG00000141959 P00024 Glycolysis         
ENSG00000171608 P00005 Angiogenesis         
ENSG00000171608 P00006 Apoptosis signaling pathway       
ENSG00000171608 P00009 Axon guidance mediated by netrin     
ENSG00000171608 P00010 B cell activation       
ENSG00000171608 P00018 EGF receptor signaling pathway      
ENSG00000171608 P00019 Endothelin signaling pathway       
ENSG00000171608 P00021 FGF signaling pathway       
ENSG00000171608 P00030 Hypoxia response via HIF activation     
ENSG00000171608 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000171608 P00033 
Insulin/IGF pathway-protein kinase B signaling 
cascade    
ENSG00000171608 P00034 Integrin signalling pathway       
ENSG00000171608 P00047 PDGF signaling pathway       
ENSG00000171608 P00053 T cell activation       
ENSG00000171608 P00056 VEGF signaling pathway       
ENSG00000171608 P00059 p53 pathway        
ENSG00000171608 P04393 Ras Pathway        
ENSG00000171608 P04398 p53 pathway feedback loops 2     
ENSG00000105499 P00005 Angiogenesis         
ENSG00000105499 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000101333 P00002 Alpha adrenergic receptor signaling pathway     
ENSG00000101333 P00019 Endothelin signaling pathway       
ENSG00000101333 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000101333 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000101333 P00041 Metabotropic glutamate receptor group I pathway    
ENSG00000101333 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000101333 P00057 Wnt signaling pathway       
ENSG00000101333 P04374 5HT2 type receptor mediated signaling pathway    
ENSG00000101333 P04385 Histamine H1 receptor mediated signaling pathway    
ENSG00000101333 P04391 Oxytocin receptor mediated signaling pathway     
ENSG00000101333 P04394 
Thyrotropin-releasing hormone receptor signaling 
pathway     
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ENSG00000108387 P00049 Parkinson disease        
ENSG00000120910 P00010 B cell activation       
ENSG00000120910 P00053 T cell activation       
ENSG00000120910 P00057 Wnt signaling pathway       
ENSG00000163932 P00002 Alpha adrenergic receptor signaling pathway     
ENSG00000163932 P00003 Alzheimer disease-amyloid secretase pathway      
ENSG00000163932 P00005 Angiogenesis         
ENSG00000163932 P00006 Apoptosis signaling pathway       
ENSG00000163932 P00010 B cell activation       
ENSG00000163932 P00018 EGF receptor signaling pathway      
ENSG00000163932 P00019 Endothelin signaling pathway       
ENSG00000163932 P00021 FGF signaling pathway       
ENSG00000163932 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000163932 P00042 
Muscarinic acetylcholine receptor 1 and 3 signaling 
pathway  
ENSG00000163932 P00056 VEGF signaling pathway       
ENSG00000163932 P00057 Wnt signaling pathway       
ENSG00000163932 P04374 5HT2 type receptor mediated signaling pathway    
ENSG00000163932 P04385 Histamine H1 receptor mediated signaling pathway    
ENSG00000163932 P04391 Oxytocin receptor mediated signaling pathway     
ENSG00000163932 P04394 
Thyrotropin-releasing hormone receptor signaling 
pathway     
ENSG00000163932 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000163932 P06959 CCKR signaling map       
ENSG00000181790 P00059 p53 pathway        
ENSG00000101182 P00049 Parkinson disease        
ENSG00000120899 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000120899 P00034 Integrin signalling pathway       
ENSG00000120899 P06664 Gonadotropin releasing hormone receptor pathway     
ENSG00000120899 P06959 CCKR signaling map       
ENSG00000111679 P00005 Angiogenesis         
ENSG00000111679 P00010 B cell activation       
ENSG00000111679 P00021 FGF signaling pathway       
ENSG00000111679 P00035 Interferon-gamma signaling pathway       
ENSG00000081237 P00010 B cell activation       
ENSG00000081237 P00038 JAK/STAT signaling pathway       
ENSG00000081237 P00053 T cell activation       
ENSG00000262418 P00010 B cell activation       
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ENSG00000262418 P00038 JAK/STAT signaling pathway       
ENSG00000262418 P00053 T cell activation       
ENSG00000128340 P00007 Axon guidance mediated by semaphorins     
ENSG00000128340 P00008 Axon guidance mediated by Slit/Robo     
ENSG00000128340 P00009 Axon guidance mediated by netrin     
ENSG00000128340 P00010 B cell activation       
ENSG00000128340 P00016 Cytoskeletal regulation by Rho GTPase     
ENSG00000128340 P00018 EGF receptor signaling pathway      
ENSG00000128340 P00021 FGF signaling pathway       
ENSG00000128340 P00029 Huntington disease        
ENSG00000128340 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000128340 P00034 Integrin signalling pathway       
ENSG00000128340 P00053 T cell activation       
ENSG00000128340 P00056 VEGF signaling pathway       
ENSG00000128340 P04393 Ras Pathway        
ENSG00000128340 P05918 p38 MAPK pathway       
ENSG00000172575 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000171791 P00006 Apoptosis signaling pathway       
ENSG00000171791 P00046 Oxidative stress response       
ENSG00000171791 P06959 CCKR signaling map       
ENSG00000090104 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000090104 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000090104 P00031 
Inflammation mediated by chemokine and cytokine 
signaling pathway  
ENSG00000127074 P00026 
Heterotrimeric G-protein signaling pathway-Gi alpha 
and Gs alpha  
ENSG00000127074 P00027 
Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha  
ENSG00000127074 P00031 
Inflammation mediated by chemokine and cytokine 










ENSG00000187122 P00008 Axon guidance mediated by Slit/Robo 
ENSG00000153147 P00057 Wnt signaling pathway   
ENSG00000139613 P00057 Wnt signaling pathway   
ENSG00000115904 P00005 Angiogenesis     
ENSG00000115904 P00010 B cell activation   
ENSG00000115904 P00018 EGF receptor signaling pathway  
ENSG00000115904 P00021 FGF signaling pathway   
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ENSG00000115904 P00031 Inflammation mediated by chemokine and 
ENSG00000115904 P00032 
Insulin/IGF pathway-mitogen activated protein 
kinase 
ENSG00000115904 P00034 Integrin signalling pathway   
ENSG00000115904 P00036 Interleukin signaling pathway   
ENSG00000115904 P00047 PDGF signaling pathway   
ENSG00000115904 P00048 PI3 kinase pathway   
ENSG00000115904 P00053 T cell activation   
ENSG00000115904 P04393 Ras Pathway    
ENSG00000115904 P06664 Gonadotropin releasing hormone receptor pathway 
ENSG00000115904 P06959 CCKR signaling map   
ENSG00000070808 P00031 Inflammation mediated by chemokine and 
ENSG00000070808 P00037 Ionotropic glutamate receptor pathway  
ENSG00000110395 P00018 EGF receptor signaling pathway  
ENSG00000101199 P00034 Integrin signalling pathway   
ENSG00000078814 P00016 Cytoskeletal regulation by Rho GTPase 
ENSG00000078814 P00031 Inflammation mediated by chemokine and 
ENSG00000078814 P00044 Nicotinic acetylcholine receptor signaling pathway 
ENSG00000078814 P00057 Wnt signaling pathway   
ENSG00000198276 P02775 Salvage pyrimidine ribonucleotides   
ENSG00000009335 P00060 Ubiquitin proteasome pathway   
ENSG00000145819 P00034 Integrin signalling pathway   
ENSG00000145819 P00047 PDGF signaling pathway   
ENSG00000156650 P00059 p53 pathway    
ENSG00000281813 P00059 p53 pathway    
ENSG00000049618 P00057 Wnt signaling pathway   
ENSG00000172602 P00034 Integrin signalling pathway   
ENSG00000168615 P00003 Alzheimer disease-amyloid secretase pathway  
ENSG00000282230 P00003 Alzheimer disease-amyloid secretase pathway  
ENSG00000033800 P00035 Interferon-gamma signaling pathway   
ENSG00000033800 P00038 JAK/STAT signaling pathway   
ENSG00000004975 P00004 Alzheimer disease-presenilin pathway   
ENSG00000004975 P00005 Angiogenesis     
ENSG00000004975 P00057 Wnt signaling pathway   
ENSG00000100393 P00026 Heterotrimeric G-protein signaling pathway-Gi alpha 
ENSG00000100393 P00029 Huntington disease    
ENSG00000100393 P00052 TGF-beta signaling pathway   
ENSG00000100393 P00055 Transcription regulation by bZIP transcription 
ENSG00000100393 P00057 Wnt signaling pathway   
ENSG00000100393 P00059 p53 pathway    
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Table 43 (continued). 
 
ENSG00000100393 P06211 BMP_signaling_pathway-drosophila     
ENSG00000100393 P06212 DPP-SCW_signaling_pathway     
ENSG00000100393 P06213 DPP_signaling_pathway     
ENSG00000100393 P06214 GBB_signaling_pathway     
ENSG00000100393 P06216 SCW_signaling_pathway     
ENSG00000100393 P06664 Gonadotropin releasing hormone receptor pathway 
ENSG00000151422 P00012 Cadherin signaling pathway   
ENSG00000213930 P02744 Fructose galactose metabolism   
ENSG00000161905 P00031 Inflammation mediated by chemokine and 
ENSG00000161905 P06664 Gonadotropin releasing hormone receptor pathway 
ENSG00000105464 P00029 Huntington disease    
ENSG00000105464 P00037 Ionotropic glutamate receptor pathway  
ENSG00000105464 P00039 Metabotropic glutamate receptor group III 
ENSG00000105464 P00041 Metabotropic glutamate receptor group I 
ENSG00000105464 P00042 Muscarinic acetylcholine receptor 1 and 
ENSG00000197386 P00029 Huntington disease    
ENSG00000173110 P00006 Apoptosis signaling pathway   
ENSG00000173110 P00049 Parkinson disease    
ENSG00000120868 P00006 Apoptosis signaling pathway   
ENSG00000120868 P00020 FAS signaling pathway   
ENSG00000120868 P00029 Huntington disease    
ENSG00000120868 P00059 p53 pathway    
ENSG00000185507 P00054 Toll receptor signaling pathway  
ENSG00000276561 P00054 Toll receptor signaling pathway  
ENSG00000169967 P00010 B cell activation   
ENSG00000169967 P00018 EGF receptor signaling pathway  
ENSG00000169967 P00021 FGF signaling pathway   
ENSG00000169967 P00034 Integrin signalling pathway   
ENSG00000169967 P00047 PDGF signaling pathway   
ENSG00000169967 P06664 Gonadotropin releasing hormone receptor pathway 
ENSG00000120500 P00057 Wnt signaling pathway   
ENSG00000066136 P06664 Gonadotropin releasing hormone receptor pathway 
ENSG00000177463 P06959 CCKR signaling map   
ENSG00000138801 P02778 Sulfate assimilation    
ENSG00000204967 P00012 Cadherin signaling pathway   
ENSG00000204967 P00057 Wnt signaling pathway   
ENSG00000253953 P00012 Cadherin signaling pathway   
ENSG00000253953 P00057 Wnt signaling pathway   
ENSG00000112033 P00057 Wnt signaling pathway   
ENSG00000050820 P00034 Integrin signalling pathway   
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Table 44 (continued). 
 
ENSG00000050820 P06959 CCKR signaling map   
ENSG00000285460 P00034 Integrin signalling pathway   
ENSG00000285460 P06959 CCKR signaling map   
ENSG00000035928 P00017 DNA replication    
 
Table 45 Accuracy by cancer type. 
5-Fluorouracil Cancer Type Accuracy Count 
Colon adenocarcinoma  85.71% 7 
Esophageal carcinoma  25.0% 4 
Pancreatic adenocarcinoma  90.0% 10 
Rectum adenocarcinoma  100.0% 16 
Stomach adenocarcinoma  76.0% 25 
Gemcitabine Cancer Type Accuracy Count 
Bladder Urothelial Carcinoma  100.00% 12 
Breast invasive carcinoma  100.0% 3 
Cervical squamous cell carcinoma and endocervical adenocarcinoma  100.0% 2 
Cholangiocarcinoma  100.0% 7 
Head and Neck squamous cell carcinoma  100.0% 2 
Liver hepatocellular carcinoma  100.0% 3 
Lung adenocarcinoma  100.0% 5 
Ovarian serous cystadenocarcinom 75.0% 4 
Pancreatic adenocarcinoma  86.0% 43 
Pheochromocytoma and Paraganglioma  100.0% 2 
Sarcoma  88.9% 9 
Skin Cutaneous Melanoma  100.0% 2 
Testicular Germ Cell Tumors  100.0% 1 






Figure 44 Optimal model workflow. 
A pipeline was created for evaluating the performance of models with varying N (number 
of clusters) for each N between 180 and 220, and clustering algorithms: clara, 
hierarchical, k-means, model, pam, and sota.  All clusters were ranked by a variable 
importance measure calculated using a random forest classifier.  N models were created, 
where model 1 contained the most informative cluster, and model N contained top N most 
informative clusters.  The mean accuracy for each model was calculated using random 
forest with 200x cross validation.  The model which produced the best accuracy was 




Figure 45 Survival data as a predictor of drug response. 
Survival data was downloaded for all patients from both GCB and 5FU models.  Kaplan–
Meier plot for responders (res) and non-responders (non) depicting patient survival over 
time. 
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D.1  Supplementary Methods 
D.1.1 Data Pre-Processing 
Pre-processing was required to make the data viable for our study.  The clinical 
data was first cleaned, and records were removed if vital data was missing.  Records 
missing drug name, response, cancer type, days on drug therapy, or days to drug therapy 
start were removed.  We also removed records for which gene expression data was not 
available. We required a sample size of at least 30 records for a drug to be considered for 
the study and at least 15 records for each response type. 
D.1.2 Gene Standardization & Gene Selection 
We accounted for the differences of gene expression within cancer types.  We 
calculated the mean (cancer type mean) and standard deviation (cancer type sd) of the 
logged expression values for every TCGA patient with a given cancer type. We 
standardized the gene expression for the patients included in the study by subtracting the 
cancer type mean and dividing by the cancer type standard deviation. 
We reduced the number of genes to effectively use clustering algorithms.  We 
wanted to retain the genes that have the highest amount of variation (standard deviation) 
and the highest number of unique values (Figure 43).  Genes with less than 70% unique 
values across all patients were removed first.  Next, we calculated the standard deviation 
for each remaining gene. We used the product of the standard deviation and percentage of 
unique values to rank the remaining genes. The top 5,000 genes ranked by this method 
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were included in the clustering algorithm, which is discussed in the next section.  Genes 
selected by the variable selection method can be found in Table 27. 
D.1.3 SPD Results 
We compared single cancer and pan-cancer models using Sample Progression 
Discovery (SPD) clustering and random forest classification. SPD was borrowed from a 
previously published paper, because it discovers patterns of biological progression within 
data by building relatively same-size clusters of arbitrary shape.  Under SPD, the model 
cross-validation accuracy was 71.4% for 5-FU and 73.5% for GCB.  The number of clusters 
created by SPD was higher for 5-FU (251) than GCB (202), but the number of clusters 
selected with random forest was lower (25 vs 35).  The results of the single cancer models 
showed lower accuracy rates than the pan models: 5-FU STAD (70.90%) and GCB PAAD 
(67.7%). This result supported our decision to only focus on pan-cancer models for the 
remaining analysis of the study. 
D.1.4 Validation Set Investigation 
The limited size of the data set was also a bottleneck to performing a robust model 
validation. We tried two different validation methods.  For the first method, we attempted 
to use the patients who had been treated with 5-FU or GCB but were missing a documented 
measure of response to treatment.  We first proved that the survival data is a good predictor 
of drug response, and we were going to use survival curves to validate our predictions (See 
Figure 45 for additional information).  Despite its promise, there were too few patients for 
this approach to be of value.  As a second attempt, we used patients who were on 
combination therapy with the drugs of interest [5-FU/Leucovorin and 
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Gemcitabine/Cisplatin,] as their first line of treatment.  We performed the standard process 
for model validation (using all training data to train the model, and then testing accuracy 
on the testing data).  The results were not promising [5-FU/Leucovorin: 53.1% and 
Gemcitabine/Cisplatin: 51.0%].  Thus we left out half of the most populous cancer from 
the training set as described in the methods.  
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